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SUMMARY
Extensive study of the active site of angiotensin 
converting enzyme (ACE) has led to the development of 
specific inhibitors which are now successfully used in the 
treatment of hypertension and cardiac failure. The work 
carried out within this thesis has been concerned with the 
evaluation of the disposition characteristics of the ACE 
inhibitors and their concentration effect relationships. 
Characterisation of the pharmacokinetics of any compound 
is dependent upon the availability of accurate, precise, 
sensitive and specific assay methodology. Three groups of 
methods have been compared within this thesis, two 
different methods to measure plasma ACE activity, three 
methods to measure plasma enalaprilat levels and three 
methods to measure plasma benazeprilat levels. The 
methods to measure plasma ACE activity yielded results in 
good agreement. One of the three methods to measure 
plasma enalaprilat levels gave results that were 
significantly lower than the remaining two methods. No 
obvious explanation could be found for this. Of the three 
methods to measure benazeprilat, the specific method gave 
significantly lower results than the two non specific 
methods, the possible existence of unstable glucuronides 
contributing to the discrepancy between the methods. 
These results highlight the need to know the specificity 
of any assay technique being used.
The concentration effect relationship of two different 
series of ACE inhibitors was assessed in plasma from
22
individual rabbits and volunteers. Differences were found 
in both the rank order of potency of the compounds between 
rabbit and man, and also, there were significant 
differences in the potency of single compounds between 
rabbit and man. These differences may reflect variations 
in the tertiary structure of ACE between rabbit and man 
and indicate that different doses would be needed to 
obtain the same degree of ACE inhibition.
The in vivo/in vitro relationship for plasma ACE 
inhibition was assessed for perindoprilat and quinaprilat. 
For both compounds the in vivo values were significantly 
lower than those found in vitro, indicating greater 
inhibition of ACE in vivo. Any calculations based upon 
the in vitro values would overestimate the amount of drug 
needed to elicit the same response in vivo.
The third group of in vitro studies examined the effect of 
the presence of parent compound on the in vitro potency of 
the metabolite. In vitro dose response curves for five 
metabolites were characterised in the presence and absence 
of parent compound. The presence of parent compound 
brought about a significant decrease in potency for 
S-10211 (the active metabolite of S-9650) and quinaprilat 
in rabbit, and for enalaprilat and perindoprilat in man. 
The decrease in potency seen for some of the metabolites 
studied may be due to the parent compound binding to a 
second active site sequence on the ACE molecule where it 
causes steric hindrance but not ACE inhibition.
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The rabbit was used as a model to characterise the effect 
of saturation of ACE binding sites on the pharmacokinetics 
of radiolabelled spiraprilat. Rabbits were pretreated 
with either placebo or unlabelled spiraprilat and the 
pharmacokinetics of a tracer radiolabelled intravenous 
dose of spiraprilat characterised. The pharmacokinetics 
of radiolabelled spiraprilat were best described by a 
three compartment model with a terminal elimination half 
life of the order of 2.5 hours. The effect of saturation 
of plasma and tissue ACE binding sites caused an increase 
in the rate of elimination during the second phase, the 
effect was small and did not contribute to a change in 
total clearance of the radiolabelled dose. Despite higher 
plasma ACE activity values in rabbit, the long terminal 
half life, a characteristic feature of ACE inhibitor drugs 
in man, was not observed in rabbit for radiolabelled 
spiraprilat. Thus, the rabbit would appear not to be a 
good model for the disposition of ACE inhibitors in man. 
The pharmacokinetics of enalaprilat, formed after an oral 
dose of enalapril, were characterised in the presence and 
absence of saturated plasma and tissue ACE binding sites. 
Captopril was the agent used to saturate ACE binding 
sites. Eight volunteers received a single 1Omg dose of 
enalapril. A washout period ensued then the volunteers 
were pretreated with captopril, 50mg twice daily, followed 
by a second 1Omg dose of enalapril. Analysis of 
enalaprilat pharmacokinetics revealed no differences in 
the presence and absence of captopril. Analysis of the
24
plasma ACE activity data indicated that induction of 
plasma ACE had occurred during the pretreatment with 
captopril. Thus, the lack of any detectable change in 
enalaprilat pharmacokinetics could have been due to the 
induction of ACE by pretreatment with captopril. The 
resulting increase in the number of ACE binding sites may 
have negated the effect of captopril's occupancy of 
original ACE binding sites.
The pharmacokinetics of benazeprilat, formed after the 
acute and chronic administration of benazepril 
hydrochloride, were characterised in young and elderly
volunteers. Nine young and nine elderly healthy
volunteers were studied after the first and last doses of 
1Omg benazepril hydrochloride, once daily, for eight days. 
A series of models were fitted to the combined acute and 
chronic data, standard one and two compartmental models, 
and, models based upon a one compartment model which 
incorporated either binding to plasma ACE, binding to
tissue ACE or binding to both plasma and tissue ACE. The
vast majority of the subjects were best described by the 
one compartment model which incorporated tissue binding 
only. The value for the half life of elimination of free 
drug obtained from the model which best described the data 
for any one subject, was of the order of 2.5 hours. This 
is in keeping with the accumulation characteristics of 
benazeprilat.
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CHAPTER 1 
INTRODUCTION
1.1 INTRODUCTION
The use of Angiotensin Converting Enzyme (ACE) inhibitors 
in the treatment of hypertension and heart failure is 
increasing. Since the major mechanism of action of the 
ACE inhibitors is the competitive inhibition (Ondetti and 
Cushman, 1982) of the conversion of angiotensin I (AI) to 
angiotensin II (All), it is appropriate to discuss the 
renin angiotensin system (RAS) in some detail.
1.2 Renin Angiotensin System
1.2.1 Renin Substrate
Renin substrate or angiotensinogen is an alpha globulin
2
synthesized in the liver. The liver would appear to have 
a dual role in controlling angiotensinogen levels in that 
it synthesises the substrate and regulates its consumption 
through its control of renin metabolism.
1.2.2 Renin
Renin, first discovered in 1896 by Tiegerstedt and Bergman 
who observed that a crude saline extract of kidney could 
elicit a pressor response, is found predominantly in the 
kidney although it has also been found within other body 
tissues such as vascular wall. Within the kidney renin is 
localised in the outer zone of the renal cortex and is
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synthesised and stored in juxtaglomerular cells. Renin 
release by the kidney is influenced and controlled by a 
multiplicity of interrelated factors which work directly
or indirectly on the kidney. Factors which increase renin
secretion are those which decrease blood pressure or 
increase sympathetic output. These factors in turn depend
on the status of Na+ reabsorption across the macula densa,
All, antidiuretic hormone (ADH), circulating
catecholamines and an intrarenal baroreceptor mechanism 
which responds to the level of intraarteriolar pressure at 
the juxtaglomerular cells.
Renin, an acid protease acts on angiotensinogen, a 
polypeptide, splitting the bond between two leucine 
amino acids.
Renin has a molecular weight of about 40000 and a half 
life in the circulation of 15-30 minutes. It is 
metabolised mainly by the liver. Larger inactive forms of 
renin ("big renins") have been isolated from the kidney 
and found in plasma. The significance of these inactive 
forms of renin which can be activated by trypsin, 
acidification or storage of plasma in the cold is not yet 
known.
1.2.3 Angiotensin I
Angiotensin I, a decapeptide, is the product of the action 
of renin on angiotensinogen. It has little or no
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intrinsic pharmacological activity.
1.2.4 ACE
Angiotensin converting enzyme was discovered by Skeggs and 
co-workers (Skeggs et al, 1956). It is a single chain 
glycoprotein and has a molecular weight of 140000-480000, 
depending on the source of the enzymes and the techniques 
used to solubilise them. ACE is a metallopeptidase with 
zinc in the active centre, hence its inhibition by metal 
binding agents (Erdbs, 1975). Activation of enzyme 
activity by chloride and other monovalent anions is 
possibly due to the protection from methylation of a 
single lysine residue at or near the active site (Shapiro 
and Riordan, 1983). It is now recognised that ACE is very 
widely distributed in the body and in addition to cleaving 
AI by the removal of a dipeptide in vascular beds, it 
catalyses the hydrolysis of peptides in ways other than by 
the release of the C-terminal dipeptide.
1.2.4.1 Purification And Substrate Specificity 
Angiotensin converting enzyme was first purified from 
animal tissues (Erdtis, 1975) and then from human tissues 
(Erdtis and Skidgel, 1985). The human enzyme appeared to 
be more hydrophobic than that extracted from animal lung 
or kidney. Its substrates include enkephalins (Palenker 
et al, 1984), the precursors of the enkephalins (Norman, 
1985, Yang et al, 1981) and bradykinin (Erdtis and
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Yang, 1967), all of which have a free C-terminus. In 
addition to substrates with a free C-terminal amino acid, 
ACE also cleaves peptides with a protected C-terminus such 
as Substance P (Skidgel et al, 1984) and luteinising 
hormone releasing hormone (LHRH) (Skidgel and Erdtis,
1985). In addition, LHRH has a blocked N-terminus which 
can also be cleaved by ACE.
1.2.4.2 Distribution
Immunohistochemical techniques have been used to 
demonstrate the cellular and subcellular localisation of 
the enzyme. In man the enzyme is detected in the vascular 
endothelium of most organs and in the epithelium of the 
renal proximal tubule and intestine (Takada et al, 1981).
At the ultrastructural level the enzyme is located on the 
luminal surface of the vascular endothelial cells (Takada 
et al, 1982), thus ACE maintains direct contact with the 
blood in the pulmonary circulation, one of the major sites 
of conversion of Al to All. Within the kidney the enzyme 
is localised mainly on the brush border membrane and to a 
lesser extent, on the intercellular and basal infolding 
membrane of proximal tubular cells (Takada et al, 1982).
Kinins which enter the kidney from plasma are eliminated
by ACE in the proximal tubules (Erdtts, 1979). Human
prostate contains a high amount of the enzyme (van Sande 
et al, 1985) as does the placental microvilli (Johnson et 
al, 1984). The function of ACE in these locations is as
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yet unknown.
1.2.4.3 Regulation Of ACE Biosynthesis
The regulation of ACE is not well known but three stimuli 
to ACE biosynthesis have been documented, treatment with 
glucocorticoids, by macrophage activating factors and 
treatment with ACE inhibitors. Fyhrquist et al (1983a) 
treated Wistar-Kyoto rats for 14 days with either a) 
control b) captopril c)dexamethasone or d) captopril + 
dexamethasone. Both the dexamethasone and captopril 
increased the ACE content in purified lung plasma membrane 
but only captopril increased serum ACE. Macrophage 
activating stimuli such as E. Coli lipopolysaccharide B 
have been shown to potentiate the cellular increase of ACE 
in response to captopril in adherent macrophages prepared 
from peripheral defibrinated blood (Fyhrquist et al, 
1983b). Both captopril and enalapril have been shown to 
induce biosynthesis in rats (Fyhrquist et al, 1980, and 
Forslund et al, 1982) and in man (Fyhrquist et al, 1983b) 
The precise mechanism of ACE induction and its possible 
biological relevance await further clarification.
1.2.5 Angiotensin II
Angiotensin II is the octapeptide released from Al after 
the removal of histidyl-leucine by ACE. All is rapidly 
removed from the circulation by uptake into tissues and 
metabolism by the angiotensinases to form angiotensin III
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and then to inactive peptide fragments.
All is the most potent vasoconstrictor substance known. 
On a molar basis it has approximately forty times the 
potency of noradrenaline. The effect is exerted by a 
direct action on vascular smooth muscle, however, the 
action is not uniform for all blood vessels. The most 
potent vasoconstriction occurs in the vessels of the skin, 
kidneys and splanchic region. Less pronounced effects are 
seen in brain and skeletal muscle blood vessels. 
Arterioles exhibit a more pronounced vasoconstriction than 
that in veins (Kostis et al, 1987). In addition to its 
direct vasoconstrictor action, All releases catecholamines 
from the adrenal medulla, acts on the cells of the zona 
glomerulosa in the adrenal cortex to release aldosterone 
and contracts smooth muscle in the gastrointestinal tract, 
the urogenital system and the bronchi. Within the central 
nervous system All increases arterial pressure by 
increasing sympathetic nervous activity and can produce 
marked changes in hydration.
1.2.6 Tissue ACE Systems
An increasing number of studies suggest the existence of 
local angiotensin generating systems within individual 
tissues ( Dzau, 1987 and Unger et al, 1988). The local 
tissue systems may be involved in blood pressure 
regulation, either independently of, or in conjunction
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with the circulating RAS. The existence of discrepancies 
between levels of renin in the plasma and blood pressure 
levels during long term use of the ACE inhibitors (Waeber 
et al, 1980) indicates the involvement of the tissue 
systems during the response to chronic ACE inhibitor 
therapy (Dzau, 1989). It is clear that the physiological 
control of blood pressure, whether by a circulating 
endocrine system, by a series of local tissue systems or a 
synergistic action of the two types of system, remains to 
be established.
1.3 The Development Of Captopril And Enalapril
The action of most drugs is initiated by the interaction 
of the drug molecule to specific receptors, the chemical 
constitution of which is unknown. For ACE inhibitors the 
receptor is the active site of the enzyme and the 
development of these drugs was highly dependent on an 
understanding of the active site of ACE.
The isolation of specific inhibitors of ACE from the venom 
of Bothrops Jaracara (Ferreira, 1965) and the widespread 
study of the substrate specificity of ACE with simple 
peptide substrates enabled a picture of the active site of 
ACE to be built up (Ondetti et al, 1977). Early studies 
indicated that peptide substrates bound to the active site 
of ACE via their carboxyl-terminal tripeptide residues and 
this region of the active site was designated the 
'obligatory binding site' (Figure 1.1). Three discrete
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FIGURE 1.1
A Diagramatic Representation Of The Binding Site Of ACE
areas within the the obligatory binding site that 
specifically interact with the amino acid side chains of
i i
substrates were named subsites S , S and S . It was also
1 1 2
clear from these early studies that a positively charged 
group on the active site of ACE formed an ionic bond with 
the negatively charged terminal group of the substrate and 
thus initiated the proper alignment of the terminal amino 
acid residues of the substrates with subsites of the 
active site. In addition to the subsites, it was seen 
that the zinc ion of ACE was located between two of the
subsites and participated in the hydrolytic cleavage of
the peptide bond between antipenultimate and penultimate 
amino acid residues of the substrate. A further 
interaction between ACE and various substrates led to the 
inclusion in the obligatory binding site model of a
hydrogen bond donating group, also located between the
subsites, this group could bind the terminal nonscissile 
bond of a peptide substrate (Cushman et al, 1981). An 
effective inhibitor of ACE must bind to these sites 
although binding to other sites on the enzyme is also 
possible (auxiliary binding).
Teprotide (SQ 20,881), was first isolated from the venom 
of Bothrops Jaracara, sequenced and then synthesised. 
Although it is an effective antihypertensive drug its lack 
of oral activity would severely restrict its use. Thus, 
in early 1974 the efficacy of ACE inhibitors as 
antihypertensive drugs had been demonstrated and awaited
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the development of an orally active agent.
As the understanding of the nature of the active site 
grew, it led to the design and synthesis of hundreds of 
specific active site binding agents and eventually in 
1980, to the introduction onto the market of captopril, 
the first orally effective ACE inhibitor available for 
medical use. Early studies with captopril were associated 
with a high incidence of side effects, some of which were 
potentially quite severe (Vlasses et al, 1982). Although 
these early studies were with very high doses of the drug 
it was postulated that since captopril contains a 
sulfhydryl moiety in its chemical structure, this was 
thought to be at least partly responsible for certain of 
these effects. The search for compounds that would 
inhibit ACE but were devoid of the sulfhydryl group led to 
the synthesis and evaluation of enalapril (MK421), itself 
a weak inhibitor of ACE but rapidly converted by ester 
hydrolysis to enalaprilat (MK422), a potent ACE inhibitor 
(Patchett et al, 1980). Enalapril was introduced onto the 
market in 1986.
With the increasing use of both captopril and enalapril 
there is now considerable interest in the pharmaceutical 
industry to provide additional compounds to compete in 
this lucrative market. Lisinopril was the third ACE 
inhibitor to become clinically available and was 
introduced onto the market in 1988. Many more potential 
ACE inhibitors are currently being developed.
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1.4 The Pharmacokinetics Of Captopril, Enalapril And 
Lisinopril
The elucidation of the pharmacokinetics of these compounds 
depends entirely on the existence of analytical techniques 
to measure their concentration in a variety of biological 
fluids. Whilst this has not been a major problem for 
enalapril or lisinopril, the instability of captopril in 
biological media due to rapid autoxidation to form the 
disulphide dimer (Kripalani et al, 1980), created 
difficulties in describing the pharmacokinetic profile of 
captopril as comprehensively as that for enalapril, 
during development and early after release on to the 
market.
1.4.1 Captopril
The instability of captopril in biological fluids has made 
quantitation difficult and several approaches have been 
utilised to overcome this problem. Initial method 
development involved the use of antioxidants, chelating 
agents and derivatising agents. The addition of N- 
ethylmaleimide (NEM) to collection tubes and subsequent 
derivatisation of captopril will stabilise captopril in 
blood and urine samples (Duchin et al, 1982b).
Early pharmacokinetic studies utilised thin layer 
radiochromatography (TLRC) to quantify captopril but were 
limited in that only radiolabelled drug could be
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administered. The development of gas chromatographic 
techniques with selective ion monitoring mass 
spectrometric detection (GC/MS) enabled quantitation of 
cold captopril doses. High performance liquid
chromatography (HPLC) and RIA techniques have also been 
developed.
Methods utilised in pharmacokinetic studies usually 
measure free and total captopril. Total captopril 
comprises unchanged captopril, captopril disulphide 
dimers, disulphide conjugates of captopril with low 
molecular weight thiol-containing compounds (glutathione, 
cysteine) and captopril bound to protein (via covalent 
disulphide bonds).
1 .4.1.1 Absorption
Captopril is rapidly absorbed from the gastrointestinal 
tract, peak captopril levels following a radiolabelled 
1Omg dose were reached at 0.7 hours (Duchin et al, 1982b) 
and then declined rapidly. Absolute oral bioavailability 
of captopril, calculated with reference to a 1Omg 
intravenous dose, was 62% based on urinary excretion 
values and 65% based on plasma captopril AUC values. 
There is a linear relationship between oral dose (range 
10-150mg) and the Cmax and AUC for unchanged captopril in 
plasma (Duchin et al, 1988).
The consumption of food prior to a single radiolabelled 
dose of captopril in healthy subjects has been reported to 
cause a 35 to 40% reduction in the bioavailability of
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captopril (Singhvi et al, 1982b). However, in a long term 
study in patients with essential hypertension, whilst the 
Cmax and AUC values for total and free captopril were 
slightly reduced by food consumption, the blood pressure 
lowering effect was unchanged (Ohman et al, 1985).
1 .4.1.2 Distribution
Captopril is not extensively bound to plasma proteins, 
only 23.0 and 30.6% captopril equivalents of a 
radiolabelled 5mg dose given orally were bound at 0.5 and
2 hours after dosing respectively (McKinstry et al, 1978). 
The drug is primarily bound to albumin via covalent 
disulphide linkages (Migdalof et al, 1984).
It is not known if captopril crosses the placenta in 
humans and only 1 % of the peak blood concentration was 
detectable in human breast milk (Devlin and Fleiss, 1981). 
The volumes of distribution of unchanged captopril at 
steady state following intravenous administration of 
captopril, 2.5, 5 and 10mg, were 0.84, 0.80 and 0.801/kg
respectively (Duchin et al, 1988), indicating extensive 
partitioning of captopril into the tissues.
1.4.1.3 Metabolism And Excretion
Once absorbed captopril is metabolised to several forms 
including a disulphide dimer, mixed disulphides of 
captopril and endogenous sulfhydryl compounds and some 
polar metabolites (Kripalani et al, 1980). At 1 hour
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after a radiolabelled dose of captopril, 100mg, unchanged 
captopril accounted for about 52% of total radioactivity 
in the blood and the disuphide dimer for about 10%. 
Excretion of captopril is rapid and primarily by the 
kidneys, with minor elimination in the faeces. Of the 
radiolabelled dose 86% was recovered, 67% of which was in 
the urine and 18% in the faeces. Urinary excretion of 
radioactivity was essentially complete within 24 hours, 
66% of the dose being recovered in that time and very 
little further urinary excretion on subsequent days. 
Unchanged captopril accounted for over half of the 
radioactivity excreted in the first 24 hours. The primary 
mechanism of renal elimination is tubular secretion and 
accounts for 78% of radiolabelled captopril when the drug 
is given alone (Duchin et al, 1982a). The co­
administration of probenecid with captopril reduced renal 
clearance by 44% and total clearance by 19% (Singhvi et 
al, 1982a).
The elimination half life for unchanged captopril in 
healthy subjects was found to be 1.7 and 1.9 hours 
following oral and intravenous administration of 1Omg 
captopril respectively (Duchin et al, 1982b). The 
pharmacokinetics of captopril, 100mg t.i.d. to healthy 
subjects showed no accumulation of unchanged captopril, 
but there was a significant increase in AUC for total drug 
(Kubo and Cody, 1985). A similar accumulation of total 
but not unchanged captopril was also seen in patients with 
chronic heart failure who had received 25mg t.i.d. (Cody
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et al, 1982c).
1.4.1.4 Effect Of Age And Disease States
The effect of age on the pharmacokinetics of captopril has 
been studied in twelve healthy male volunteers aged 65-7 6 
years (Creasey et al, 1986). The mean values of Cmax and 
Tmax were essentially the same as those reported in an 
earlier study in which identical study design and 
analytical methods had been used (Kripalani et al, 1980), 
indicating that age alone does not significantly affect 
the pharmacokinetics of captopril.
Acute administration of captopril, 100mg, to patients with 
hypertension (Jarrott et al, 1982) gave rise to 
pharmacokinetic parameters which were in close agreement 
to those observed in healthy volunteers (Kripalani et al, 
1980). These normal pharmacokinetic findings were 
confirmed in a further study in which 10 patients with 
essential hypertension were given captopril, 1 mg/kg 
orally, in the fasting state (Richer et al, 1984).
Single dose pharmacokinetics have been studied following a 
25mg oral dose of captopril to 12 patients with CHF in the 
fasting state (Cody et al, 1982c). The parameters 
obtained, with the exception of a slightly delayed Tmax, 
were similar to those from normal and hypertensive 
subjects.
Administration of a radiolabelled 100mg dose of captopril 
to patients with varying degrees of renal dysfunction
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indicated that a linear relationship exists between the 
overall elimination rate constant and endogenous 
creatinine clearance (over the range 0-56ml/min) (Rommel 
et al, 1980).
A further study in patients with normal renal function, 
moderate chronic renal failure and severe chronic renal 
failure showed that degree of renal impairment had no 
effect on Cmax, total clearance or relative 
bioavailability. However, the elimination rate constant 
decreased and the elimination half life increased with 
degree of renal impairment. The authors proposed a 
decrease in the dosage of captopril or an increase in the 
dosage interval in patients with moderate to severe renal 
dysfunction (Guidicelli et al, 1984).
1.4.2 Enalapril
The analytical methodology used to measure enalapril, 
radio-immunoassay (RIA) (Hichens et al 1981), is specific 
for enalaprilat (the diacid metabolite of enalapril) but 
total drug (enalapril plus enalaprilat) can be measured 
after hydrolysis of intact enalapril to enalaprilat, 
levels of enalapril may then be obtained by subtraction. 
Radiometric methods utilising radiolabelled drug and a 
more general method which relies on enalaprilat's ability 
to inhibit ACE are also commonly used to measure drug 
levels.
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1.4.2.1 Absorption
In man enalapril is well absorbed, 60-70% (Ulm, 1983), and 
is rapidly and extensively hydrolysed to enalaprilat. 
Following oral administration of 1Omg enalapril maleate, 
peak serum concentrations (Cmax) of enalapril are observed 
0.5-1.5 hours post dose and disappear from the circulation 
after about 4 hours (Ulm et al 1982). In contrast, the 
Cmax for enalaprilat is delayed, reaching a maximum at 4 
hours before declining (Ulm et al, 1982) and detectable 
levels are still found after 72 to 96 hours. In healthy 
subjects the extent of enalapril absorption and hydrolysis 
to enalaprilat appears similar over the dose range 2.5- 
40mg as the maximum serum concentration is linearly 
related to dose (Davies et al, 1984a). Till et al (1982) 
also showed that the AUC of intravenous enalaprilat, after 
factoring out the terminal phase which represented 
approximately 1mg of the dose, was linearly related to 
dose.
The presence of food did not appreciably alter the 
absorption of 40mg enalapril administered to healthy 
volunteers or the bioavailability of enalaprilat when 
compared to data obtained after administration of the drug 
in the fasting state (Swanson et al, 1984).
1.4.2.2 Distribution
Enalaprilat is less than 50% bound to plasma proteins. 
Two types of binding site have been identified, a high
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affinity low capacity site and a low affinity high 
capacity site (Davies et al, 1984b).
The nature of the distribution of enalaprilat in human 
tissue is unknown as is whether parent drug or metabolite 
can enter breast milk or cross the placental barrier. The 
intravenous administration of 1Omg enalaprilat to 9 young 
and 9 elderly subjects enabled the volume of distribution 
at steady state, adjusted for weight, to be calculated 
(Hockings et al, 1986). The value of 0.2781/kg for the 
elderly was significantly less than the value for the 
young volunteers of 0.3751/kg suggesting that enalaprilat 
distribution may be altered by ageing.
1.4.2.3 Metabolism And Excretion
In man, the rapid and extensive metabolism of enalapril to
enalaprilat occurs mainly in the liver (Ulm et al, 1982).
There is no detectable metabolism of enalapril beyond its
hydrolysis to enalaprilat (Ulm, 1983). A radiolabelled
14
study in which 1Omg of C-enalapril was given orally 
showed that more than 90% of the dose was recovered in the 
urine and faeces over 72 hours (Ulm, 1983). Most of the 
drug (61% of the dose) was in the urine, a substantial 
fraction of which (70%) was enalaprilat. The main route 
of elimination is via the kidneys and in healthy subjects 
the renal clearance of enalaprilat is 9.5 1/h (Ulm et al,
1982) which is of the same order as glomerular filtration. 
Serum profiles of enalaprilat exhibit a polyphasic decline 
with a prolonged terminal phase of the order of 35 hours,
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following both oral administration of enalapril (Ulm et 
al, 1982) and intravenous administration of enalaprilat 
(Hockings et al, 1986). Prolonged binding of enalaprilat 
to ACE and its subsequent dissociation may be responsible 
for the long half life of elimination. Despite the 
prolonged terminal phase, little accumulation of 
enalaprilat was seen following multiple dosing (Kelly et 
al, 1986, and Till et al, 1984) in subjects with a normal 
renal function.
1.4.2.4 Effect Of Age And Disease States
The influence of age on the pharmacokinetics of 
enalaprilat has been studied following acute (Hockings et 
al, 1986) and chronic (Lees and Reid, 1987) 
administration. Acute administration of 1Omg enalapril 
maleate resulted in a significant increase in the 
enalaprilat area under the curve (AUC) for the elderly 
when compared to the young volunteers (997 v 772 ng.h/ml). 
Total systemic clearance (Cl/F) was significantly reduced 
in the elderly. Renal function as measured by creatinine 
clearance was also significantly less in the elderly and 
was positively correlated with enalaprilat clearance. 
There was no difference in the response of young and 
elderly to repeated administration of the drug.
The influence of various degrees of renal impairment on 
the pharmacokinetics of enalaprilat has been studied 
(Kelly et al, 1986 and Lowenthal et al, 1985). Renal
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impairment resulted in elevated serum concentrations,
delayed time to peak concentration (Tmax), decreased
excretion rates and reduced urinary elimination. A
threshold level of renal impairment (GFR less than 
2
30ml/min/1.73m ) exists below which smaller doses of 
enalapril are required when compared to patients with 
normal or less severly impaired renal function (Kelly et 
al, 1986). A similar threshold for creatinine clearance 
(less than 60ml/min) has been reported (Lowenthal et al,
1985) below which serum concentrations of enalaprilat are 
related to kidney function.
The pharmacokinetics of enalapril have been studied in 
patients with CHF (Dickstein et al, 1987, and Swartz et 
al, 1985). Following single dose administration of 
enalapril there was a slower clearance of enalapril and 
reduced elimination of enalaprilat in patients with CHF 
compared to those with hypertension, however, the 
differences may be associated with age as well as disease 
state. After twice daily administration of enalapril for 
two weeks, plasma enalaprilat levels were similar in 
patients with CHF and hypertension (Johnston et al, 1984).
1.4.3 Lisinopril
Lisinopril, like enalaprilat, can be measured by specific 
RIA (Hichens et al, 1981, Worland and Jarrott, 1986) or 
any of the more general methods relying on the drugs 
ability to inhibit ACE.
45
Lisinopril has only recently been introduced onto the 
market and so the number of published studies describing 
the pharmacokinetics of the compound are fewer than for 
enalapril.
1.4.3.1 Absorption
Lisinopril is absorbed intact following oral 
administration and is not metabolised further, so, for 
this drug, bioavailability equals absorption. The 
absorption of lisinopril after oral administration is 
slower than that for enalapril, peak serum concentrations 
were attained at about 6 hours after oral administration 
of a 1Omg dose to healthy subjects (Beerman et al, 1985, 
Mojaverian et al, 1986). Absorption, based upon urinary 
recovery following oral administration of 1Omg to normal 
volunteers was 29% (Ulm et al, 1982). Similarly, 
bioavailability was found to be 25% when compared to the 
same dose administered intravenously (Beerman et al,
1986). Administration of lisinopril with food did not 
appreciably alter its absorption (Mojaverian et al, 1986).
1 .4.3.2 Distribution
Ultrafiltration studies have shown that lisinopril binds 
to human serum only to a very small extent, possibly only 
to ACE present in the serum with little or no binding to 
other serum components ("Zestril". ICI Product Monograph). 
The volume of distribution after oral administration
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(Vd/F) of 10mg to 19 healthy subjects was found to be 124 
litres (Ajayi et al, 1985). Given that the 
bioavailability of this dose has previously been found to 
be approximately 25%, the value of Vd/F indicates 
extensive partitioning of lisinopril into the tissues. No 
information is yet available as to whether the drug enters 
breast milk or is transferred across the placenta.
1.4.3.3 Metabolism and Excretion
Lisinopril is not metabolised in man and is excreted 
unchanged, primarily in the urine. Following 
administration of 1Omg to twelve healthy subjects 29 and 
69% of the dose were recovered in the urine and faeces 
respectively (Ulm et al, 1982). Urinary recovery of an 
intravenous dose is essentially complete (Beerman et al,
1986).
The elimination of lisinopril from plasma is polyphasic 
with a prolonged terminal phase which has a half life of 
about 30 hours (Ulm et al, 1982). As with enalaprilat, 
the long terminal phase has been said to represent 
saturable binding to ACE. An effective half life of 12.6 
hours has been reported, steady state concentrations being 
reached within three days with once daily administration 
(Beerman et al, 1985, 1986).
1.4.3.4 Effect Of Age And Disease States
The effect of age on lisinopril pharmacokinetics has been 
studied by Cirillo et al (1986) and Gautam et al (1987).
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Elevated serum concentrations were found in the elderly 
following oral administration of 20mg lisinopril to two 
groups of 8 young and old healthy subjects. However, 
following administration of 5mg/day for 7 days to 6 young 
and old healthy subjects lisinopril clearance was found to 
be significantly correlated with creatinine clearance and 
so the elevated serum levels of lisinopril in the elderly 
possibly reflect a decreased renal function associated 
with increasing age.
The influence of various degrees of renal impairment on 
the pharmacokinetics of lisinopril has been studied after 
acute and chronic oral administration of 5mg (Kelly et al, 
1987, van Schaik et al, 1987 and Jackson et al, 1988a). 
The effect of haemodialysis has also been examined (Kelly 
et al, 1988). In patients with severe renal failure peak 
concentrations were higher, the decline in serum 
concentrations was slower and the time to peak serum 
concentration extended. The changes in the
pharmacokinetics were correlated with creatinine 
clearance. Haemodialysis had a large effect on the plasma 
levels of lisinopril, haemodialysis plasma clearance was 
of the order of 40ml/min.
Till et al (1989) and Gautam et al (1987) have studied 
the pharmacokinetics of lisinopril in patients with heart 
failure. Absorption of an oral dose of lisinopril is 
reduced in patients with congestive heart failure when 
compared to normal subjects (16% vs 29%). Clearance of
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intravenous lisinopril is reduced in congestive heart 
failure patients although this could be a function of age 
associated with a reduced renal clearance. It has been 
speculated that the reduced clearance is associated with a 
decrease in the apparent volume of distribution. Thus, in 
CHF patients given oral lisinopril, the plasma
concentrations are a result of reduced absorption and 
clearance and could be reduced when compared to normal 
subjects. However, after intravenous administration 
elevated plasma levels may be seen.
1.4.4 Other ACE Inhibitors Under Development
Many other ACE inhibitors are currently under development, 
two that have been introduced onto the market are,
quinapril and perindopril, both are non sulfhydryl
containing molecules.
A new chemical class of ACE inhibitors has recently been 
developed (Petrillo et al, 1987), the phosphorus 
containing compounds such as fosinopril. This class of 
compounds have a somewhat different structure activity
relationship when compared to the sulfhydryl containing 
compounds or the carboxyalkyldipeptides (Ondetti, 1988).
1.5 The Effect Of ACE Inhibition On The Renin Angiotensin 
System
The changes seen in the plasma RAS brought about by ACE
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inhibitors depend on the state of activation of the system 
and the pathophysiological state of the patient prior to 
administration of the drug. Different results may 
therefore be obtained depending on the patient population, 
study design and analytical techniques employed.
Oral administration of captopril or enalapril causes a 
marked reduction in plasma All and an increase in AI and 
plasma renin activity (PRA). After inhibition of ACE an 
increase in renin release rather than accumulation of AI 
(Nussberger et al, 1987) causes the rise in AI which is 
then degraded quickly to inactive compounds. The increase 
in PRA is probably due to the loss of feedback inhibition 
by All and decreased renal perfusion pressure (Johnston et 
al, 1984, and de Leeuw et al, 1983). The fall in All 
brings about a gradual reduction in plasma aldosterone 
concentrations although levels may slowly return to 
pretreatment values during chronic therapy (Johnston et 
al, 1984).
1.6 Haemodynamic Effects Of ACE Inhibitors In 
Hypertensive Patients
Acute interference with the RAS using ACE inhibitors has 
been shown to produce a substantial blood pressure 
lowering effect, not only in patients with high and normal 
renin levels but. also in those exhibiting a suppressed 
renin secretion (Gavras et al, 1981). The reduction in
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blood pressure is due to lowering of systemic vascular 
resistance secondary to a reduction in All mediated 
vasoconstriction. The scale of the initial reduction in 
blood pressure has been found to be directly related to 
the pretreatment plasma renin and All levels (Atkinson and 
Robertson, 1979). In some investigations carried out in 
small numbers of patients however, the magnitude of blood 
pressure reduction did not correlate with baseline plasma 
renin activity levels (Gavras et al, 1981). The
relationship between pretreatment plasma renin activity 
and the resulting fall in blood pressure due to ACE 
inhibition tends to be weaker when the long term rather 
than the initial blood pressure response is considered 
(Case et al, 1980).
The time courses of the acute blood pressure lowering 
effects of captopril and enalapril are not the same. The 
first dose of captopril induces a rapid decrease that is 
evident within 15 minutes and reaches its peak by 0.5-1. Oh 
post dose (Brunner et al, 1979). In comparison, the blood
pressure reduction induced by enalapril is delayed, peak
effect is approximately 4h post dose and persists for
several hours (Gavras et al, 1981). Blood pressure can be 
kept at a low level throughout the day during chronic 
therapy with an ACE inhibitor even when 24h blockade of 
the plasma RAS is not achieved (Waeber et al, 1980). 
Characteristically, heart rate does not accelerate when 
blood pressure is reduced with an ACE inhibitor (Campbell 
et al, 1982, and Millar et al, 1982). The lack of change
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in heart rate may be due to the simultaneous fall in left 
ventricular filling pressure and/or an interaction with 
the autonomic nervous system. No change in noradrenaline 
levels or significant effects of drug treatment on a 
variety of tests of autonomic function were seen in normal 
subjects (Millar et al, 1982). However, enalapril has 
been shown to induce a resetting of the baroreflex in 
normotensive subjects (Guidicelli et al, 1985) and this 
could probably account for the lack of reflex tachycardia. 
Cardiac output is unchanged or slightly increased due to a 
rise in stroke volume.
Acute ACE inhibition with captopril consistently increased 
renal plasma flow with no parallel change in the GFR in 
patients on unrestricted sodium intake (Mimram et al, 
1979). In one patient on a low sodium intake however, GFR 
was significantly increased. Cerebral blood flow 
measurements in 20 patients after 8 weeks of treatment 
demonstrated that good blood pressure control was achieved 
without reducing cerebral blood flow (Frei and MUller- 
Brand, 1986) .
1.7 Haemodynamic Effects Of ACE Inhibitors In Patients 
With Cardiac Failure
Cardiac failure is manifested by reduced left ventricular 
systolic function and reduced cardiac output and stroke 
volume. As end diastolic volume increases to compensate
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for decreased output, left ventricular wall stress and 
pulmonary capillary wedge pressure increase. Compensatory 
mechanisms that are activated to maintain perfusion 
pressure to vital organs include vasoconstriction and 
sodium retention by the kidney to increase total blood 
volume. The vasoconstriction although initially a 
beneficial compensatory response may contribute to the 
progression of heart failure. Circulatory levels of 
noradrenaline are also elevated and the heightened 
sympathetic tone contributes to the elevation of systemic 
vascular resistance and arterial vasoconstriction (Cody et 
al, 1982a). The decreased renal perfusion pressure, 
reduction in distal tubular sodium as sensed by the macula 
densa and enhanced sympathetic nervous system activity 
will all contribute to the stimulation of the RAS in 
chronic heart failure.
The magnitude of the haemodynamic response following the 
first dose of captopril (Cody and Laragh, 1982b, and 
Levine et al, 1980) and enalapril (Cody et al, 1983)
appears to be closely related to the baseline level of RAS 
activity as estimated by plasma renin activity. In 
general the acute haemodynamic effects of enalapril and 
captopril are qualitatively similar with important
differences in the time course of the changes. Oral
administration of both drugs leads to a reduction in 
systemic vascular resistance due to a reduction in All 
mediated vasoconstriction. The reduction in systematic 
resistance is usually accompanied by a reduction in mean
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arterial pressure. The reduced afterload results in 
improvements in cardiac output and stroke volume and a 
reduction in pulmonary capillary wedge pressure. Heart 
rate is generally unchanged (Cody and Laragh, 1982b, and 
Cody et al, 1983) although profound bradycardia associated 
with hypotension has been seen during the initiation of 
captopril (Ader et al, 1980) and enalapril (Dicarlo et al,
1983). The first dose hypotension can usually be 
minimised by starting with low doses and titrating 
upwards.
1.8 Mechanism Of Action Of ACE Inhibitors
Although ACE inhibitors seem to exert their primary effect 
via inhibition of ACE there has been considerable indirect 
evidence that this may not be their only mode of action. 
In part this stems from the fact that ACE degrades the 
potent vasodilator bradykinin, the level of which has been 
reported to rise after captopril (Williams and Hollenberg, 
1977). Other studies have failed to demonstrate a 
significant increase (Shoback et al, 1983). The 
conflicting results are difficult to assess because of the 
lack of accurate and reproducible bioassays for kinins. 
Also, as the principle site of action for the kinins is 
within the tissue it is not unreasonable that measurements 
of total kinin concentrations in circulating plasma 
necessarily reflect the true role of the kinin system in
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blood pressure regulation.
Direct or indirect effects between the vasodilatory
prostaglandins, especially PGE and PGI and the RAS have
2 2
been proposed (Wennmalm, 1979). Although an association
has been indicated (Moore et al, 1981) no consistent
relationship between blood pressure effects of ACE
inhibitors and changes in plasma or urinary metabolites of
these prostaglandins has been observed (Hornych et al,
1982, and Freeman et al, 1984). Shoback et al (1983) and
Swartz (1987) compared the effects of captopril and
enalapril on PGE metabolite production. In both studies
2
increases in PGE metabolite were demonstrated only with
2
captopril and not with enalapril. Vlasses et al (1984), 
by demonstrating that captopril and enalapril reduce blood 
pressure to a similar extent and that adding the two ACE 
inhibitors together did not result in a further blood 
pressure reduction, suggested that the two drugs shared a 
common antihypertensive action. This further questions 
the relevance of the changes in prostaglandins reported 
for captopril.
The complex clinical effects of ACE inhibition appear to 
be a result of inhibition of both the kinin and renin 
angiotensin systems, both in plasma and in tissue. In 
most instances, the inhibition of the production of All is 
the predominant mechanism whereby these drugs mediate 
their effects (Edwards and Padfield, 1985).
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1.9 Scope Of Thesis
Despite the fact that the use of ACE inhibitors has become 
an established treatment for hypertension and heart
failure, the exact nature of the pharmacokinetics and 
pharmacodynamics and the interaction of the two has not 
been adequately described. The thesis presented herein 
describes some studies designed to further evaluate the 
disposition characteristics and concentration effect 
relationships of the ACE inhibitors.
The background information and an introduction to the
thesis are presented in chapter 1, materials and methods 
are described in chapter 2.
For any drug, the understanding and description of its
pharmacokinetic properties is entirely dependent on the 
availability of analytical methodology to measure drug 
levels in a variety of biological fluids. Chapter 3 
presents a comparison of several different techniques to 
analyse plasma samples for both ACE activity and active
ACE inhibitor drug levels. The methods used are compared 
and contrasted by different statistical techniques.
For both captopril and enalapril the initial dose range 
was reduced after introduction onto the market, probably 
due to the initial doses being at the top of the dose 
response relationship. Much of the early work to 
elucidate the structure activity relationships and hence 
the dose response relationship was done in animal species.
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For this reason, in chapter 4, comparisons of the in vitro 
potencies of the active species of several ACE inhibitors 
within individual rabbits and men have been made. The 
effect of parent compound on the in vitro potency of the 
metabolite has also been studied. In addition the in 
vivo/in vitro relationship for inhibition of plasma ACE 
has been examined with reference to perindoprilat and 
quinaprilat, the active metabolites of perindopril and 
quinapril respectively.
With the exception of captopril, for all ACE inhibitors 
currently in use, long terminal half lives have been 
reported which are of doubtful clinical significance. It 
has been proposed that drug persistence during this long 
terminal phase represents binding to ACE, a saturable 
phenomenon, and consequently makes no contribution to the 
accumulation of these drugs with chronic administration. 
The contribution of binding by spiraprilat to plasma and 
ACE tissue sites to the pharmacokinetics of the compound, 
in rabbit, was studied in chapter 5.
In chapter 6 a study was carried out with enalapril and 
its active metabolite enalaprilat. The study was designed 
to elucidate the contribution of the long terminal phase 
of elimination to pharmacokinetics of enalaprilat, in man. 
Administration of any drug to different subgroups of the 
population, for example the elderly or patients with renal 
disease, may give rise to a different pharmacokinetic 
profile. In chapter 7 the effect of age on the 
pharmacokinetics of benazepril, an ACE inhibitor currently
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under development, was examined. The clinical rslsvance 
of induction of ACE following chronic administration of 
ACE inhibitors was also considered, again with reference 
to benazepril. In addition to standard compartmental 
models, pharmacokinetic models that take into account the 
binding of drug to ACE in plasma and/or tissue were used 
to describe the benazeprilat data.
Chapter 8 contains a discussion of the pharmacokinetics of 
the ACE inhibitors with reference to the work presented in 
this thesis.
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CHAPTER 2 
MATERIALS AND METHODS
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2.1 MATERIALS
2.1.1 Chemicals
Di-potassium hydrogen orthophosphate tri-hydrate, sodium 
di-hydrogen orthophosphate, di-sodium hydrogen
orthophosphate, sodium metabisulfite, hydrochloric acid 
(sp. gr. 1.18), glacial acetic acid and orthophosphoric 
acid (sp. gr. 1.75) were obtained from BDH Chemicals Ltd., 
Poole, Dorset. Sodium chloride was obtained from 
Formachem, Strathaven. Ethyl acetate, methanol and 
ammonium acetate were obtained from May & Baker Ltd., 
Dagenham. Potassium di-hydrogen orthophosphate (HPLC 
grade) was obtained from FSA Laboratory Supplies,
Loughborough. Charcoal (Norit A) was obtained from Serva,
Heidelberg. Phthalic acid, hippuric acid, bovine serum 
albumin, dextran (Mol. Wt. 9400), chloramine T, sodium 
iodide, rabbit gamma globulin, EDTA (di-sodium salt) and 
hippuryl-his-leu (Hip-His-Leu) (free base) were obtained 
from Sigma, Poole, Dorset. Donkey anti-rabbit globulin 
was obtained from Immuno Diagnostic Systems Ltd., Tyne & 
Wear. Ecoscint was obtained from National Diagnostics, 
New Jersey. Rabbit serum, used as a source of ACE
activity, was supplied by the Scottish Antibody Production 
Unit (Law Hospital, Carluke). Hionic Fluor and Soluene 
were obtained from Packard, Pangbourne, Berks.
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2.1.2 Radiochemicals
14 125
(Glycine-1- C)Hippuryl-His-Leu, I-Sodium iodide and
3
H-n-hexadecane were obtained from Amersham International 
pic, Amersham.
2.1.3 Consumables
SP-Sephadex C25 was obtained from Pharmacia Fine 
Chemicals, Uppsala. Dialysis membranes (Visking Tubing, 
size 9-36/32") were obtained from Medicell International 
Ltd., London. Polypropylene tubes were obtained from 
Sarstedt, Leicester. HPLC vials and caps were obtained 
from Chromacol Ltd., London. Polythene tubing (ID 1.50mm, 
OD 2.70mm) was obtained from Portex, Hythe, Kent. Aqueous 
filters, 0.8 micron, were obtained from Millipore, 
Molsheim, France.
2.1.4 Drugs
Enalapril, enalaprilat, MK-351A and MK-422 antibody were 
gifts from Merck Sharp & Dohme Research Laboratories, 
Pennsylvania, USA. Benazepril (CGS 14824A) and 
benazeprilat (CGS 14831) were gifts from Ciba-Geigy Ltd., 
Basle, Switzerland. Captopril was a gift from E.R. Squibb 
and Sons Ltd., Moreton, England. Quinapril and 
quinaprilat were gifts from Warner-Lambert, Michigan, USA. 
Perindopril, perindoprilat, S-9650 and S-10211 were gifts
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Perindopril, perindoprilat, S-9650 and S-10211 were gifts 
from Servier Institute of International Research, Neuilly 
sue Seine Cedex, France. Trandolaprilat (RU 44403) was a 
gift from Roussel UCLAF, Romainville, France. spiraprilat 
was a gift from Sandoz, Basle, Switzerland. 3H- 
Spiraprilat was gift from Sandoz, Hanover, New Jersey, 
USA.
2.1.5 Equipment
2.1 .5.1 HPLC Apparatus
Two HPLC systems were used. The first system consisted of 
a Hewlett Packard 1084B Liquid Chromatograph connected to 
a Pye Unicam variable wavelength UV detector set at 228nm 
and a Hewlett Packard 79850B integrator. The second 
system consisted of a Waters 510 pump, Waters WISP 71 OB 
autosampler, Waters 481 Spectrophotometer set at 228 nm 
and a Waters 740 integrator. The column used in both 
systems measured 10cm by 4mm (i.d.) and was packed with 
Spherisorb 5 micron ODS-1.
2.1.5.2 Protein Binding Apparatus
The binding of drugs under study was determined using the 
Dianorm Equilibrium Dialyser (MSE) equipped with Macro 
D1000 Teflon cells (volume 1.0ml per half cell). The 
advantages of this system were that standardised 
equilibrium dialysing experiments could be performed in up 
to 20 cells simultaneously, short dialysis times could be
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achieved due to thorough mixing brought about by the slow
rotation of the cells and that the teflon cells minimised
adsorption to the cell wall. Dialysis was carried out in a
o
temperature controlled water bath at 37 C with a constant 
rotational speed of 8rpm.
2.1.5.3 Gamma Counter
The gamma counter used was a Packard Cobra, model 5005, an 
automated counter system with five detectors for the 
quantitative measurement of gamma radiation. The system 
was controlled by an IBM compatible computer. The 
detectors consist of 1.5 inch thallium-activated, sodium 
iodide crystals of the through-hole design. Crystal 
design is important in assuring that when gamma rays fall 
on the crystal, most of the energy is absorbed by the 
crystal and is not scattered and lost. Gamma rays which 
traverse the sodium iodide crystal interact with electrons 
in the crystal to produce scintillations of light which 
are detected at the end of the photomultiplier tube (PMT). 
Output at the end of the PMT is proportional to the gamma 
ray energy absorbed by the detector crystal.
2.1.5.4 Hamilton Microlab M
The Microlab M is a programmable microprocessor controlled 
diluter/dispenser for fast accurate diluting and 
dispensing. Its ability to be used as a multi reagent 
diluter lends it to be used in radioimmunoassays (RIA).
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2.1.5. 5 Scintillation Counter
The scintillation counter used was a Packard Model 3255 
Tri-Carb liquid scintillation spectrometer system. The 
detection system consists of two matched bialkali PMT's. 
Background noise from the detector was reduced by the 
presence of a high speed coincidence circuit. Beta energy 
released from samples excites the scintillation fluid 
causing it to emit photons of light which interact with 
the bialkali cathode and eject photoelectrons. These are 
then multiplied by a series of diodes and detected as an 
electrical pulse at the end of the PMT. The height of the 
pulse is proportional to the energy of the beta particles 
in the sample.
2.2 METHODS
The quality control data and details of accuracy and 
precision of the methods described will be presented, 
compared and discussed in Chapter 3.
2.2.1 Iodination Of MK-351A
2.2.1.1 Solutions
2.2.1.1.1 MK-351A
MK-351A was supplied in 0.98mg quantities. The compound 
was taken up in 1ml distilled water to give a solution of 
0.98mg/ml which was then diluted 1:19.6 to give a working
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solution of 0.05mg/ml, 5 pi of which was taken for
iodination.
2 .2.1.1.2 0.5M Phosphate Buffer pH 7.5
Solutions of NaH PO and Na HPO were prepared by
2 4 2 4
dissolving 7.8g and 7.1g respectively in 100ml distilled
water. The NaH PO was added to the Na HPO using a
2 4 2 4
pasteur pipette until the pH reached 7.5.
2.2.1.1.3 0.1M Phosphate Buffer pH 7.5
The 0. 5M Phosphate buffer was diluted 1 :5 to give 0.1M 
buffer and the pH checked to ensure it was still 7.5.
2.2.1.1.4 Chloramine T
This reagent was freshly prepared prior to use. 10mg of 
chloramine T was weighed into a glass vial and 10mls of 
0.1M phosphate buffer pH 7.5 added.
2.2.1.1.5 Sodium Metabisulfite
This reagent was freshly prepared prior to use. 100mg 
sodium metabisulfite was weighed into a glass vial and 
20ml distilled water added.
2.2.1.1.6 Sodium Iodide/ Bovine Serum Albumin
This reagent was freshly prepared prior to use. 100mg of 
sodium iodide was weighed into a glass vial and 10ml 
distilled water added. 100mg of bovine serum albumin was
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weighed into a further glass vial and the sodium iodide 
added by pasteur pipette.
2 .2.1.1.7 0.1M Ammonium Acetate Buffer pH 3.5
3.854g of ammonium acetate was dissolved in approximately 
150-200mls distilled water. The pH was adjusted to 3.5 
using glacial acetic acid and the volume made up to
500mls. The pH was then rechecked.
2.2.1.1.8 0.1M Ammonium Acetate Buffer pH 3.0
The buffer was made as above except that the pH was
adjusted to 3.0.
2.2.1.1.9 0.01M Ammonium Acetate Buffer pH 3.0
The 0.1M ammonium acetate buffer pH 3.0 was diluted 1:10 
with distilled water and the pH rechecked.
2.2.1.2 Setting Up Of Separation Column
Approximately 5-8g of SP-sephadex C25 was mixed with 0.01M 
ammonium acetate buffer pH 3.0. A 5ml disposable plastic 
syringe was clamped by a retort stand behind a lead 
shield. A glass wool plug was inserted inside the bottom 
of the syringe and a thin plastic tube with a gate clamp 
attached to the syringe nozzle. The syringe was filled
with the sephadex C25 up to the 5ml mark and washed with
0.01M ammonium acetate buffer pH 3.0.
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2.2.1.3 Reaction Step For Iodination
The 1 0 1 1 mCi Na Iodide was opened according to the
Amersham instruction sheet, within a fume hood, behind a 
lead shield. Added to the radioactive compound in 
succession were 5/Jl (250ng) MK-351A, 25/il 0. 5M phosphate
buffer pH 7.5, 10yL/1 chloramine T, the mixture vortexed and 
the stop clock started. The reaction was terminated after 
45 seconds by the addition of 10jJl sodium metabisulfite 
and 50/L/l sodium iodide/ bovine serum albumin.
2.2.1.4 Separation Of Radiolabelled MK-351A
The reaction mixture was transferred to the 5ml syringe 
and washed with 20mls 0.01M ammonium acetate buffer pH 
3.0. The wash buffer was collected in a beaker for safe 
disposal. The radiolabelled compound was then eluted with 
0.1M ammonium acetate buffer pH 3.5 and collected as 1ml 
fractions. The fractions were counted in a gamma counter 
and the fractions with the highest counts pooled and 
stored (approximately fractions 12-25) in a universal 
container at room temperature. The elution of radioactive 
MK-351A is shown in Figure 2.1.
2.2.2 Determination Of ACE Activity By The Measurement 
Of The Formation Of Hippuric Acid From Hip-His-Leu
Hip-His-Leu is a synthetic substrate for ACE. By 
quantifying the amount of hippuric acid formed by the 
action of ACE on Hip-His-Leu an indirect index of ACE
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The Elution Of Radiolabelled MK-351 A
activity can be calculated. One unit of ACE activity
(1EU/l) is that which produces 1 Mole hippuric acid per 
o
minute at 37 C.
2.2.2.1 Solutions
2.2.2.1.1 100mM Potassium Phosphate Buffer pH 8.3
(Substrate Buffer)
5.705g of K HPO and 4.375g NaCL were dissolved in 250mls 
2 4
distilled water. 1.361g of KH PO was dissolved in 100mls
2 4
distilled water. The monopotassium salt was then added to 
the dipotassium salt until the pH reached 8.3.
2.2.2.1.2 5mM Hip-His-Leu (Substrate)
21.48mg Hip-His-Leu was dissolved in 1Omls assay buffer. 
This was freshly made for each assay since there is a 
gradual degradation of the substrate to hippuric acid, the 
reaction product.
2. 2. 2.1.3 Internal Standard
20.4mg phthalic acid was dissolved in 20mls methanol and 
made up to 100mls with distilled water. The solution was 
then diluted 1:2.5 with distilled water to give the 
working solution (0.40mMol/l)
2.2.2.1.4 Hippuric Acid Standards
179.2mg of hippuric acid was added to 100mls of distilled
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water, & 0 1 which was taken amd madte nip t©> ©^siils with
drug free plasma (5mMol/l)„ a  standard calibration line 
of hippuric acid over the range 0,05 to 1,0w»ol/X was 
prepared.
2 . 2 . 2 .1.5 Mobile Phase
5.44g KH PO (HPLC grade) was dissolved in 1,51 distilled 
2 4
water and the pH adjusted to 4,0 with orthophosphoric
acid. The volume was made up to 2,01 with distilled
water, 140mls discarded and replaced with 140mls methanol. 
The mobile phase was filtered through a 0.8 micron aqueous 
filter and finally degassed by bubbling helium through for 
a minimum of 10 minutes.
2. 2.2.2 Analytical Procedure
2 . 2.2.2 .1 Procedure For Standards
Into 4ml polypropylene tubes in duplicate was placed;
a) 200pl substrate buffer.
b) 50/J1 50%HCL (v/v). Vortex briefly.
c) 20jUl standard plasma.
d) 50/J1 internal standard solution. Vortex briefly.
e) 50mg (approximately) NaCl. Vortex briefly.
f) 1ml ethyl acetate. Vortex for 15 seconds.
g) Centrifuge at 2000rpm for 5 minutes.
h) Remove 500 U1 of the organic layer to a clean 4ml
o
polypropylene tube and concentrate under air/N at 37 C.
2
i) When dry add 100)1/1 of mobile phase and vortex briefly.
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j) Inject 20^1 onto HPLC system.
2 .2. 2. 2.2 Procedure for Unknown Samples
Into 4ml polypropylene tubes in duplicate were placed;
a) 200/il 5mMol Hip-His-Leu in substrate buffer.
b) 20^ L/1 unknown plasma sample. The reaction was started 
by vortexing briefly.
o
c) Samples were incubated in a water bath at 37 C for 30 
minutes.
d) Reaction stopped by the addition of 50/il 50% HC1 and 
vortexing.
e) Procedure as from step d) in section 2.2.2.2.1.
2.2.2.3 Results
Typical chromatograms for a blank plasma extract and a 
sample containing both hippuric acid and phthalic acid are 
shown in Figure 2.2. A typical calibration line is shown 
in Figure 2.3.
2.2.3 Determination Of ACE Activity By Inhibitor Binding 
Assay (IBA).
IBA is a specific assay for the measurement of ACE
activity and is based on the specific and avid binding of 
125
I-MK-351A to the active site of the enzyme. The ACE 
activity value is quantified using standards assayed 
previously by the technique described in section 2.2.2.
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2.2.3.1 Solutions
2.2.3.1 .1 0.15M Phosphate Buffer pH 7.4 (Assay Buffer)
34.2g K HPO and 26.3g NaCl were dissolved in 
2 4
approximately 700mls distilled water and the pH adjusted 
to 7.4 using concentrated hydrochloric acid. The buffer 
was then made up to 1 litre and 1g bovine serum albumin 
allowed to slowly dissolve. The pH was rechecked.
2 . 2.3.1.2 Coated Charcoal
0.4g dextran (Mol. Wt. Cutoff 9400) was allowed to 
dissolve in 100mls assay buffer overnight prior to the 
addition of 1g charcoal. The mixture was thoroughly mixed 
by means of a magnetic stirrer in order to keep the 
charcoal in suspension.
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2.2.3.1.3 I-MK-351A
The radiolabelled MK-351A was prepared as described in
section 2.2.1. A working solution was prepared prior to
use in each experiment by diluting the label approximately
1:300-700 with assay buffer such that 300/il of the diluted
label contained 20000cpm. The dilution was calculated
125
after each synthesis of I-MK-351 A and the same dilution
used for all experiments with a particular batch of label.
Each batch had a shelf life of 6 weeks, the half life of 
125
I.
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2 .2 .3.1.4 ACE Activity Standards
Human plasma previously assayed for ACE activity by the
method described in section 2.2.2 was used to prepare the
calibration standards for the IBA assay. Typically, the
plasma would have an ACE activity of 20EU/1. Blank plasma
with no ACE activity was prepared by heating control 
o
plasma to 60 C for 1 hour to inactivate any endogenous ACE
activity. The progressive inactivation of ACE with time 
o
at 60 C is shown in Figure 2.4. The standards prepared 
in section 2.2.2 utilised plasma previously assayed to 
have a value of 20.3 EU/1. Three quality control samples 
were prepared in an identical fashion from a second batch 
of plasma such that their ACE activity values were at the 
bottom, middle and top of the standard calibration line.
2.2.3.2 Non Specific Binding Estimation
125
The degree of non specific binding (NSB) of the I-MK-
351 A was estimated in the presence of a high concentration 
of MK-422 (1 mg/ml) and individual results corrected.
2. 2.3.3 Assay Procedure
Standards and quality control samples (QC's) were prepared 
as described previously and diluted 1:100 with assay 
buffer prior to use. Unknown samples were also diluted by 
a minimum of 1 :5 prior to assay. The dilution factor was 
calculated such that the unknowns could be read from the 
linear portion of the standard calibration line. 
Duplicate tubes were set up containing 100 /i 1 diluted
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standard, QC or unknown and 300/il of diluted I-MK-351 A.
Two tubes containing 100/il of MK-422 (1 mg/ml) and 300 fjl
label were used to estimate NSB and two tubes containing
only 300JJ1 label were prepared to estimate total counts.
All tubes were capped, mixed, and incubated in a water 
o
bath at 37 C overnight (16-18 hours). Tubes were then
centrifuged briefly, uncapped, 400/il of coated charcoal
added and vortexed for 15 seconds. Following further
o
centrifugation (20 minutes, 3000rpm, 4 C) the supernatant 
was removed to waste and the charcoal pellets counted in a 
gamma counter for 1 minute.
2. 2.3.4 Results
The results were calculated for each duplicate sample as 
shown;
% NSB = Mean Counts in NSB samples .100
Mean Total Counts
% Bound = (Mean Counts per Sample .100) - % NSB
Mean Total Counts
A typical calibration line for ACE activity versus 
% Bound is shown in Figure 2.5. The calculation of the % 
NSB and the % Bound is shown in Table 2.1.
2.2.4 Assay Of Enalaprilat By Radioimmunoassay (RIA)
The RIA method described is specific for enalaprilat and 
has been reported by Hichens et al (1981 ) . RIA is a
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FIGURE 2.5
A Typical Calibration Line For ACE Activity Measured By IBA
TABLE 2.1
Calculation Of % Bound For ACE Activity Standards.
Sample ACE
Activity
(EU/L)
Mean
Counts
% Bound % Bound-NSB
Total 20402
NSB - 721 3.53 -
Std 1 0 590 - 0
Std 2 2.9 886 - 0.81
Std 3 6.8 1400 - 3.33
Std 4 9.6 1660 - 4.61
Std 5 12.5 1833 - 5.45
Std 6 16.4 2032 - 6.43
Std 7 19.3 2214 — 7.32
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competitive reaction of antibody with labelled MK-351A and 
unlabelled enalaprilat. The binding that takes place 
results in both labelled and unlabelled drug being bound 
to the antibody in a competitive manner, the greater the 
amount of enalaprilat present the smaller the amount of 
MK-351A that is bound. The second antibody binds to the 
first antibody-drug complex causing it to precipitate out 
and enabling quantification.
2.2.4.1 Solutions
2.2.4.1.1 0.1M Phosphate Buffer pH 7.5 (Buffer (1))
11.41g K HPO and 9.306g EDTA (Na salt) were dissolved in 
2 4 2
500mls of distilled water. After dissolving 0.5g of
bovine serum albumin in the buffer the pH was checked and
adjusted to 7.5.
2.2.4.1.2 Buffer Gamma Globulin
5mg of rabbit gamma globulin was dissolved in 100mls of
o
buffer (1). The buffer was stored at 4 C between use.
2.2.4.1.3 Label And Second Antibody
Donkey anti-rabbit globulin (supplied in solution) was
diluted 1:10 with buffer (1). 10fJl of the radiolabelled
125
I-MK-351A was counted in a gamma counter. The counts 
in one particular experiment were 578580 CPM. For the 
label 20000 CPM were required in 100/il of a 1:10 dilution
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of the second antibody.
Therefore; 1 0/il = 578480 CPM
100/il = 5784800 CPM
Approximately 20000 CPM are required in 100/il
5,784800 CPM = 289.24 in 100/il 
20000
Only 50/il are used so, 289.24 = 144
2
The label must be diluted 1:144 thus 100/il of label was 
made up to 14.4mls with buffer (1).
Equal volumes of the diluted (1:10) second antibody and 
diluted (1:144) label were then mixed (approximately 5mls 
of each) to give a final solution containing second 
antibody and 20000 CPM label in 100/il.
2.2.4.1.4 First Antibody (Anti MK-521)
Vials were supplied containing 50/il anti MK521 . The vial
was reconstituted with 5mls of buffer (1) and stored in
o
100/il aliquots at -70 C.
2.2.4.2 Preparation Of First Antibody Titre Curve
Dilutions of the first antibody were prepared over the
range 1/500 to 1/100000. The range of dilutions of first
o
antibody were incubated overnight at 4 C with 100/il of the
label/second antibody. The samples were then centrifuged
o
at 3000rpm at 4 C for 30 minutes. The supernatant was 
decanted off and the precipitate counted for 1 minute in a
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gamma counter. The percent first antibody bound was 
calculated and plotted against the dilution. A first 
antibody titre curve is shown in Figure 2.6. The dilution 
of first antibody which gave closest to 50% binding and 
the dilution used in all subsequent assays was 1/16000.
2.2.4.3 Preparation Of Enalaprilat Standards And 
Quality Control Samples 
Two enalaprilat solutions were prepared, the first 
solution was used to prepare the standards and the second 
solution the quality control samples. For both solutions 
approximately 20mg of enalaprilat was weighed out and 
dissolved in 20mls distilled water. The solutions were 
diluted 1:10 with distilled water prior to an appropriate 
dilution with buffer (1) to give a final concentration of 
1/ig/ml. The enalaprilat standards were prepared over the 
range from 0.4 to 200ng/ml.
The first of the three QC's was prepared by diluting the 
second solution by 1:10 with buffer (1) to give a 
concentration of 100ng/ml (QC No.1). The second QC was
prepared by diluting QC No.1 by 1:10 with buffer (1) to
give a concentration of 10ng/ml. The third QC was
prepared by diluting QC No.2 by 1:5 with buffer (1) to
give a concentration of 2ng/ml.
2. 2.4.4 Assay Procedure
All samples were prepared in triplicate using a Hamilton
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FIGURE 2.6
The First Antibody Titre Curve For Enalaprilat Measured By RIA
micro lab M for pipetting. Tubes 1-3 contained 100 JJ1
label/second antibody to estimate total counts. Tubes 4-6
contained 100/il label/second antibody plus 700/il of buffer
(1) to estimate nonspecific binding (NSB). The remaining
tubes contained 100/il label/second antibody, 590/il buffer
(1), 100/il first antibody and 10/il of standard, QC or
unknown. All tubes were placed in foam racks and kept at 
o
4 C overnight to equilibrate. Following centrifugation at 
o
3000rpm, 4 C for 30 minutes the supernatant was removed to 
waste and the pellet counted for 1 minute in a gamma 
counter.
2. 2.4.5 Results
The % bound and % NSB were calculated as shown;
%NSB = Mean CPM (NSB Samples) .100 
Mean Total CPM
% Bound = ( Mean CPM .100) - % NSB 
Mean Total CPM
The % bound was then plotted against the concentration of 
enalaprilat and the QC values and unknowns read off the 
curve. A typical standard line is shown in Figure 2.7.
2.2.5 Determination Of Benazeprilat Levels By Gas 
Chromatography With Mass Spectrometry Detection
2. 2.5.1 Assay Procedure
The assay of benazeprilat samples by gas chromatography
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FIGURE 2.7
A Typical Calibration Line For Enalaprilat By RIA
with mass spectrometry detection was kindly carried out by 
Ciba-Geigy Limited (CRB, Rueil Malmaison, France). The 
method used was according to Kaiser et al, 1987. The 
method is specific for benazeprilat only.
2.2.6 Assay Of Enalaprilat And Benazeprilat By IBA
The method relies on the inhibition of the specific and
125
avid binding of I-MK351A to the active site of ACE by 
enalaprilat or benazeprilat.
2. 2.6.1 Solutions
All solutions used were prepared as described in section
2.2.3.1 .
2.2.6.2 Preparation Of Standards And Quality Control 
Samples
The methods used to prepare the standards and QC1 s were 
the same for both enalaprilat and benazeprilat. Two 
solutions were prepared for each drug, one to prepare the 
standards and one to prepare the QC's. In the case of 
benazeprilat the drug was dissolved in 0.5% ammonia, for 
enalaprilat, distilled water was used. All solutions were 
diluted with assay buffer and then spiked into plasma to 
give standard concentrations ranging from 0 to 100ng/ml. 
Three QC's were prepared for each compound, one each at 
the top, middle and bottom of the standard line.
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2 . 2.6.3 Assay Procedure
, o
All standards, QC s and unknowns were heated to 60 C for 1
hour prior to use to inactivate any endogenous ACE
activity. All samples (plasma) were then diluted 1:100
with assay buffer and stored frozen between assays.
Rabbit plasma, used as the source of ACE activity, was
125
diluted 1:10 with assay buffer before use. I-MK351A
was prepared as described as in section 2.2.1 and an
appropriate dilution made with assay buffer to give
20000 CPM in 200/il when the label was freshly prepared.
All samples were prepared in duplicate. Tubes 1-2
contained only 200 jjl diluted label- to estimate total
counts. To estimate non specific binding tubes 3-4
contained a high concentration of the drug under assay
(typically 1 mg/ml), 200/il label and 100/il diluted rabbit
plasma. The remaining tubes contained 100/il diluted
sample, 100/il label and 100/il diluted rabbit plasma. All
o
tubes were capped and allowed to equilibrate at 37 C
overnight in a water bath. Following brief centrifugation
(2 minutes, 500rpm) the caps were removed and 400/il coated
charcoal added to separate the free from bound label. The
o
tubes were recapped, centrifuged for 30 minutes at 4 C, 
3000rpm, and the supernatant removed to waste. The 
charcoal pellet containing only free label was then 
counted for 1 minute in a gamma counter.
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2 . 2. 6.4 Results
The results were calculated as shown;
% NSB = Mean Counts in Charcoal (C) (Samples 3&4) .100
Mean Total Counts (T)
% Bound = ((T-C).100) - % NSB 
(T)
% Maximum Bound = ________% Bound__________  .100
% Bound for Zero Standard
Typical standard curves of % Maximum Bound versus drug 
concentration are shown in Figures 2.8 and 2.9 for 
enalaprilat and benazeprilat respectively.
2.2.7 Assay For Enalaprilat And Benazeprilat By The 
Inhibition Of Formation Of Hippuric Acid From Hip- 
His-Leu
The principle of this method is the same as that described 
in section 2.2.2. The inhibition of formation of hippuric 
acid from a known amount of Hip-His-Leu by enalaprilat or 
benazeprilat enables the quantification of these drugs.
2.2.7.1 Solutions
All solutions used were prepared as described in section
2.2.3.1. The source of ACE activity used in the assay was 
rabbit plasma diluted 1:3 with 0.9% saline.
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A Typical Calibration Line For Benazeprilat By IBA
2 .2 .7.2 Preparation Of Standards And Quality Control 
Samples
The methods used to prepare the standards and QC's were 
the same for both enalaprilat and benazeprilat. Two
solutions were prepared for each drug, one to prepare the 
standards and one to prepare the QC's. In the case of 
benazeprilat the drug was dissolved in 0.5% ammonia, for 
enalaprilat, distilled water was used. To prepare the 
standards for both drugs a 500ng/ml solution was diluted 
1:25 with blank plasma giving a concentration of 20ng/ml 
which was then further diluted with blank plasma to give 
standards ranging in concentration from 20 to 0.3ng/ml. 
Two QC's for each compound were prepared from solutions of 
100 and 50ng/ml which were diluted 1:25 with blank plasma 
to give final concentrations of 2 and 4ng/ml.
2.2.7.3 Assay Procedure
The following method was used with all samples being 
assayed in duplicate;
a) 100/il sample plasma (standard, QC or unknown). This
o
was heated for 1 hour at 60 C to inactivate endogenous ACE 
activity.
b) Allow to cool for 10 minutes.
c) Add 400/il substrate in buffer.
d) Add 50/il diluted rabbit plasma. Mix.
o
e) Incubate for 1 hour at 37 C in a water bath.
f) Add 100/il 50% (v/v) HC1. Mix.
g) Add 100/il internal standard (500 Mol/1 phthalic acid).
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Mix'.
h) Add approximately 50mg NaCl. Mix.
i) Add 1 ml ethyl acetate. Mix for 10 seconds.
j) Centrifuge for 5 minutes at 2000rpm, room temperature.
k) Remove 500 fJtl ethyl acetate to a clean tube and
o
concentrate under air at 37 C.
1) Redissolve in 200/il mobile phase and inject aliquot 
into HPLC system.
m) For all assays an aqueous blank (150/il 0.9% saline) and 
a plasma blank (100/il plasma used to prepare the standard 
curve) were also processed.
2. 2.7.4 Results
Typical calibration lines for enalaprilat and benazeprilat 
are shown in Figures 2.10 and 2.11 respectively. All 
unknown samples were diluted by an appropriate amount such
that they could be read from the linear section of the
standard line.
2.2.8 Assay For Enalaprilat By The Inhibition Of
14
Formation Of C-Hippuric Acid From Radiolabelled 
Hip-His-Leu
2. 2.8.1 Assay Procedure
All standards and QC's were prepared as in section
2.2.7.2. The method was the same as that described in 
section 2.2.7.3 with the following exceptions;
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a) No internal standard was used.
b) The substrate in buffer also included a 1% solution of
1 4
(glycine-1- C)Hip-His-Leu (approximately 10^ L/Ci/ml).
c) Instead of transferring 500^ /1 ethyl acetate to a clean 
tube and subsequent steps, 800/11 was taken and 400/11 acid 
wash (4 volumes substrate buffer to 1 volume concentrated
HCl) added to reduce background counts. The mixture was 
vortexed and then centrifuged for 2000rpm for 5 minutes. 
500 fjl ethyl acetate was taken into a scintillation vial
and 10mls of Ecoscint added. The samples were then
counted for 5 minutes.
2.2.9 Protein Binding
Protein binding studies were carried out for benazeprilat.
2.2.9.1 Preparation Of Membranes
Dialysis membranes were prepared by soaking in three 
changes of distilled water over a 24 hour period. The 
membranes were then transferred to phosphate buffer 
(0.15mol/l, pH 7.4, containing NaCl 0.15mol/l) and soaked 
in a further three changes of the buffer over 24 hours.
2.2.9.2 Dialysis Procedure
A diagram of the cell unit is shown in Figure 2.12. Each 
half cell had three holes. The two located close together 
were for filling, one accepted the pipette tip and the
other acted as an air vent. The single hole was for
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FIG U R E 2.12  
A Diagram Of The Cell Unit Used For 
Protein Binding Determinations
emptying the cell. To set up the cell unit the two clean,
dry halves of each cell (lid and base) were placed on a
clean surface and the membrane gently stretched over the
lid. The base was then lowered onto the lid making sure
that the filling and emptying holes were aligned. The
assembled cell was then picked up, inverted and placed on
top of the spring loaded spacer within the driving flange.
The previous steps were then repeated four more times
until the driving flange was full then the bearing flange
was secured in position with three knurled nuts and the
unit mounted onto a clamp for filling. The emptying holes
were stoppered and the half cells filled in quick
succession. For all experiments plasma or buffer
containing drug was placed on the left hand (lid) side of
the cell and drug free buffer placed on the right hand
(base) side of the cell. The filling holes were then
quickly stoppered, the cell unit mounted in the drive unit
o
and immersed in the water bath at 37 C for the requisite 
length of time. To empty the cells the cell unit was 
placed back in the filling clamp, The emptying holes 
rotated to the top, stoppers removed and a piece of
polythene tubing inserted. The cell unit was then rotated 
round so that the emptying hole was at the bottom and the 
cell emptied with the assistance of blowing air through 
the filling hole if necessary.
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2.2.9.3 Determination Of Time To Equilibrium 
Preliminary work had demonstrated that benazeprilat was 
very highly protein bound and so the determination of the 
time to equilibrium was carried out by dialysing 
benazeprilat in plasma (200ng/ml) against drug free plasma 
for times ranging between 30 minutes and 24 hours. A 
graph of the time to equilibrium for benazeprilat is shown 
in Figure 2.13. A dialysis time of 16 hours (usually 
overnight) was used in all subsequent experiments.
2. 2.9.4 Analysis Of Drug Levels
The levels of benazeprilat were determined using the IBA 
technique described in section 2.2.6.
2. 2.9.5 Recovery Of Drug From The Cells
The recovery of drug from each cell was measured during 
the determination of time to equilibrium experiments. 
The mean recovery of drug was 101% (SD=12.4%, n=12).
Thus, there was no problem with the drug binding to either 
to the teflon cell or the membrane. In each experiment a 
control cell was included in which a known amount of drug 
in plasma was dialysed against drug free plasma enabling 
the recovery and whether equilibrium had been reached to 
be checked.
2.2.10 Preparation Of Tritium Quench Curve
The non quenching standard used was 3H-n-hexadecane, 5.04
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Determination Of The Time To Equilibrium 
For Benazeprilat Protein Binding Analysis
6
* 10 dpm/g (+ or — 3%). The quenching agent used was
CHCl . A series of vials were prepared, each containing 
3
20 fjl of 3H-n-hexadecane (10800 DPM) in 10mls of Hionic
Fluor and an increasing volume of CHCl . The volumes of
3
CHCl used were 0, 5, 10, 20, 50, 75, 100, 150, 200, 300,
3
400 and 500/il. The vials were counted for five minutes 
using the external standard channels ratio method which 
produces an AES value. The counting efficiency was calculated a 
shown;
Efficiency (%) = Sample CPM - Background CPM * 100
Sample DPM (10800)
A quench curve was drawn by plotting AES against 
efficiency and is shown in Figure 2.14. All samples CPM 
values were corrected to DPM using the AES value and the 
quench curve.
2.2.11 Pharmacokinetic Analysis
Pharmacokinetics is the science of the relationships 
between the movement of a drug through the body and the 
processes affecting it. It is a discipline which 
describes the time-course of the movement of a drug into, 
around and out of the body. Mathematical models are used 
to describe and predict drug behaviour. Many different 
models have been used in this thesis and the methods used 
to fit the various models to the data will be described in
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full in subsequent chapters.
2.2.12 Statistical Analysis
Statistics is the science of collecting, summarising, 
presenting and interpreting data, and of using them to 
test hypotheses. There is a great deal of intrinsic 
variation in most biological processes and it is the 
interpretation of data in the presence of such variability 
that the statistical techniques have been used for in this 
thesis. The methods used will be described in detail 
within the individual chapters.
Throughout this thesis the level at which statistical 
significance was achieved was p<0.05.
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CHAPTER 3
COMPARISON OF DIFFERENT ANALYTICAL TECHNIQUES
89
3.1 INTRODUCTION
3.1.1 Scope Of Chapter
The work described in this chapter details four different 
analytical techniques and their application to the 
measurement of ACE activity and the ACE inhibitors 
enalaprilat (the active metabolite of enalapril) and 
benazeprilat (the active metabolite of benazepril). All 
but one of the techniques have been employed in later 
sections of this thesis. The four techniques were GC-MS 
(gas chromatography with mass spectrometry), RIA 
(radioimmunoassay), IBA (inhibitor binding assay) and HHL 
(the formation or inhibition of formation of hippuric acid 
from the synthetic substrate Hip-His-Leu). ACE activity 
was measured by HHL and IBA. Enalaprilat was measured by 
RIA, IBA and HHL. Benazeprilat was measured by GC-MS, IBA 
and HHL. All measurements were made in plasma. The 
analytical techniques have been described in detail in 
chapter 2.
3.1.2 Analytical Methodology To Measure ACE And Its 
Inhibitors
The introduction of ACE inhibitors onto the market has 
seen the development of many different analytical methods 
to measure both ACE itself and also ACE inhibitor drug 
levels.
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The first methods reported to measure ACE activity used 
bioassay techniques. A bradykinin-potentiating factor 
present in the venom of Bothrops Jaracara was quantified 
by measuring the contractions induced in guinea pig ileum 
and rat uterus preparations (Ferreira, 1965). The 
converting enzyme activity in liver was also measured 
using the rat uterus, the contractions of the preparation 
were proportional to the amount of Angiotensin II (All) 
present in the perfusate from the liver (Andersen, 1967). 
Rat colon has also been used to measure All concentrations 
generated from the metabolism of Angiotensin I (AI) in 
isolated perfused tissues (Bakhle et al, 1969). Loyke 
(1970) estimated converting enzyme activity in rat serum 
by measuring the pressor response in the vagotomised, 
pentolinium blocked rat. The main disadvantages of all 
bioassay techniques are that they are time consuming to 
perform and lack sensitivity.
Bioassay techniques were replaced by direct measurement of 
an enzyme reaction product, either the natural product, 
All, or hippuric acid, generated from the synthetic 
substrate Hippuryl-Histidyl-Leucine (Hip-His-Leu). A 
series of synthetic substrates has been developed, but 
Hip-His-Leu is one of the most commonly used. Hippuric 
acid generated during incubation of Hip-His-Leu with ACE 
can be extracted into ethyl acetate and quantified by 
spectrophotometry (Cushman and Cheung, 1971, Lieberman, 
1975) or by High Pressure Liquid Chromatography (HPLC)
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with Ultra Violet (UV) detection (Chiknas, 1979). 
Histidyl-Leucine, also a breakdown product of Hip-His-Leu, 
can be measured by fluorescence detection following 
derivatisation (Conroy and Lai, 1978, Cheung and Cushman, 
1973) as can All (Sakamoto et al, 1986).
A radiochemical assay for ACE measured the liberation of 
14
[Glycine-1- C] hippuric acid from radiolabelled Hip-His- 
Leu by liquid scintillation counting (Rohrbach, 1978). 
Advantages of the radiochemical assay were cited as 
increased sensitivity and lack of interference by nonionic 
detergents or lipids.
The introduction of radioimmunoassay (RIA) methods enabled 
the true ACE activity to be measured by using antibodies 
for All (Hidaka et al, 1985) or ACE (Alhenc-Gelas et al, 
1983). Both techniques are sufficiently sensitive to 
measure extremely small amounts of ACE activity accurately 
and may also be used during acute inhibitor therapy since 
synthetic inhibitors such as captopril or enalapril do not 
interfere with the RIA. An alternative to RIA utilises an 
enzyme in place of the radioisotope, thus simplifying the 
assay procedure whilst maintaining sensitivity and lack of 
interference from either serum components or 
pharmacological ACE inhibitors (Lanzillo and Fanbury, 
1982).
The recent development of specific inhibitors of ACE as 
antihypertensive drugs has provided the stimulus for the 
development of a new assay principle, Inhibitor Binding 
Assay (IBA) (Tikkanen et al, 1984, Jackson et al, 1986).
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Compound MK-351A, an analogue of enalapril (Patchett et
al, 1980) retains the stability and potency of the parent
125
substance after labelling with I. The labelled
analogue can then be used as a marker for ACE in
biological fluids and tissues. The assay procedure is
simple# specific for pharmacologically active drug,
sensitive and is not subject to interference from other
enzymes or immunologically similar substances. As one
inhibitor molecule binds to one ACE molecule, the IBA
could be modified to a stochiometric measurement of ACE.
Thus, at equilibrium, the concentration of ACE could be
125
calculated from the specific activity of I-MK-351A, the
degree of binding saturation and gamma counting
efficiency. However, groups working with IBA use it
mainly to measure ACE activity and not concentration. 
Changes in ACE "concentration" are usually ACE activity 
values measured after the removal of active ACE inhibitor 
which would mask any change in the amount of ACE present. 
Many of the methods used to measure ACE can, and have, 
been modified to measure specific drug levels by
quantifying the degree of inhibition of ACE. In addition
to these non specific methods, HPLC, RIA and GC-MS 
techniques have been developed to quantify drug levels 
with a much greater degree of specificity. The IBA method 
can be applied to the measurement of any pharmacologically 
active ACE inhibitor in blood (Fyhrquist et al, 1984), 
including captopril. Captopril is unstable in biological
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fluids, but samples can be taken for assay by IBA and
o
stored for 1-2 days at 4 C with good stability (less than 
5% degradation) (Grtthagen-Riska et al, 1987). Other 
compounds that have been reported to have been measured by 
IBA include lisinopril, perindoprilat (the active 
metabolite of perindopril), cilazaprilat (the active 
metabolite of cilazapril) (Jackson et al, 1987a) and 
enalaprilat (Jackson et al, 1987b).
3.1.3 Assay Validation
Characterisation of the pharmacokinetics of any compound 
depends entirely on the accurate measurement of the 
compound in body fluids or tissues. Experience has shown 
that all analytical results are subject to errors arising
from a variety of causes. Many errors arising during
analysis are due to chemical or instrumental causes 
although there are other, and often larger, errors. These 
may include human error and transcription or calculation 
errors which may be separated from other errors during 
statistical analysis.
The main emphasis of quality control is the monitoring of 
the performance characteristics of any given method. In 
the first instance this involves selection of a suitable 
method. Such selection involves assessing reliability by 
considering the accuracy, precision, specificity and
sensitivity of the method. These parameters are defined
as follows:
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Accu.iT3.cy. Agreement between the measured value of 3 known 
standard and its true velue. This can be expressed 3s 3 
percentage of the expected value.
Precision. Agreement between replicate measurements. 
This is often described by the percentage coefficient of 
variation (CV) of the results in 3 set of replicste 
measurements.
Specificity. The ability of an analytical method to
determine solely the component(s) it purports to measure. 
Sensitivity. The ability of an analytical method to
detect small quantities of the measured component. There 
are two aspects to sensitivity. Firstly, the limit of 
detection, the smallest amount of analyte that can be 
measured above background. Secondly, the minimum limit of 
quantitation (MLQ), the lowest concentration of analyte 
measurable in the test matrix keeping within predefined 
limits of precision and accuracy.
Once methods have been examined and found to meet the
desired specification, routine quality control (QC) 
samples may be included and analysed within batches of the 
unknown samples. Quality control samples are prepared 
separately from standard calibration samples and are 
analysed solely for quality control purposes, not for 
calibration. The results for these samples are accepted 
as they arise and are then used to assess the accuracy and 
precision of the method on a particular day (intra assay 
variation). Comparison of the results for the QC's over
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several days permits the assessment of day to day 
variation (inter assay variation).
3.1.4 Statistical Comparison Of Different Analytical 
Methods
During the development of a new drug or class of drugs, 
ever more sophisticated or faster analytical techniques 
are often defined. Where more than one analytical 
technique is being used for the same measurement, a 
comparison of methods is essential to ensure the 
compatibility of results. Comparisons are usually made, 
inappropriately, by the use of correlation coefficients. 
The correct statistical approach is not obvious. To 
compare the groups of methods assessed in this chapter a 
dual approach has been adopted.
Firstly the groups were analysed by the paired t-test or 
repeated measures analysis of variance (ANOVA) depending 
on whether two or three methods were under comparison. 
These techniques take no account of the relative precision 
or bias of the methods under comparison. The second 
technique, the jackknife (Salsburg, 1975), compares the 
variance of the two methods under comparison and gives a 
confidence interval on the difference in the squared 
coefficient of determination.
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3 . 2 METHODS
3.2.1 Quality Control Samples
The preparation of the QC samples has been described in 
detail in chapter 2 . Intra assay variation was determined 
by repeated measurements of the QC's within a single 
assay. The inter assay variation was determined from the 
QC results measured in at least four assays, conducted on 
different days. The accuracy for each QC was calculated 
from the mean of the QC results, expressed as a percentage 
of the expected value. Throughout this thesis assays were 
only accepted if the QC results were within 10% of the 
target value otherwise the assay was rejected and 
subsequently repeated.
The minimum limit of quantitation (MLQ) was the lowest 
concentration of analyte measurable within the limits of 
precision and accuracy.
3.2.2 Samples
3.2.2.1 ACE Activity Samples
Thirty plasma samples containing varying degrees of ACE 
activity were measured by the IBA method and also by the 
formation of hippuric acid from Hip-His-Leu (HHL method). 
The 30 samples constitute 2 concentration time profiles 
from the study described in detail in Chapter 7.
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3 . 2.2.2 Enalaprilat Samples
Thirty six plasma samples were assayed for enalaprilat by 
three different techniques. Firstly an RIA specific for 
enalaprilat, then by IBA and finally by the inhibition of 
formation of hippuric acid from Hip-His-Leu (HHL method). 
The latter two methods measure any active ACE inhibiting 
component. However, since it has been reported that 
enalaprilat is not metabolised further (Ulm, 1983), both 
methods should also be specific for enalaprilat. The 36 
samples analysed were the 2 and 6 hour samples taken 
during the study described in greater detail in chapter 7.
3. 2.2.3 Benazeprilat Samples
Three methods were used to assay 40 plasma samples 
containing varying concentrations of benazeprilat. The 
benazeprilat samples were first analysed by a specific GC- 
MS technique (Kaiser et al, 1987) (samples analysed 
courtesy of Ciba-Geigy) then by IBA, and finally by 
inhibition of the formation of hippuric acid from Hip-His- 
Leu (HHL method). Benazepril is a new ACE inhibitor 
currently under development, as yet there is very little 
published data relating to its further metabolism in man. 
Hence it is not known whether the latter two methods are 
specific for its active metabolite, benazeprilat. The 40 
samples analysed constitute 3 concentration time profiles 
from the study described in detail in Chapter 7.
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3.2.3 Statistical Analysis
In general the data were analysed by two different 
statistical approaches.
1 ) The data were assessed as to whether they were 
normally distributed. Analysis of the enalaprilat and 
benazeprilat data, where three methods of measurement were 
being compared, was carried out using the relevant 
parametric or nonparametric analysis of variance (ANOVA). 
The purpose of analysis of variance is to determine 
whether the means of several populations are equal, by 
partitioning the variation in the data and ascribing the 
variation to treatment or subject effects. In order to do 
this several assumptions must be made:
a) That the samples are independent of each other and are 
normally distributed (parametric analysis only).
b) The responses are generated by a linear model, thus the 
observed response is assumed to consist of an overall mean 
plus deviations due to the experiment (plus their 
interactions) plus a random error.
c) The random errors are independent and follow a normal 
distribution.
Analysis of the ACE activity data (measured by two 
different analytical techniques) was done using a paired 
t-test. A paired t-test examines the differences between 
two methods and tests whether the mean difference is 
significantly different from zero. Again an assumption is 
made that the differences between the data pairs come from
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a normal distribution.
2) The data were also analysed using the jackknife 
technique (Salsburg, 1975). The jackknife is the name of 
the method for estimating the variance of a statistic by 
sample re-use. The method can be applied to parameter 
estimation and determination of the error of the estimated 
parameter. The jackknife has been applied in this thesis 
to estimating the difference in variance when comparing 
two methods of assay.
In general the method involves using all the data points
A
to estimate a parameter, 0 . The first data point is then 
deleted and the parameter reestimated, 0^. A pseudo-value 
can then be calculated according to
0j = n 0 - (n-1 ) 01
The pseudo-value can be thought of as the contribution of 
the data point to the overall variance. The first data 
point is then restored, the second data point deleted and 
the second pseudo-value calculated. The process is 
repeated sequentially until pseudo-values for all the data 
points have been calculated. The pseudo-values, which are 
assumed to follow a Students t-distribution, are then used 
to calculate the confidence limits of the parameter under 
estimation according to
0 + tn,5% * Si
/n"
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where 0 end Si are the mean and variance of the pseudo- 
values respectively.
The parameter being estimated in this case is the
covariance between Log(method X * method Y) and Log(method
X/method Y). Thus there are two methods, X and Y.
The null hypothesis (Ho) is that the variance (Var) of
method X is equal to variance of method Y.
Thus, Ho; Var (X) = Var (Y)
ie Var(X) - Var(Y) = 0
But, Var(X) - Var(Y) = Cov (X + Y, X - Y)
where Cov is the covariance.
Thus, Ho becomes Cov (X+Y, X - Y ) = 0
If W = Ln (X)
and V = Ln (Y)
then W + V = Ln (XY)
and W - V = Ln (X/Y)
and Ho becomes Cov (Ln (XY), Ln (X/Y)) = 0.
This makes use of the first order approximation that
Var (Ln X) is equivalent to Var (X)
2
X
Since Var (W) = Var (V)
then, Var (Ln X) = Var (Ln Y)
therefore Var (X) = Var (Y)_
2 2 
X Y
2 2 
which is CV (X) = CV (Y)
2where CV is the squared coefficient of variation.
The technique does not involve a knowledge of the between 
measure correlation and can be applied in spite of
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suspected non normality in the data.
The jackknife does not allow three methods to be compared 
at one time. In the case of enalaprilat and benazeprilat 
three separate comparisons were made, ie for each pair of 
methods within the group.
3.3 RESULTS
3.3.1 Quality Control Data
The results for the accuracy and MLQ of each method are 
shown in Table 3.1. The details of inter assay variation 
and intra assay variation (when measured) are shown in 
Table 3.2.
There were no obvious differences for MLQ within any of 
the sets of methods being assessed. The exception to this 
was the GC-MS technique used to measure benazeprilat 
levels which was shown to have much greater sensitivity, 
2.4pg/ml compared to 0.1 and 0.5ng/ml for the HHL and IBA 
methods respectively.
In all cases the accuracy of the QC samples was within 10% 
of the target value, an acceptable variation. Again, 
there were no marked differences within the sets of 
methods.
The inter and intra assay variation figures showed 
slightly more variation within the sets of methods. In 
most cases there was a slight increase in both types of
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TABLE 3.1
The Accuracy And Limit Of Detection For Each Method
Measurement Method QC Accuracy MLQ
ACE Activity HHL
a
18EU/L 104% 0.2EU/L
IBA 2EU/L
5EU/L
8EU/L
109%
102%
104%
0.5EU/L
Enalaprilat RIA 2ng/ml 
1Ong/ml 
1OOng/ml
100%
103%
101%
0.4ng/ml
HHL 4ng/ml 
5ng/ml 
1Ong/ml 
15ng/ml
96.8%
97.2%
97.8%
94.5%
0.2ng/ml
IBA 7ng/ml
30ng/ml
60ng/ml
95.1%
96.7%
98.0%
0.5ng/ml
Benazeprilat GC-MS 15pg/ml 
77pg/ml 
155pg/ml 
309pg/ml 
513pg/ml
90.9% 
102.4% 
100.8% 
101.3% 
100.2%
2.4pg/ml
HHL 2ng/ml
4ng/ml
102%
97.8%
0.1ng/ml
IBA 1Ong/ml 
30ng/ml 
60ng/ml
107%
107%
106%
0.5ng/ml
a - 1 EU/L is that which produces 1nmol hippuric acid
o
per ml per minute at 37 C.
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TABLE 3.2
Intra and Inter Assay Variation For Each Method
■Measurement Method QC n Variation 
Intra Inter
ACE Activity HHL 18EU/L 10 2.0% 3.3%
IBA 2EU/L 10 8.5% 14.2%
5EU/L 10 5.4% 8.8%
8EU/L 10 5.6% 7.7%
Enalaprilat RIA 2ng/ml 5 4.8% 5.1%
■I— 1Ong/ml 5 5.4% 5.8%
1OOng/ml 5 1 .7% 4.4%
HHL 4ng/ml 18 __ 6.7%
5ng/ml 6 5.4% -
1Ong/ml 7 3.9% -
15ng/ml 18 - 8.9%
IBA 7ng/ml 10 5.1% 6.9%
30ng/ml 10 7.6% 8.1%
60ng/ml 10 4.4% 6.3%
Benazeprilat GC-MS 15pg/ml 8 - 12.9%
77pg/ml 8 - 2.8%
155pg/ml 8 - 3.7%
309pg/ml 8 - 2.1%
513pg/ml 8 — 2.8%
HHL 2ng/ml 6 4.0% 6.4%
4ng/ml 6 3.8% 6.9%
IBA 1Ong/ml 10 5.2% 9.2%
30ng/ml 10 4.8% 7.3%
60ng/ml 10 5.0% 6.6%
n - number of samples used to determine intra assay 
variation. To determine inter assay variation n was
repeated for at least four assays.
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assay variation as the amount of analyte decreased. 
Whilst no intra assay variation data were reported for the 
benazeprilat GC-MS method, the inter assay variation (with 
the exception of the lowest QC) was two to three times 
lower than that for the IBA method, even though the QC's 
being measured were much lower in concentration than those 
assessed for the other two methods.
The inter and intra assay variation observed when 
measuring ACE activity by HHL was again two to three times 
lower than the values for the IBA method. However, a 
greater disparity in the actual values of the QC's may 
have contributed to this difference.
There were no marked differences in the values reported to 
measure variation in the three methods used to measure 
enalaprilat.
3.3.2 Measured Data
The means of the samples measured for ACE activity by HHL
and IBA were both 8.0 EU/L. The means of the enalaprilat
samples were 22.8, 20.7 and 16.2 ng/ml, measured by RIA,
HHL and IBA respectively. The results of the means for
the benazeprilat samples were 179, 302 and 324 mMol/L
measured by GC-MS, HHL and IBA respectively. The means, 
SD' s and ranges for all the samples analysed by the 
different methods are shown in Table 3.3.
There was no difference between the means of the samples 
assayed for ACE activity by HHL and IBA. There were 9.2,
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TABLE 3.3
Results For The Mean, Standard Deviation And Range Of 
The Samples Measured By The Different Analytical
Techniques
Measurement Method n Mean SD Range 
Low High
a
ACE Activity HHL 30 8.0 5.8 1 .2 20.5
IBA 30 8.0 5.9 0.8 22.1
b
Enalaprilat RIA 36 22.8 13.2 5.2 61 .0
HHL 36 20.7 11 .9 3.7 55.0
IBA 36 16.2 12.0 2.6 59.5
c
Benazeprilat GC-MS 40 179 182 0.0 644
HHL 40 302 309 0.0 1033
IBA 40 324 361 0.0 1303
a - All data have units of EU/L
b - All data have units of ng/ml
c - All data have units of mMol/L
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28.9 and 21.7% differences between the means of the 
methods used to measure enalaprilat when comparing 
RIA - HHL, RIA - IBA and HHL - IBA respectively. For 
benazeprilat there were 68.7, 81.0 and 7.3% differences
between the means of the methods when comparing 
GC-MS - HHL, GC-MS - IBA and HHL - IBA respectively.
The ACE activity data, enalaprilat data and the 
benazeprilat data are illustrated in the form of 
Box and Whisker plots in Figures 3.1, 3.2 and 3.3
respectively. The benazeprilat data (representing three 
concentration time profiles) have been averaged with 
respect to time for each method and are illustrated 
graphically in Figure 3.4.
3.3.3 Statistical Analysis
3. 3.3.1 ACE Activity Data
The data were not normally distributed. Neither were the 
differences between the data. It was not possible to 
logarithmically transform the data since there were some 
zero differences. Therefore, the data were analysed by 
the Wilcoxon Matched Pairs Test which is the nonparametric 
equivalent of the paired t-test. There was no significant 
difference between the methods (P=0.767). There was also 
no significant difference in the squared coefficients of 
determination of the methods as measured by the jackknife 
technique. The confidence intervals for the difference in
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Analysis Of The Benazeprilat Data By Three
Different Analytical Techniques With Respect To Time
mean and squared coefficient of determination between the
methods are shown in Table 3.4.
3 .3.3.2 Enalaprilat Data
The data were not normally distributed. However the 
natural logarithmically transformed data were normally 
distributed and so the transformed data were analysed by 
repeated measures ANOVA. This technique analyses the 
differences between the methods and assumes that the 
residuals are normally distributed. This was seen to be 
the case by the plot of the standardised residuals v 
normal scores of the data. The normal scores of the data 
are the expected values if the data come from a normal 
distribution ( fJ=0, O' =1). When the sampled scores normal 
data are plotted against the standardised residuals, a 
straight line is evidence that the original data were 
normally distributed.
Using repeated measures ANOVA, the RIA method and HHL
methods were not significantly different, but the IBA
method was significantly different from both the RIA and
c*,
HHL methods. Bonferroni confidence intervals, which take 
account of the number of comparisons being made, are shown 
in Table 3.4. Analysis of the transformed data by the 
jackknife technique also revealed significant differences 
in the squared coefficients of determination of the IBA 
method when compared to the other two methods. No 
difference was found between the RIA and HHL methods. 
Confidence intervals for the difference in the squared
108
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coefficients of determination for the methods are shown in
Table 3.4.
3 .3.3.3 Benazeprilat Data
The data were not normally distributed and again could 
not be logarithmically transformed due to the presence of 
zero values. Thus, the methods were analysed 
nonparametrically using Friedmans ANOVA. The test gave a 
significant result and so multiple comparisons were 
performed and confidence intervals for the ranks of the 
data calculated to discover where the differences lay. 
The IBA and HHL methods were not significantly different 
from each other, but both differed significantly from the 
GC-MS method. Jackknife analysis revealed a significant 
difference in the squared coefficient of determination 
between all three methods. The confidence intervals for 
the Friedmans ANOVA and the jackknife analysis of the 
untransformed data are shown in Table 3.4.
3.4 DISCUSSION
The correlation coefficient has often been used to assess 
agreement between two methods (Jackson et al, 1986, 
Grtinhagen-Riska et al, 1986). However, a high correlation 
coefficient, r, does not necessarily mean that two methods 
agree, for a number of reasons (Bland and Altman, 1986). 
Firstly, r measures strength of a relation between two
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TABLE 3.4
95% Confidence Intervals For The Differences 
Between The Means (Conventional Analysis) And The 
Squared Coefficients Of Determination (Jackknife 
Analysis) For The Analytical Methods
a
Method Conventional Jackknife
Analysis Analysis
ACE Activity
HHL v IBA -0.15 to 0.20 -0.22 to 0.05
Enalaprilat
* *
RIA v IBA 0.29 to 0.52
*
-0.09 to i o o
 
* 
o
IBA v HHL
CNoI to -0.19 0.01 to 0.06
RIA v HHL -0.01 to 0.22 i o o u) to 0.008
Benazeprilat
* *
GC-MS v IBA -52.1 to i 00 VO (_n -1 .64 to -0.61
*
IBA v HHL -32.6 to 10.6
*
0.33 to 0.94
*
GC-MS v HHL -63.0 to
i
O 
1
O 
1 
CN 
1
1 
1
-0.86 to -0.12
* Denotes a significant difference
a - Parametric ANOVA or paired t-test for ACE Activity and 
enalaprilat methods. The benazeprilat methods were 
compared nonparametrically and so the confidence intervals 
are for the ranks of the data.
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variables and not the agreement between them. Secondly, a 
significant correlation value shows that the two methods 
are related, not unexpected if they are both measuring the 
same sample! Thirdly, correlation depends on the range of 
values in the samples being compared, since methods are 
usually compared over the whole range of typically 
encountered values, high correlations are not unusual. 
Finally, the calculation of a correlation coefficient 
assumes no error in the X variable which is plainly not 
the case when two methods of analysis are being compared. 
The statistical approach employed to compare the methods 
under study within this thesis has sought to look at both 
the possible differences in the accuracy and the 
variability of the different methods. In all cases except 
one, the two statistical techniques were in agreement. 
The single instance where a discrepancy occurred was 
between the HHL and IBA methods to measure benazeprilat. 
The ANOVA found no difference but the jackknife showed a 
significant difference between the two methods. Whilst 
the ANOVA compares the means of the data (120 v 128ng/ml 
for HHL and IBA respectively) the jackknife looks at the 
variance of the two methods. The range of concentrations 
found by the IBA method was approximately 20% higher than 
that found by the HHL method. Since the samples at the 
top end of the range had been highly diluted prior to 
analysis, it is possible that variations in dilution could 
have contributed to the difference in the variance between 
the two methods.
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Excellent agreement was found between the two methods used 
to measure ACE activity, either method could be used with 
equal confidence in the results. The same was not found 
for enalaprilat. Since enalaprilat has been reported as 
not being metabolised any further, all methods, specific 
(RIA) or specific for any pharmacologically active moiety 
(HHL and IBA), should give the same result. There was 
good agreement between the RIA and HHL methods. 
Comparison of the results from the IBA method gave 
consistently lower answers for the individual samples and 
this resulted in significant differences between this and 
the other methods. In the absence of any reported active 
metabolite of enalaprilat no obvious reason could be found 
for this phenomenon.
Agreement was found between the HHL and IBA methods to 
measure benazeprilat, but both were significantly 
different to the results for the GC-MS method. Since the 
GC-MS method measures specifically benazeprilat, and the 
HHL and IBA methods measure any pharmacologically active 
moiety, it could be inferred that there may be other 
active molecules present in the plasma. This supposition 
is further encouraged by examining Figure 3.4 where the 
three averaged concentration time profiles that formed the 
40 samples are presented. The discrepancy occurs only 
between 0—8 hours, at the higher levels of benazeprilat. 
Later time points, where the levels are much lower, show 
very similar results regardless of the method of
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measurement. These results imply that there axe other 
pharmacologically active moieties present during 0 to 8 
hours. There are very few published data relating to the 
possible further metabolism of benazeprilat in man, 
however, glucuronide conjugates have been identified in 
urine (Waldmeier et al, 1990). In baboon, unstable 
glucuronide conjugates have been identified in plasma 
(Waldmeier and Schmid, 1989). The observed differences 
for the methods used to measure benazeprilat highlight the 
need to know the specificity of any analytical method. 
Both the GC-MS and the IBA methods have been used during 
the work presented within this thesis, the implications of 
the particular method used will be discussed at the 
relevant time.
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CHAPTER 4
IN VITRO STUDIES WITH THE ACE INHIBITORS
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4.1 INTRODUCTION
4.1.1 Scope Of Chapter
In this chapter three groups of in vitro studies have been 
carried out. The first group examines two different 
series of ACE inhibitors and compares the rank order of 
potency of the drugs in rabbit and man. The second group 
characterises the in vivo/in vitro relationship of plasma 
ACE inhibition for perindoprilat and quinaprilat. The
third group of studies examines the effect of the presence 
of parent compound on the in vitro potency of the active 
metabolite, in rabbit and man.
All studies described in this chapter are based on the 
evaluation of dose response curves in which known or 
analytically measured concentrations of an ACE inhibitor 
are plotted against the measured percent ACE inhibition.
The resulting curves can then be described mathematically
enabling comparisons of drugs or species to be made.
4.1.2 Rank Order Of Potency Of ACE Inhibitor Drugs
For any new drug entity much of the early work to
elucidate structure activity relationships, and 
subsequently, to characterise dose response relationships, 
is undertaken in animal species. After captopril and 
enalapril were introduced onto the market the initial dose 
range for both drugs was reduced, probably due to the
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initial doses being at the top end of the dose response 
relationship. Whilst comparisons of drug potency have 
been made between species (Ibarra-Rubio et al, 1989, and 
Chen et al, 1984) these experiments have generally used 
samples obtained from a group of subjects or animals and 
have not addressed possible inter individual variation 
between subjects or animals. Since inter individual 
variation may contribute to interspecies variation, the 
first group of studies described in this chapter compares, 
in vitro, two series of ACE inhibitors within individual 
rabbits and human volunteers. The potency of the drugs 
are compared between the two species and any possible 
differences in the rank order of potency of the two series 
of ACE inhibitors between the two species are 
characterised.
4.1.3 The In Vivo/in Vitro Relationship For Plasma ACE 
Inhibition
Many authors have cited the usefulness of in vitro tests 
to predict what will happen in vivo (Swanson et al, 1981, 
Ibarra-Rubio et al, 1989 and Unger et al, 1984). Swanson 
et al (1981) investigated the relationship between the in 
vivo and in vitro percent ACE inhibition response to 
enalaprilat. Whilst the results were similar, the data 
were obtained from different groups of subjects, the in 
vivo and in vitro responses had been characterised in mild
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to moderate hypertensive patients and normal subjects 
respectively. A large amount of data has been published 
describing various in vivo and in vitro responses to ACE
inhibitors but no data is available to describe the
relationship between in vivo and in vitro values within 
individual subjects. The second group of studies 
described in this chapter examines the in vivo/in vitro 
relationship within individual subjects for two ACE 
inhibitors.
4.1.4 The Effect Of The Presence Of Parent Compound On
The In Vitro Potency Of The Metabolite
Many of the new ACE inhibitors currently under development 
are prodrugs and require deesterification in the liver to 
form the active metabolite. Whilst the hypotensive action 
of the metabolite is a consequence of its inhibition of 
ACE, little work has been done to study the effect of 
parent compound on the efficacy of the metabolite. This
type of interaction has been addressed in only a small 
number of studies. Work carried out by Funck-Brentano et 
al (1989) has shown a pharmacokinetic and pharmacodynamic 
interaction between procainamide and its metabolite N- 
acetyl procainamide. The presence of metabolite increased 
the procainamide elimination half life and potentiated 
procainamide induced QTc prolongation in the 
electrocardiogram. The study did not examine the effect 
of procainamide on the pharmacokinetics and
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pharmacodynamics of the metabolite. Thomson et al (1987) 
examined the pharmacokinetics of lignocaine and its 
metabolite, MEGX, administered separately or together to 
eight healthy male volunteers. When lignocaine and MEGX 
were administered in combination, MEGX inhibited 
lignocaine clearance.
Previous work (Lees, 1986) has demonstrated the presence 
of hysteresis in the relationship between the plasma 
levels of the active metabolite perindoprilat and percent 
ACE inhibition following an oral dose of the parent 
compound, perindopril. This effect was not seen following 
an intravenous dose of perindoprilat. The presence of 
hysteresis after oral administration is unusual. 
Conventional thinking would predict the presence of 
hysteresis after an intravenous dose of a compound where 
high plasma drug levels are attained almost immediately 
but a lag time is observed before maximum effect can be 
measured. After oral administration a lag time would be 
predicted before the peak of both plasma drug levels and 
effect. The third group of studies described within this 
chapter examines the effect of parent compound on the in 
vitro potency of the metabolite for five ACE inhibitors, 
in rabbit and in man.
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4.2 METHODS
4.2.1 Preparation And Reproducibility Of In Vitro Dose 
Response Curves.
In vitro dose response curves were prepared by obtaining 
plasma samples from each rabbit or volunteer, aliquoting 
it, the individual aliquots were then spiked with known 
amounts of drug such that the assayed ACE activity was 
inhibited from 0 to 100%. The drug concentrations used 
for the rabbit studies ranged from 0-1000 ng/ml for all 
compounds with the exception of captopril where the range 
studied was 0-20000 ng/ml. The range of drug 
concentrations studied in man again varied between 0-1000 
ng/ml with the exception of captopril where a range of 0- 
2000 ng/ml was used. The resulting dose response curves
were analysed as described in section 4.2.6.
Dose response curves were typically prepared by 'spiking' 
10 yLi 1 of drug solution into 90^1 plasma aliquots. To 
assess the variability in pipetting the 10/11 spike, eight 
10/11 aliquots of water were weighed. In order to assess
the combined variability in preparing the 10/11 spike plus
the 90/11 plasma aliquot, together with the assay 
variability, 10 /J1 water was spiked into eight 90/11 
aliquots of plasma and the ACE activity assayed. In both 
experiments the mean, standard deviation (SD) and percent 
coefficient of variation (CV) were calculated.
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4.2.2 Assessment Of The In Vitro Rank Order Of Potency 
Within Individual Rabbits And Human Volunteers.
Four series of studies were carried out, the first two 
series compared dose response curves for captopril, and 
the active metabolites enalaprilat, perindoprilat and 
trandolaprilat within each of eight individual volunteers 
and rabbits (study series 1 and 2 respectively). The 
third and fourth series of studies compared dose response 
curves for enalaprilat, perindoprilat, benazeprilat and S- 
10211 (the active metabolite of S-9650) within each of six 
individual volunteers and rabbits (study series 3 and 4 
respectively).
4.2.3 The In Vivo/in Vitro Relationship For Perindoprilat 
And Quinaprilat.
The perindoprilat in vitro dose response curves were 
constructed using the pooled plasma for each volunteer 
from the placebo phase of an intravenous dose ranging 
study in which eight healthy volunteers received placebo, 
1/ 2 and 4mg of perindoprilat. The in vivo dose response
curves for the individual subjects were prepared by 
plotting the percent ACE inhibition data against assayed 
perindoprilat plasma levels for the three active doses of 
the study.
Quinaprilat in vivo and in vitro dose response curves were 
prepared as described for perindoprilat, using plasma
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samples generated from an oral dose ranging study in which 
ten healthy male volunteers received placebo, 0.5, 2.5, 5 
and 20mg of quinapril.
All generated dose response curves were analysed as 
described in section 4.2.6.
4.2.4 The Effect Of Parent On The In Vitro Potency Of 
Metabolite In Rabbit And Man.
The effect of parent compound on the in vitro potency of 
the metabolite was studied for five different ACE 
inhibitors, enalapril, perindopril, benazepril, S-9650 and 
quinapril. Each study was carried out using plasma from 
rabbit and man. In addition, in man only, the effect of 
perindopril on the dose response curve for enalaprilat was 
studied. The studies were carried out using pooled plasma 
samples, plasma from at least ten individual rabbits or 
human volunteers contributing to the relevant pool.
Firstly, in vitro dose response curves for the individual 
metabolites were constructed as described in section
4.2.2. Secondly, in vitro dose response curves were 
constructed for the parent compounds, again using aliquots 
of plasma from either pool. The parent dose response 
curves were analysed as described in section 4.2.6 and the 
concentrations of parent compound that inhibited ACE by 5, 
10 and 25% calculated. Finally, the dose response curves 
for the individual metabolites were repeated in the
121
presence of the three calculated concentrations of the 
respective parent compound. In addition, in man only, the 
enalaprilat dose response curve was repeated in the 
presence of the three concentrations of perindopril.
4.2.5 Analytical Methods.
In all the studies described in this chapter ACE activity 
was measured by the method detailed in chapter 2, section
2.2.2. The method involves the quantitation of hippuric 
acid by HPLC with UV detection after its liberation from 
the synthetic substrate Hip-His-Leu by the action of ACE. 
The in vitro studies described in sections 4.2.1, 4.2.2
and 4.2.3 involved the preparation of known concentrations 
of the various ACE inhibitors in plasma aliquots. This 
was done by dissolving a known amount of drug, and then by 
serial dilution, preparing a range of standards in 
distilled water, the concentration of which was ten times 
the desired concentration in the plasma aliquot. The 
individual drug standards were then diluted 1:10 with 
plasma to give the desired concentration.
Measurement of the perindoprilat and quinaprilat plasma 
levels, forming the in vivo dose response curves described 
in section 4.2.2, was a modification of the method 
detailed in section 2.2.7. Quality control data for the 
two compounds is shown in Table 4.1.
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TABLE 4.1
Quality Control Data For Perindoprilat and Quinaprilat
Drug QC Variation Accuracy MLQ
Intra Inter 
(ng/ml) (%) (%) (ng/ml)
Perindoprilat 2 3.30 
(n=7)
5.75 
(n=30)
95.5 0.1
4 2.52 
(n=9)
5.09 
(n=30)
98.2
Quinaprilat 2 4.64 
(n=8)
6.31 
(n=12)
95.0 0.1
4 3.68 
(n=10)
5.33 
(n=12)
98.5
MLQ - Minimum limit of quantitation
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4.2.6 Data Analysis.
All the dose response curves were of the form shown in 
Figure 4.1 which can be described by the equation;
Y
E = C* * Emax 
C(50)^ + C*
where; E - percent ACE inhibition
Emax - maximum inhibition of ACE 
C - concentration of ACE inhibitor 
C(50) - concentration of ACE inhibitor that 
produces 50% inhibition of ACE 
y - a parameter to describe the sigmoidicity of 
the curve
The equation is known as the Langmuir equation when ^ is 
constrained to equal 1 and the Hill equation when ^ is 
allowed to vary. Four models were fitted to each dose
response curve, the first two were Langmuir models 
( ^ constrained to equal 1 ), one allowing Emax to vary and 
one constraining Emax to equal 100%. In the third and
fourth models the Hill equation was used ( if allowed to
vary), again Emax was either allowed to vary or to be
constrained to 100%.
The estimates of model parameters, Emax, and C(50)
where appropriate, were obtained by non-linear least 
squares regression with unweighted data using the 
statistical package VASP on a Nodecrest V76 computer.
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FIGURE 4.1
A Schematic Representation Of A Typical Dose Response Curve
All model comparison was done using the F-Ratio test. In 
the first instance the two Langmuir models and the two 
Hill models were compared to assess whether allowing Emax 
to vary significantly improved the fit of the model to the 
data. For the vast majority of the data this was not the 
case and so final model selection was made by comparing 
the Langmuir and Hill models where Emax was constrained to 
100%.
All comparisons of potency, assessment of the in vivo/in 
vitro relationship or the examination of the effect of 
parent drug on the activity of the metabolite were made 
using the C(50) parameter, the concentration of drug which 
produced 50% inhibition of ACE.
4.2.7 Statistical Analysis.
Comparison of the rank order of potency of the two series 
of ACE inhibitors, each series characterised in rabbits 
and volunteers was carried out by repeated measures ANOVA. 
The two sets of in vivo/in vitro data were compared by 
paired t-test. Different numbers of data pairs were used 
to estimate the in vivo and in vitro model parameters 
(approximately 20 data pairs for the in vitro data and 
approximately 55 data pairs for the in vivo data). Since 
this may affect the degree of confidence with which the 
C(50) parameter was estimated, the in vivo/in vitro data 
ware also compared using a weighted t-test in which the
125
inverse error in estimating C (5 0) was used as the 
weighting function.
Any possible effect of parent compound on the in vitro 
potency of the metabolite was assessed by firstly fitting 
the models to the individual dose response curves. The 
four data sets were then combined into one and the models 
refitted. The General Linear or F-Ratio test was used to
test if there was any statistically significant
justification for fitting with four individual C(50) 
parameters or whether one combined C(50) parameter was
adequate.
4.3 RESULTS
4.3.1 Reproducibilty In The Preparation Of The Dose 
Response Curves.
The results for the mean, SD and CV of the eight weighed 
10 fjl aliquots of water were 9.82mg, 0.14mg and 1.41%
respectively. The results for the mean, SD and CV of the 
eight assayed 10fjX water plus 9QfJil plasma samples, in 
which ACE activity was determined, were 20.4EU/L, 
0.316EU/L and 1.55% respectively. The value of 1.55% 
encompasses both variability in preparing the samples and 
the assay variability.
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4.3.2 Assessment Of The Rank Order Of Potency Within 
Individual Rabbits And Volunteers.
In order to assess which model, Hill or Langmuir, best 
described the data the results of model choice from study 
series 1 and 3 and study series 2 and 4, in which 
volunteers and rabbits were studied respectively, were 
combined. For each species fifty six dose response curves 
had been prepared. For man, thirty two of the dose 
response curves were best described by a Hill model. In 
the case of rabbit all but four out of the fifty six dose 
response curves were best described by a Hill model. The 
individual C(50) values for each study are shown in Tables
4.2 to 4.5. Graphs of the four dose response curves 
within a single representative subject, one subject per 
study, are shown in Figures 4.2 to 4.5.
In the case of study series 1 where enalaprilat, 
perindoprilat, captopril and trandolaprilat were compared 
within eight individual subjects the rank order of potency 
for all eight subjects was trandolaprilat > perindoprilat 
> enalaprilat > captopril. The mean values for C(50) (SD) 
were 1.10(0.34), 2.59(1.48), 7.21(2.41) and 107(24.2)
ng/ml respectively. In study series 2 where the same four 
compounds were compared in rabbit the mean rank order of 
potency was perindoprilat > enalaprilat > trandolaprilat > 
captopril, which is different to that seen in man. Six 
out of the eight rabbits exhibited the same rank order as 
that of the mean values, in one of the remaining rabbits,
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TABLE 4.2
C(50) Values For Enalaprilat, Perindoprilat, Captopril 
And Trandolaprilat In Eight Human Volunteers.
Subject C(50) Value (ng/ml) 
Trandol.lat Perind.lat Enal.lat Captopril
1 1.15 4.14 5.88 75.9
2 1 .71 2.68 12.0 87.6
3 1 .31 1 .70 6.14 99.5
4 0.67 1 .20 7.09 145
5 0.80 1.10 3.68 131
6 0.87 2.17 6.57 96.2
7 0.97 2.34 7.66 127
8 1 .31 5.38 8.67 94.3
Mean 1.10 2.59 7.21 107
SD 0.34 1 .48 2.14 24.2
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FIGURE 4.2
Dose Response Curves For Subject No. 1
From Study No. 1
TABLE 4.3
C(50) Values for Enalaprilat, Perindoprilat, Captopril 
And Trandolaprilat In Eight Rabbits.
Rabbit
Trandol.lat
C(50) Values (ng/ml) 
Perind.lat Enal.lat Captopril
1 1 .41 0.60 1 .20 1333
2 1 .72 0.76 2.35 1227
3 1 .73 0.90 1 .67 638
4 1.10 1 .30 1 .54 449
5 2.25 1 .30 1 .31 1382
6 2.85 1 .35 2.10 1308
7 1 .65 0.66 1 .25 461
8 2.05 1 .33 1 .73 1436
Mean
SD
1 .84 
0.54
1 .02 
0.33
1 .64 
0.41
1029
433
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Dose Response Curves For Rabbit No. 3
From Study No. 2
TABLE 4.4
C(50) Values For Enalaprilat, Perindoprilat, S-10211 And 
Benazeprilat In Six Human Volunteers.
Subject
Enal.lat
C(50) Values (ng/ml) 
Perind.lat S-10211 Benaz.lat
1 2.43 1 .09 0.81 5.81
2 7.62 1 .23 2.73 6.91
3 7.91 1 .68 4.81 5.26
4 6.34 1 .36 2.31 4.24
5 6.13 1 .25 1 .78 4.55
6 7.31 1 .56 2.12 4.09
Mean 6.29 1 .36 2.43 5.14
SD 2.02 0.22 1 .33 1 .08
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TABLE 4.5
C(50) Values For Enalaprilat, Perindoprilat, S-10211 And 
Benazeprilat In Six Rabbits.
Rabbit
Enal.lat
C(50) Values (ng/ml) 
Perind.lat S-10211 Benaz.lat
1 1 .47 0.69 0.78 0.99
2 1 .58 0.78 0.71 1.13
3 2.33 0.83 1.12 1 .22
4 2.11 1 .04 0.99 1 .27
5 1 .92 0.90 1 .06 1 .00
6 1 .74 0.98 1 .02 1 .21
Mean 1 .86 0.87 0.95 1.14
SD 0.33 0.13 0.16 0.12
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FIGURE 4.5
Dose Response Curves For Rabbit No. 1
From Study No. 4
enalaprilat and trandolaprilat were transposed and in the 
other rabbit the most potent compound was trandolaprilat. 
The mean values of C(50) (SD) in rabbit were 1.02(0.33), 
1.64(0.41), 1.84(0.54) and 1029(433) ng/ml for
perindoprilat, enalaprilat, trandolaprilat and captopril 
respectively.
The data from the four drugs studied in the eight 
individual rabbits and volunteers were assessed 
statistically by repeated measures analysis of variance. 
Analysis of the data revealed trends in the residual plots 
coupled with a non linear normal scores plot and so the 
analysis was repeated on the logarithmically transformed
data. There were significant effects for both species and 
drug as well as an interaction between the two and so the 
results were considered with respect to the interaction by 
means of Bonferroni confidence intervals which make 
corrections for the number of comparisons made. There 
were significant differences between rabbit and man for 
all the drugs studied. There were also significant
differences between all the drugs in man. In rabbit 
however, there were no significant differences between
enalaprilat and trandolaprilat or enalaprilat and 
perindoprilat. There were significant differences between 
the remaining drugs. These statistical differences are in 
keeping with the rank order of potency results where, in 
man, where all the drugs had significantly different C(50) 
values, all eight volunteers exhibited the same rank order
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of potency. In rabbit where the results for the drugs 
were not all statistically significantly different, six 
out of the eight rabbits showed the same rank order of 
potency, in the remaining two animals transpositions 
occured between enalaprilat, perindoprilat and 
trandolaprilat.
In study series 3 and 4 enalaprilat, perindoprilat,
benazeprilat and S-10211 were compared within six 
individual volunteers and rabbits. In man the rank order 
of potency was perindoprilat > S-10211 > benazeprilat > 
enalaprilat where the mean values of C(50) (SD) were 
1.36(0.22), 2.43(1.33), 5.14(1.08) and 6.29(2.02) ng/ml
respectively. Five of the six subjects demonstrated the 
same rank order of potency as the mean values. In the
remaining subject the rank order of potency was S-10211 >
perindoprilat > enalaprilat > benazeprilat. In the six 
rabbits the mean rank order was the same as that seen in 
man, the mean values of C(50) (SD) were 0.87(0.13),
0.95(0.16), 1.14(0.12) and 1.86(0.33) for perindoprilat,
S-10211, benazeprilat and enalaprilat respectively. Only 
half of the six rabbits exhibited the same rank order as 
that of the mean values, in two rabbits S-10211 and 
perindoprilat were transposed and in the remaining rabbit 
the rank order of potency was perindoprilat > benazeprilat 
> S-10211 > enalaprilat.
Again, statistical analysis of the original data for study 
series 3 and 4 revealed trends in the standard residual 
plots plus a non linear normal scores plot so the data
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were logarithmically transformed. There was also one 
result which was far outside the range of the other 
results, the enalaprilat C(50) for subject number 1. 
Omission of this data point did not improve the standard 
residual plot and so the data point was restored and the 
data analysed as a complete set. Once again, due to an 
interaction between species and drug, the data were 
assessed by Bonferonni confidence intervals. There were 
statistically significant differences between rabbit and 
man in the C(50) values for all the drugs. In man there 
was no significant difference between enalaprilat and 
benazeprilat, the remaining drugs all showing significant 
differences. In rabbit, only enalaprilat was
significantly different, the remaining three drugs showed 
no significant differences. These results are also in 
keeping with the rank order of potency results, one 
volunteer out of six had enalaprilat and benazeprilat 
reversed. In rabbit various orders of potency were seen 
but all rabbits had enalaprilat as the least potent drug, 
as measured by the C(50).
4.3.3 The In Vivo/in Vitro Relationship For Perindoprilat 
And Quinaprilat.
The placebo plasma used to prepare the in vitro 
perindoprilat dose response curves had been stored, 
frozen, for up to one year prior to pooling and subsequent
134
evaluation of the in vitro dose response curves. The 
original range of ACE activity values for the placebo 
plasma samples, measured up to one year prior to the 
pooling of the plasma samples, and the value for the 
pooled placebo plasma are shown in Table 4.6. For three 
of the volunteers the value for the pooled plasma was 
lower than the range originally encountered, and in one 
case, subject no. 4, had fallen so low such that the in 
vitro dose response curve could not be characterised. Of 
the seven in vitro dose response curves assessed three 
were significantly better described by the Hill model. 
All eight of the in vivo dose response curves were best 
described by the Hill model.
The quinaprilat in vitro dose response curves were
prepared within days of the placebo phase of the study, 
allowing no time for any deterioration in the ACE activity 
in the placebo plasma. Of the ten volunteers, eight of 
the in vitro dose response curves and four of the in vivo 
dose response curves were best described by the Hill
model.
The values of C(50) for the in vivo and in vitro dose 
response curves are shown in Tables 4.7 and 4.8 for 
perindoprilat and quinaprilat respectively. The mean in 
vivo and in vitro values of C(50) (SD) for perindoprilat
were 1.8(0.9) and 5.8(2.1) ng/ml respectively. The mean
values of C(50) (SD) for quinaprilat were 1.5(0.8) and 
3.9(1.3) ng/ml for the in vivo and in vitro dose response 
curves respectively. Graphs of the in vivo and in vitro
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TABLE 4.6
ACE Activity Values Of Plasma Used To Prepare The 
Perindoprilat In Vivo And In Vitro Dose Response Curves
Subject Original ACE Activity 
Range (In Vivo) 
(EU/L)
Pooled ACE Activity 
Value (In Vitro) 
(EU/L)
1 17.2 - 22.6 22.9
2 24.9 - 32.2 24.0
3 17.7 - 23.5 18.5
4 24.2 - 32.0 10.3
5 29.5 - 35.4 32.8
6 29.9 - 40.3 20.4
7 17.5 - 25.0 27.8
8 30.0 - 36.7 22.0
The original ACE activity was measured up to one year
prior to the pooling of the placebo plasma
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TABLE 4.7
Perindoprilat C(50) In Vivo/in Vitro Relationship
Subject C(50) Values (ng/ml) 
In Vivo In Vitro
1 1 .2 5.0
2 0.7 6.4
3 1 .1 9.6
4 1.4 nr
5 3.1 6.3
6 2.9 2.9
7 1 .9 4.3
8 2.2 5.8
Mean
SD
1 .8 
0.9
5.8
2.1
nr denotes no result
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Perindoprilat In Vivo And In Vitro Dose Response 
Curves For Subject No. 8
TABLE 4.8
Quinaprilat C(50) In Vivo/in Vitro Relationship
Subject C(50) Values 
In Vivo
(ng/ml) 
In Vitro
1 2.3 2.2
2 0.6 6.6
3 2.1 2.6
4 1 .6 3.2
5 1 .5 4.9
6 1 .1 3.5
7 3.2 5.1
8 0.8 3.2
9 1.1 4.2
10
00o 3.5
Mean 1 .5 3.9
SD 0.8 1 .3
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dose response curves for a single representative subject 
for each compound are shown in Figures 4.6 and 4.7.
For both compounds, as assessed by the paired t-test, the 
in vivo values were significantly lower than the in vitro 
values ( P<0.01 and p<0.001 for perindoprilat and
quinaprilat respectively). When the inverse error in 
estimating the C(50) parameter was used as a weighting 
function in the t-test (see section 4.2.7), the in vivo 
values were still significantly lower than the in vitro 
values (p<0.05 ) .
4.3.4 Effect Of Parent On The In Vitro Potency Of The 
Metabolite In Rabbit And Man.
The results presented in section 4.3.2 demonstrated a 
remarkable consistency in the rank order of potency for 
different ACE inhibitors within individual rabbits or 
volunteers. For this reason the evaluation of the effect 
of parent on the in vitro potency of the metabolite was
undertaken in pooled plasma, samples from at least ten
individual rabbits or volunteers contributing to each 
pool.
The effect of parent was assessed for five different 
compounds. For each compound a dose response curve for
parent and four dose response curves for the metabolite
were prepared, one for the metabolite alone and three with 
metabolite and parent compound. In rabbit, eighteen of
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the twenty dose response curves were best described by a 
Hill model whereas, in man, this was the case in only ten 
of the dose response curves.
The dose response curves for the parent compounds are 
shown in Figures 4.8 and 4.9 for man and rabbit 
respectively. After characterising the parent compound 
dose response curves the concentrations of parent that 
inhibit ACE by 5, 10 and 25% were calculated. These
values (for both rabbit and man) are shown in Table 4.9. 
The results for the C(50) values of the in vitro dose 
response curves for the five metabolites, characterised in 
the presence and absence of parent compound, are shown in 
Table 4.10. The effects of enalapril and quinapril on 
enalaprilat and quinaprilat in rabbit plasma are shown in 
Figures 4.10 and 4.11 respectively. The effects of 
enalapril and perindopril on enalaprilat and perindoprilat 
respectively, in human plasma, are shown in Figures 4.12 
and 4.13. The effect of perindopril on enalaprilat, again 
in human plasma, is shown in Figure 4.14.
The results of the F-Ratio test showed that each of the 
four curves for S-10211 and quinaprilat in rabbit plasma 
were significantly better described by individual C(50) 
values and not a single combined C(50) value. For both 
S-10211 and quinaprilat, the presence of parent compound 
caused a significant decrease in the potency of the 
metabolite, reflected by increased C(50) values. The 
value of C(50) increased from 0.82 to 1.27ng/ml ( a 54.9% 
change) and from 1.03 to 2.10ng/ml (a 104% change) for S-
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TABLE 4.9
The Concentrations Of Parent Compound Calculated To 
Inhibit ACE Activity By 5, 10 And 25%.
Drug Species Concentration 
5% 10%
(ng/ml)
25%
Enalapril Man 200 500 2000
Perindopril Man 5 10 50
Benazepril Man 750 1500 5000
S-9650 Man 20 40 120
*
Quinapril Man 1800 3900 1.16
Enalapril Rabbit 50 100 200
Perindopril Rabbit 15 50 100
Benazepril Rabbit 15 25 50
S-9650 Rabbit 2 4 8
Quinapril Rabbit 150 300 900
* Value in mg/ml
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Dose Response Curves For Parent Compound In Rabbit
TABLE 4.10
The C (50) Values For The Metabolite In The Presence And Absence 
Of Parent Compound In Rabbit And Man.
Compounds 
Parent Metabolite
Species
Alone
C{50) Values 
5%
(ng/ml)
10% 25%
Enalapril Enalaprilat Rabbit 2.17 2.04 1.97 2.38
Perindopril Perindoprilat Rabbit 0.99 1.14 0.86 0.98
Benazepril Benazeprilat Rabbit 1.28 1.20 1.18 1.02
S-9650 S-10211 Rabbit 0.82 1.18 1.01 1.27*
Quinapril Quinaprilat Rabbit 1.03 1.56 1.48 2.10*
Enalapril Enalaprilat Man 6.78 8.01 7.84 8.21*
Perindopril Perindoprilat Man 1.64 1.80 1.99 3.43*
Benazepril Benazeprilat Man 4.60 5.72 5.35 5.07
S-9650 S-10211 Man 2.25 2.48 2.47 2.35
Quinapril Quinaprilat Man 3.49 3.75 3.63 3.11
Perindopril Enalaprilat Man 7.33 6.21 6.52
*
9.23
* ~ C (50) values statistically different (p<0.05) based upon the F-Ratio test
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The Effect Of Enalapril On The Dose
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The Effect Of Perindopril On The Dose
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The Effect Of Perindopril On The Dose 
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10211 and quinaprilat respectively. No effect was 
observed for the presence of parent compound on the in 
vitro potency of enalaprilat, perindoprilat or
benazeprilat in rabbit.
In man significant effects for enalapril and perindopril 
were observed on enalaprilat and perindoprilat. Enalapril 
caused a modest increase from 6.78 to 8.21 ng/ml in C(50), 
(a 21.1% change), while perindopril caused a larger 
increase in C(50) from 1.64 to 3.43ng/ml, (a 109% change). 
Also in man, the presence of perindopril caused an 
increase in enalaprilat C(50) from 7.33 to 9.23ng/ml, a 
25.9% change. Thus perindopril brought about a 
significant decrease in potency for both enalaprilat and 
perindoprilat, the decrease in potency for enalaprilat 
being of a similar order to that caused by enalapril. No 
effect of parent on the C(50) values for benazeprilat, S- 
10211 or quinaprilat was observed, in man.
4.4 DISCUSSION
Very low values for the coefficient of variation in the 
preparation and assay of the in vitro dose response curves 
were obtained. This indicates that any difference in the 
various C(50) values can be attributed to true variation 
and not to the relatively small variability within the 
experimental methods.
Two groups of compounds were compared within individual
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rabbits and men. In the first series of drugs 
enalaprilat, perindoprilat, trandolaprilat and captopril 
were compared and in the second series enalaprilat, 
perindoprilat, S-10211 and benazeprilat were compared. 
All the drugs were significantly different across the 
species studied and exhibited a greater potency in rabbit 
than in man, except for captopril. The result for 
captopril is in agreement with previously published work 
where a similar, approximately ten fold greater potency 
was observed in man when compared to rabbit (Ibarra-Rubio 
et al, 1989).
There were variations in the rank order of potency for the 
two series of compounds in rabbit and man, especially in 
the first series of compounds. In the second series of 
compounds the mean rank order of potency was the same for 
the two species, however, in man a difference could only 
be detected between enalaprilat and benazeprilat whereas 
in rabbit no difference could be detected between any of 
perindoprilat, benazeprilat or S-10211. Thus, even though 
the mean rank order of the compounds was the same, there 
were differences in the relationships between the 
compounds for the two species. Ibarra-Rubio et al (1989) 
have found differences in the C(50), the kinetic constants 
Km and Vmax, and Ki, the inhibitory rate constant across 
ACE between many species including man and rabbit. They 
postulate that the differences in these constants could 
reflect variations in the tertiary structure of ACE. This 
may explain why the two series of compounds were handled
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differently, with respect to rank order of potency, in the 
two species. Furthermore, they speculate that since ACE 
is present in many tissues serum ACE may represent ACE 
from more than one source. The differences in the kinetic 
parameters may then reflect different proportions of 
isoenzymes from the various tissues of the species 
studied.
The remarkable degree of consistency in the response of 
individuals within a species to the drugs indicates that 
interindividual variability is not high and so enables 
interspecies variability to be more easily detected. The 
recommended therapeutic dose range for both enalapril and 
captopril was reduced after the introduction of the drugs 
onto the market. The differences in C(50) found for the 
two drugs in rabbit and in man reflect the fact that 
different doses would be needed to obtain the same degree 
of ACE inhibition. Since the therapeutic range for any 
drug is based upon the dose response relationship and 
these are initially characterised in animals, then the 
differences in potency for enalapril and captopril between 
man and rabbit may have contributed to the post marketing 
dosage reduction.
The in vivo/in vitro relationship for plasma ACE 
inhibition was assessed for two drugs, perindoprilat and 
quinaprilat. For both compounds the in vivo values were 
significantly lower than those found in vitro, indicating 
greater inhibition of ACE in vivo. In the first instance,
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the lower potency observed for the in vitro perindoprilat 
study was attributed to the fact that the plasma used to 
prepare the in vitro dose response curves had been stored 
frozen, for up to one year. Thus, the decrease in potency 
seen in vitro may reflect a deterioration in the plasma 
ACE activity. However, in the case of quinaprilat the 
dose response curves were prepared almost immediately 
after obtaining the plasma allowing no change in the ACE 
activity to occur and again, the in vitro response was 
less potent than that characterised in vivo. A possible 
reason for the difference between the in vivo and in vitro 
responses is that the in vitro dose response curves 
characterise a "snap shot" in a changing picture whereas 
the in vivo curves represent the whole dynamic situation. 
In vivo, a combination of different factors such as the 
presence of the ACE inhibitor within the system or the 
ramifications of alterations in blood pressure 
(therapeutic effect) may be altering the plasma ACE 
activity response, and so contributing towards the 
discrepancy between the in vivo and in vitro values.
The renin angiotensin system has been traditionally viewed 
as an endocrine system, however an increasing body of 
evidence suggests that the ACE found in tissues may be the 
primary site of action (Moursi et al, 1986, Sakaguchi et 
al/ 1988 and Unger et al, 1985). In the light of the 
proposed tissue site(s) of action the relevance of the 
Plasma ACE inhibition to the hypotensive action of the ACE 
inhibitors must be considered. Indeed, it has been shown
146
that the antihypertensive action of the ACE inhibitors 
does not always directly relate to the inhibition of ACE 
in the plasma (Richer et al, 1984).
The discrepancy between the in vivo and in vitro values 
may further help to explain why the therapeutic dose range 
for both enalapril and captopril was reduced after 
marketing. The in vitro results have been shown to be 
less potent than those obtained in vivo. Any
calculations based upon the in vitro values would have 
overestimated the amount of drug needed to elicit the same 
response in vivo.
The third group of studies examined the effect of parent 
compound on the efficacy of the metabolite for enalapril, 
perindopril, benazepril, S-9650 and quinapril in human and 
rabbit plasma. The presence of parent compound brought 
about a significant decrease in potency for S-10211 and 
quinaprilat in rabbit and for enalaprilat and 
perindoprilat in man. In addition, in man, the presence 
of perindopril also decreased the potency of enalaprilat, 
by the same degree as the decrease caused by enalapril. 
Soubrier et al (1989) have carried out molecular cloning 
of the human ACE molecule and have demonstrated the 
presence of two regions with active site sequences similar 
to other metalloendopeptidases. It has been proposed that 
only one of these sites is capable of binding the ACE 
inhibitor molecule. The decrease in potency seen for some 
°f the metabolites studied may be due to the parent
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compound binding to the second active site sequence in the 
ACE molecule where it causes steric hindrance but not ACE 
inhibition.
The data can be extrapolated to the clinical situation and 
used to explain the reason for the apparently reduced 
incidence of first dose hypotension, observed after 
administration of perindopril when compared to that seen 
after enalapril. The decrease in potency seen for
perindoprilat in the presence of perindopril could be the 
cause of the hysteresis seen after oral perindopril (Lees, 
1986). The lag in appearance of effect behind the plasma 
drug levels may then explain the apparent reduced
incidence of first dose hypotension. To further 
investigate this possibility the incidence of hysteresis 
after oral administration of enalapril was examined. The
study and data are fully described in chapter 6 but, in
summary, nine young volunteers received 10mg of enalapril 
orally, plasma enalaprilat levels and percent inhibition 
of plasma ACE were measured and then plotted against each 
other and the data points joined up in .time sequence. The 
resulting graphs are shown in Figures 4.15-4.17. There is 
an obvious anticlockwise hysteresis loop for one volunteer 
and the possibility of hysteresis in a further volunteer. 
There was no evidence of hysteresis in the remaining seven 
volunteers. Since the effect did not appear to lag behind 
plasma drug levels in the majority of volunteers, these 
data further support the theory that the hysteresis seen 
after oral perindopril may be the reason for the reduced
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incidence of first dose hypotension observed with this 
compound.
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CHAPTER 5
THE EFFECT OF SATURATION OF PLASMA AND TISSUE 
ACE BINDING SITES ON THE PHARMACOKINETICS 
OF 3H-SPIRAPRILAT IN RABBIT
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5.1 INTRODUCTION
5.1.1 Scope Of Chapter
In this chapter the pharmacokinetics of radiolabelled 
spiraprilat in rabbit are characterised, in the presence 
and absence of saturated plasma and tissue binding sites. 
In addition, at the end of the study, the rabbits were 
sacrificed and the levels of radiolabelled spiraprilat in 
various tissues quantified.
5.1.2 The Contribution Of Tissue ACE To The 
Pharmacodynamic and Pharmacokinetic Response To 
ACE Inhibitors.
The possibility that tissue sites and not plasma may be 
the major site of action for the ACE inhibitors was first 
proposed in the early 1980's. Work carried out in animals 
demonstrated that inhibition of ACE activity in certain 
tissues better correlated with the antihypertensive 
activity of ACE inhibitors than did the inhibition of 
plasma ACE activity. Cohen and Kurz (1982) studied the 
effect of administering captopril or enalapril to 
spontaneously hypertensive rats (SHR). Both drugs 
produced a prolonged inhibition of ACE in lung, aorta and 
kidney when compared to serum. Similar findings were 
reported by Unger et al (1985) after administration of 
enalapril and Hoe498 to SHR. Two weeks of treatment with
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either drug produced markedly different responses in ACE 
inhibition within different tissues. After withdrawal of 
the drug blood pressure remained decreased for a further 
two weeks whereas plasma ACE activity returned to normal 
or elevated levels. Tissue ACE activity, measured one 
week after withdrawal, was still inhibited in aortic wall 
and kidney.
In man, a characteristic feature of the ACE inhibitors is 
a long terminal half life of elimination. The explanation 
for this phenomenon is thought to be due to binding to, 
and subsequent dissociation from, ACE in plasma and/or 
tissue. Pharmacokinetic information about the ACE 
inhibitors in animals is scant, although a slow terminal 
phase of elimination has been reported for benazeprilat 
after intravenous administration to rat, dog and baboon 
(Waldmeier and Schmid, 1989).
The study reported in this chapter sought to investigate 
the pharmacokinetics of spiraprilat, the active metabolite 
of spirapril, in rabbit. In a crossover design the 
animals were predosed with either unlabelled spiraprilat 
or dose vehicle to saturate plasma and tissue binding 
sites. The pharmacokinetics of intravenous radiolabelled 
spiraprilat were then characterised in the presence and 
absence of saturated ACE binding sites. After the second 
phase of the study the animals were sacrificed and the 
effect of the predosing regimen on tissue levels of 
spiraprilat assessed.
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5.2 METHODS
5.2.1 Study Design
The study was an open, balanced, crossover design in which
six New Zealand White male rabbits (Cheshire Rabbit Farm,
Tarpoley, EW6 OED) were pretreated with placebo or 3mg of
unlabelled spiraprilat. Pretreatment doses were
administered intraperitoneally (i.p.), twice daily, for
three days. On the third day the rabbit received their
morning i.p. dose and then the marginal ear vein and
central ear artery were cannulated. One hour after the
morning i.p. dose the rabbits received an intravenous
(i.v.) dose of 3.1 mg spiraprilat which contained a tracer
dose of 0.1 mg 3H-spiraprilat. Blood samples (1ml) were
taken from the cannulated artery at 0, 2, 5, 10, and 30
minutes, 1, 2, 4, 6, 8, 10 and 24 hours post i.v. dose.
Blood samples were separated by centrifugation (15 mins, 
o
3000rpm, 4 C), the resulting plasma and red blood cells
o
(RBC) were stored frozen (-20 C) until analysis.
In the second phase of the study the rabbits received the 
alternate pretreatment followed by a second i.v. dose 
containing 3H-spiraprilat.
Preliminary analysis of plasma levels of 3H-spiraprilat 
obtained during the first phase of the study indicated 
that the levels of radioactive counts had fallen to 
background by 8 hours post i.v. dose, and so, the 10 and 
24 hour samples were not taken in the second phase of the
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study.
At 8 hours post i.v. dose in the second phase of the study 
the animals were sacrificed by an i.v. overdose of 
barbiturate. The animals were quickly dissected and 
tissue samples taken and immersed in ice cold saline. The 
tissues removed were aorta, atria, lung, liver and kidney.
5.5.2 Preparation Of Spiraprilat Dose Solutions
Unlabelled spiraprilat was dissolved in 0.1M Phosphate
Buffer, pH7.4, to give a final concentration of 6mg/ml.
The 3H-spiraprilat was supplied in ethanol. The ethanol
o
was evaporated under air at 40 C and the drug taken up in 
7mls of the unlabelled spiraprilat solution. The final 
concentration was 6.2mg/ml, containing a tracer amount of 
3H-spiraprilat, 0.2mg/ml.
The rabbits were predosed i.p. with 0.5ml unlabelled 
spiraprilat or 0.5ml 0.1M Phosphate Buffer. The i.v. 
dose, 3.1 mg in 0.5ml, contained 0.1mg of 3H-spiraprilat.
5.2.3 Sample Analysis
5.2.3.1 Plasma And RBC 3H-Spiraprilat
Plasma aliquots, 0.4ml, were counted for 5 minutes in 
10mls of Hionic Fluor. Samples were corrected for 
counting efficiency using the automated external standard 
channels ratio method and a quench curve (chapter 2,
154
section 2.2.10). Results were expressed in ng/ml of 3H- 
spiraprilat. The limit of detection for 3H-spiraprilat 
was 0.1ng/ml, as defined by counts due to 3H-spiraprilat 
being twice the counts due to background.
The RBC, 0.1g, were decolourised with 1.0mls hydrogen 
peroxide and counted for 5 minutes in 1Omls Hionic Fluor. 
Samples were corrected for counting efficiency as 
described previously.
5.2.3.2 Tissue 3H-Spiraprilat
Tissues had been removed from the animals and stored in
ice cold saline. The tissues were thoroughly rinsed to
remove any residual blood, dried and finely chopped.
Approximately 100-150mg of chopped tissue was weighed into
a scintillation vial and 1ml of soluene added. Vials were
o
placed in a shaking water bath at 37 C and left overnight 
to allow the tissues to solubilise. The dissolved tissues 
were decolourised by the addition of 200/il of hydrogen 
peroxide and counted for 5 minutes in 1Omls of Hionic 
Fluor. Results were corrected for counting efficiency and 
sample weight, and were expressed as ng 3H-spiraprilat/g 
tissue. The limit of detection for 3H-spiraprilat in 
tissue was 0.1ng/g.
5.2.4 Pharmacokinetic Analysis
Two and three compartment intravenous bolus dose models 
were fitted to the 3H-spiraprilat plasma data. The
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estimates of the model parameters were obtained by non­
linear least squares regression on a Nodecrest V76
computer using the statistical package VASP. Model
a
selection was based on the Akaike criterion and the F- 
Ratio test.
The AUC (0-8h) was calculated by the trapezoidal rule. 
The area from 8h to infinity was calculated by dividing 
the concentration at 8h by the terminal elimination rate 
constant. Clearance of 3H-spiraprilat was calculated by 
dividing the dose by the AUC (0 to infinity).
5.2.5 Statistical Analysis
The parameters of the pharmacokinetic model which best 
described the data were compared by paired t-test. The 
paired t-test was also used to compare the calculated 
clearance values.
5.3 RESULTS
5.3.1 Rabbits
During phase 1 (pretreated with placebo), at 8.5 hours 
post i.v. dose rabbit no. 2 died. This was not thought to 
be a drug related effect. Since results had only been 
collected for one phase of the study for this animal, it 
was excluded from the final analysis.
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Yamaoka, K. et al. (1978). J. Pharmacokinetics and
Biopharmaceutics. 6(2), 165 - 175.
No other incidents occurred during either phase of the 
study.
5.3.2 Plasma 3H-Spiraprilat Analysis
After i.v. administration of 3H-spiraprilat, plasma levels 
declined rapidly in all animals and were no longer 
detectable by 10 hours post i.v. dose. Mean plasma levels 
after placebo and active pretreatment are shown in Table
5.1 and are illustrated in Figure 5.1.
Plasma levels declined in a multiphasic fashion. Two and
three compartment intravenous bolus dose models were
fitted to the data. On the basis of the Akaike criterion
and the F-Ratio test the data for all animals, in both
phases of the study, were best described by a three
compartment model. The mean (SD) half lives for the three
phases of decline were 1.8(1.0), 9.5(3.9) and 197(124)
minutes following placebo pretreatment and 1.4(0.6),
7.5(1.9) and 147(10.6) minutes following unlabelled
spiraprilat pretreatment. The individual parameter values
of the model are shown in Table 5.2. The parameters of
the model derived following placebo or active pretreatment
were compared statistically. No significant difference
was found between any of the parameters with the exception
of beta, the rate constant associated with the second
phase (p=0.03). The mean (SD) values of beta were
-1
4.83(1.34) and 5.78(1.26)h following placebo and active 
pretreatment respectively.
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TABLE 5.1
Mean Plasma Levels Of Intravenous 3H-Spiraprilat 
Following Pretreatment With Placebo Or Unlabelled
Spiraprilat
Time Plasma 3H-Spiraprilat (ng/ml)
(h:min) Placebo Active
Pretreatment Pretreatment
0:02 87.9 (24.0) 82.1 (22.0)
0:05 47.3 (14.3) 36.2 (9.80)
0:10 24.2 (12.2) 18.6 (5.76)
0:30 5.37 (2.50) 4.39 (2.79)
1 :00 1 .65 (0.44) 1 .92 (1 .02)
2:00 0.90 (0.21) 0.96 (0.29)
4:00 0.47 (0.20) 0.58 (0.22)
6:00 0.34 (0.18) 0.43 (0.15)
8:00 0.26 (0.13) 0.36 (0.18)
Data shown are mean (SD) values.
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TABLE 5.2
parameter Values For The Three Compartment IV Bolus Dose 
Model Used To Describe Plasma 3H-Spiraprilat
Data In Rabbit
Rabbit A
(ng/ml)
Alpha
(/h)
B
(ng/ml)
Beta
(/h)
C
(ng/ml)
Gamma
(/h)
Placebo Pretreatment
1 126 23.2 43.5 5.44 1 .79 0.40
3 269 61 .9 90.8 5.96 2.21 0.25
4 135 27.0 27.5 5.35 1 .64 0.28
5 102 12.2 22.3 2.54 0.46 0.10
6 106 23.6 20.7 4.88 1 .23 0.29
Mean 148 29.6 41 .0 4.83 1 .47 0.26
SD 69.3 18.9 29.3 1 .34 0.66 0.11
Active Pretreatment
1 127 43.2 40.6 7.17 1 .52 0.28
3 283 53.1 62.1 6.28 1 .97 0.26
4 112 27.3 41 .0 6.38 1 .99 0.27
5 161 28.2 42.7 3.93 3.44 0.30
6 128 18.4 23.5 5.12 1 .67 0.31
Mean 162 34.0 42.0 5.78 2.12 0.28
SD 70.0 13.9 13.7 1 .26 0.77 0.02
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The clearance of 3H-spiraprilat was calculated for both 
phases of the study. Individual data are shown in Table 
5.3. The mean (SD) clearance values were 104(36.3) and 
108(32.2)ml/min following pretreatment with placebo and 
unlabelled spiraprilat respectively. No significant 
difference was found between the clearance values.
5.3.3 RBC 3H-Spiraprilat Analysis
The methodology available to measure the concentration of 
3H-spiraprilat in RBC involved solubilisation followed by 
decolourisation with hydrogen peroxide and finally, 
counting in 1Omls of Hionic Fluor. The volume of hydrogen 
peroxide used, 1ml, was the maximum amount that the 1Omls 
of Hionic Fluor could be added to and still form a stable 
emulsion. However, for the vast majority of the samples 
the solutions were still so coloured that the AES values 
lay outwith the range of the quench curve. For the few 
samples that were able to be quench corrected, a 
qualitative assessment revealed that the levels of 3H- 
spiraprilat were low, approximately 5ng/g, and appeared to 
remain fairly constant over the 8 hour sampling period.
5.3.4 Tissue 3H-Spiraprilat Analysis
Five tissues were sampled, aorta, liver, lung, atria and 
kidney. In the case of the aorta the weight of tissue
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TABLE 5.3
Individual Clearance Data For 3H-Spiraprilat
Rabbit 3H-Spiraprilat
Placebo
Pretreatment
Clearance (ml/min) 
Active 
Pretreatment
1 110 139
3 65.0 86.0
4 107 118
5 80.2 64.2
6 160 134
Mean 104 108
SD 36.3 32.2
161
sampled was insufficient to enable any 3H-spiraprilat to 
be detected. The levels of 3H-spiraprilat measured in the 
remaining tissues were well above the limit of detection. 
Only five of the original six rabbits reached the end of 
the second phase of the study. Of these five, two had 
been pretreated with unlabelled spiraprilat and three had 
received placebo.
The mean levels of 3H-spiraprilat following unlabelled 
spiraprilat pretreatment were 1.5, 2.7, 0.62 and 23.7 ng/g 
in liver, lung, atria and kidney respectively. The mean 
levels of 3H-spiraprilat following placebo pretreatment 
were 1.0, 8.9, 0.60 and 8.7ng/g in liver, lung, atria and
kidney respectively. The individual data are illustrated 
in Figure 5.2.
5.4 DISCUSSION
The aim of the study described within this chapter was to 
characterise the pharmacokinetics of an intravenous tracer 
dose of 3H-spiraprilat in the presence and absence of 
saturated plasma and tissue ACE binding sites. Only a 
limited amount of 3H-spiraprilat was available for use. 
To ensure a sufficient presence of spiraprilat within the 
plasma such that the 3H-spiraprilat could be detected, the 
3H-spiraprilat was administered as a tracer dose within a 
thirty fold larger unlabelled spiraprilat dose.
The plasma pharmacokinetics of 3H-spiraprilat were best 
described by a three compartment model. No difference was
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found between any of the parameters of the model,
irrespective of pretreatment, with the exception of beta,
the rate constant associated with the second phase of
decline. The effect of saturation of plasma and tissue
ACE binding sites caused an increase in the value of beta
- 1
from 4.83 to 5.78h . This was manifested as a decrease
in the half life of elimination for that phase from 9.5 to
7.5 minutes. No difference was found in the calculated 
clearance values. Thus, in the presence of saturated ACE 
binding sites, while the rate of elimination was increased 
in the second phase, the effect was small and did not
contribute to a change in total clearance.
The plasma ACE activity of rabbits is typically 40-60EU/L 
which is higher than the range normally found in man, 15- 
30EU/L. Despite the greater amount of ACE activity
present in rabbit plasma, the terminal half life of
elimination of 3H-spiraprilat was short, between 2 and 3 
hours, irrespective of the pretreatment administered.
Due to the low number of animals studied with respect to 
characterisation of tissue levels of 3H-spiraprilat, the 
results can only be interpreted qualitatively. Despite 
this, some interesting trends were shown for some of the 
tissues studied. The highest levels of 3H-spiraprilat 
were found in the lung and the kidney. Both these organs 
are associated with high endogenous amounts of ACE. The 
presence and absence of saturated binding sites appeared 
to have no effect on the 3H-spiraprilat levels in kidney
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or atria. However, in the lung, lower levels of 3H- 
spiraprilat were found when binding sites had been 
saturated. The opposite was found in the liver, the 
pretreatment to saturate binding sites led to an increase 
in the amount of 3H-spiraprilat present.
In conclusion, the rabbit would appear not to be a good
model for plasma ACE inhibitor pharmacokinetics in man. 
Despite higher plasma ACE activity values, the long
terminal half life, a characteristic feature of ACE 
inhibition in man, was not observed for 3H-spiraprilat in 
rabbit. It is possible that the long terminal half life
may have been present at levels below the limit of
detection for 3H-spiraprilat in rabbit plasma. The 
presence of saturated plasma and tissue ACE binding sites 
did not cause any significant alteration in the clearance 
of 3H-spiraprilat from rabbit.
164
CHAPTER 6
THE EFFECT OF SATURATION OF PLASMA AND TISSUE ACE 
BINDING SITES ON THE PHARMACOKINETICS 
OF ENALAPRILAT IN MAN
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6.1 INTRODUCTION
6.1.1 Scope Of Chapter
In this chapter the pharmacokinetics of enalaprilat in man 
are characterised, in the presence and absence of 
saturated plasma and tissue ACE binding sites. The 
pharmacokinetics of enalaprilat were studied after two 
separate single oral doses of 1Omg enalapril to eight 
healthy male volunteers. The ACE binding sites were 
saturated by predosing the volunteers with captopril prior 
to the second dose of enalapril.
6.1.2 The Contribution Of Tissue ACE To ACE Inhibitor
Pharmacokinetics
It is only within recent years that the traditional view 
of the renin angiotensin system (RAS) as a circulating 
endocrine system has been expanded. It is now widely 
recognised that renin and angiotensinogen genes, and their 
products, are expressed at many local tissue sites.
An increasing body of evidence supports the theory that
these local tissue sites play an important role in blood
pressure regulation. That this is the case is supported 
by the relative independence of the ACE inhibitors from 
their plasma pharmacokinetics (Schoenberger and Wilson, 
1986, de Cesaris et al, 1987 and Garanin, 1986).
Work has been carried out in animal species to investigate
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the degree of inhibition of ACE within the tissues with 
respect to time. These data have shown that the ACE 
inhibition profile seen in plasma does not parallel that 
seen in tissue (Jackson et al, 1988b and Johnson et al, 
1988) .
The contribution of tissue sites of action to the plasma 
pharmacokinetics of the ACE inhibitors has not been 
investigated in man. It is a characteristic feature of 
the ACE inhibitors that they have a long terminal half 
life. Binding to ACE, in the plasma and/or in the tissues 
may be responsible for the long terminal phase (Till et 
al, 1982). The extended half life for these drugs appears 
to have no clinical significance since there is little 
accumulation after chronic dosing (Nussberger et al, 
1987) .
The study described in this chapter seeks to examine the 
pharmacokinetics of enalaprilat in the presence and 
absence of saturated plasma and tissue binding sites in 
man. Captopril was selected as the ACE inhibitor to 
saturate the binding sites because it is known to be 
unstable in plasma, undergoing rapid autoxidation to form 
disulphide dimers (Kripalani et al, 1980). As such, 
storage of the plasma samples containing both captopril 
and enalaprilat would eventually enable a 'clean' 
quantification of the enalaprilat plasma concentrations.
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6.2 METHODS
6.2.1 Study Design
Eight young healthy male volunteers were recruited to the 
study. Their mean ages and weights (SD) were 27 (8) years 
and 74 (12) kg respectively. Full demographic data are 
shown in Table 6.1. These volunteers formed part of a 
study designed to investigate the effects of age on the 
pharmacokinetics of benazepril and its active metabolite, 
benazeprilat, and to compare the results with enalapril. 
The benazepril study will be described in full detail in 
chapter 7. Thus, for the first part of the present study, 
the eight volunteers (Subjects 2-9) had already received a 
single 1Omg dose of enalapril and placebo as part of a 
double blind, randomised, crossover trial. The second 
part of the present study was an open design in which the 
eight volunteers received captopril, 5Omg, twice daily, 
for five days. Two hours after the morning dose of 
captopril on the fifth day a second oral dose of 
enalapril, 10mg, was administered. Blood samples were 
taken predose and following both enalapril doses for a 72 
hour period.
6.2.2 Sample Analysis
6.2.2.1 Captopril Analysis
Samples taken at 15 minutes before and at the time of the
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TABLE 6.1
Volunteer Demographic Data For Enalapril 
Pharmacokinetic Study In Man
Subject Age
(yrs)
Weight
(kg)
Height
(cm)
Creatinine Clearance 
(ml/min)
2 22 70 170 162
3 27 102 185 160
4 21 62 170 97
5 39 73 172 87
6 39 71 175 112
7 24 73 175 100
8 21 69 180 90
9 21 76 179 nd
Mean 27 74 176 115
SD 8 12 5 32
nd - not determined.
169
second dose of enalapril were assayed for captopril levels 
using a combination of the methods reported by Jarrot 
(1980) and Hayashi (1985). Mixed disulphides of captopril 
were reduced to form captopril which was then derivatised 
and assayed by HPLC with fluorescence detection. No 
internal standard was used so the results for total 
captopril are semi qualitative.
Measurement of 'clean' enalaprilat levels after
pretreatment with captopril depended on the instability of
captopril in biological media. To check that captopril 
does dissociate from any ACE molecules it may be bound to 
(since the presence of captopril would interfere with 
subsequent assays for plasma enalaprilat), two predose 
blood samples containing captopril, withdrawn from two 
different subjects in the second phase of the study were 
used. One sample was kept on ice and the other at room 
temperature. The samples were assayed for ACE activity 
eight times during the eight hours after sampling.
6.2.2.2 ACE Activity Analysis
ACE Activity was measured by the method described in 
chapter 2, section 2.2.2. ACE activity was measured on
four different occasions, once each after placebo and
enalapril alone and twice after enalapril plus captopril. 
Following the second dose of enalapril (taken as well as 
captopril), samples were first assayed within one hour of 
the sample being withdrawn such that the combined effect
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of captopril and enalaprilat on ACE activity could be 
measured. The second analysis was carried out at least 
one month later, when any changes in ACE activity could be 
attributed to enalaprilat only.
6.2.2.3 Enalaprilat Analysis
Following administration of enalapril, enalaprilat levels 
were measured by the technique described in chapter 2, 
section 2.2.8.
6.2.3 Pharmacokinetic Analysis
The ACE activity data were placebo corrected and the 
percent inhibition of ACE calculated. The AUC for the 
percent inhibition of ACE with respect to time was 
calculated from 0 to 72 hours by the trapezoidal rule.
The area under the enalaprilat plasma concentration v time 
curve (AUC) for 0 to CO was calculated by the trapezoidal 
rule. The area from 72 hours to GO was calculated by 
dividing the concentration at 72 hours by the terminal 
elimination rate constant.
The terminal elimination half lives (t )for enalaprilat
1 / 2
were calculated according to
t1/2 = 0.693
P
where [} is the terminal elimination rate constant.
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One and two compartment models with zero order input were 
fitted to the enalaprilat data. The estimates of the 
model parameters were obtained by non-linear least squares 
regression on a Nodecrest V76 computer. The data were 
weighted by the reciprocal of the concentration. Model 
selection was based on the Akaike criterion and the F- 
Ratio test.
6.2.4 Statistical Analysis
The three ACE activity AUC values were compared by 
repeated measures one way analysis of variance (ANOVA).
The enalaprilat AUC data, the parameters of the model and 
the terminal elimination half lives were compared by 
paired t-test.
The four ACE activity profiles (placebo, enalapril alone 
and enalapril plus captopril analysed both immediately and 
after one month) were analysed by repeated measures ANOVA. 
Where appropriate, Bonferroni multiple comparisons were 
calculated to identify significant differences both within 
and across the different ACE activity profiles.
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6.3 RESULTS
6.3.1 Volunteer Compliance
Seven of the eight volunteers completed the study. The 
remaining volunteer (subject no. 8) did not return for the 
48 and 72 hour samples following the second dose of 
enalapril. This prevented the pharmacokinetics of 
enalaprilat and ACE activity from being correctly
characterised in the second phase of the study.
6.3.2 Captopril Analysis
The results for the two samples analysed for captopril for 
each volunteer, taken 15 minutes before and at the time of 
administration of the enalapril dose are shown in Table 
6. 2 .
The results for the two samples containing captopril, one 
stored on ice and the other at room temperature, are shown 
in Table 6.3. The ACE activity values for both samples 
increased over the eight hour analysis period indicating a 
rapid dissociation of captopril from ACE.
6.3.3. ACE Activity Data
The mean ACE activity data for the seven subjects who 
completed the study are shown on Table 6.4. The mean
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TABLE 6.2
Plasma Captopril Levels In Enalapril 
Pharmacokinetic Study In Man
Subject Plasma Captopril Concentration (jjg/ml)
Time(min)
-15 0
2 nd nd
3 0.8 0.6
4 0.1 0.1
5 0.8 0.4
6 0.4 ' 0.5
7 1 .2 0.4
8 0.8 1.0
9 0.4 0.3
Mean 0.6 0.5
SD 0.4 0.3
nd - not determined.
Times relate to the second dose of enalapril.
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TABLE 6.3
The Dissociation Of Captopril From ACE 
With Respect To Time
Sample Kept At Room Temperature Sample Kept On Ice
Time ACE Activity Time ACE Activity
(min) (EU/L) (min) (e u /l )
52 2.2 32 5.3
111 8.3 72 6.0
171 12.3 133 7.4
230 13.6 173 8.1
290 12.2 225 9.8
350 13.0 291 11.8
410 13.4 345 15.0
470 12.4 460 18.3
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TABLE 6.4
Mean ACE Activity Data Measured In Enalapril Pharmacokinetic Study In Man
Time Placebo Enalapril Enalapril plus Captopril
Alone
(h) Analysed Analysed
Immediately After 1 Month
0 29.1 (5.6) 27.5 (6.5) 3.1 (2.6) 29.0 (4.9)
0.5 26.3 (5.2) 22.6 (5.0) 2.3 (0.8) 24.5 (5.8)
1.0 27.0 (5.1) 16.8 (8.3) 3.8 (1.8) 14.3 (7.1)
1.5 26.8 (5.7) 11.3 (7.2) 4.3 (2.3) 9.7 (5.5)
2.0 25.6 (5.8) 8.2 (5.8) 4.3 (2.5) 7.9 (4.5)
3.0 26.3 (6.4) 6.2 (3.4) 4.0 (2.2) 6.8 (4.0)
4.0 26.9 (6.2) 5.1 (1.8) 3.7 (2.1) 7.1 (4.4)
5.0 26.8 (5.6) 5.1 (2.3) 4.5 (2.2) 6.0 (2.4)
6.0 26.9 (5.3) 4.9 (2.7) 4.7 (2.1) 6.5 (2.3)
8.0 25.1 (4.4) 6.3 (2.6) 5.9 (2.0) 7.9 (2.3)
10.0 25.6 (5.0) 8.0 (3.5) 8.7 (2.4) 10.0 (2.4)
12.0 25.5 (4.4) 9.6 (4.0) 9.9 (2.8) 11.9 (2.5)
24.0 27.6 (5.4) 14.0 (7.1) 17.4 (5.4) 21.9 (5.2)
48.0 26.9 (6.3) 20.5 (7.8) 24.1 (7.3) 30.5 (6.3)
72.0 28.8 (5.6) 25.3 (6.2) 27.3 (5.5) 35.3 (6.8)
Values shown are mean ACE activity (SD) levels and have units of EU/L.
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percent inhibition of ACE data for the eight subjects are 
shown in Table 6.5 and represented graphically in Figure 
6.1 .
The AUC for the percent inhibition of ACE with respect to
time was determined from 0-72 hours on three occasions per
volunteer. First, when enalapril had been given alone,
thus all inhibition of ACE could be attributed to
enalaprilat (AUC ). The second ACE inhibition AUC was
1
determined from the samples analysed immediately after the
second dose of enalapril when inhibition of ACE activity
was due to the both enalaprilat and captopril (AUC ). The
2
third ACE AUC was determined one month after the second
dose of enalapril and so represents the contribution of
enalaprilat only to the inhibition of ACE activity (AUC ).
3
Subject no. 8 did not return for the 48 and 72 hour
samples following the second dose of enalapril and so his
ACE AUC data were calculated from 0-24 hours only. The
individual ACE AUC data are shown in Table 6.6.
The three ACE AUC's were analysed statistically by
repeated measures one way ANOVA. The analysis was carried
out twice, once including and once excluding the 0-24 hour
data for subject no. 8. For both analyses the test gave
the same qualitative result and so only the data excluding
subject no. 8 are presented. There was a significant
difference between the three ACE AUC's (p=0.001).
Bonferroni confidence intervals (95% Cl) were calculated
to show where the differences lay. No difference was
found between AUC and AUC (95% Cl -665 to 1136) but
1 2
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TABLE 6.5
Mean Inhibition Of ACE Activity Calculated 
In Enalapril Pharmacokinetic Study In Man
Time Enalapril Enalapril plus Captopril
Alone
(h) Analysed Analysed
Immediately After 1 Month
0 0 (0.0) 88.1 (11.5) 0 (0.0)
0.5 7.1 (8.0) 82.4 (7.2) 6.3 (15.5)
1 .0 32.6 (26.2) 79.8 (9.4) 45.1 (18.7)
1 .5 50.6 (29.5) 76.9 (9.7) 59.5 (16.3)
2.0 57.0 (25.9) 73.1 (9.3) 61 .0 (14.5)
3.0 69.0 (17.7) 78.5 (7.9) 66.8 (10.6)
4.0 73.0 (10.6) 79.2 (10.1 ) 68.2 (14.9)
5.0 74.0 (6.1 ) 76.3 (10.2) 71 .6 (11.2)
6.0 74.2 (10.5) 74.9 (11.5) 69.4 (12.4)
8.0 63.4 (13.6) 65.5 (9.4) 59.1 (10.3)
10.0 58.4 (16.0) 57.8 (10.3) 54.4 (11.6)
12.0 53.2 (13.6) 52.8 (8.3) 46.8 (9.7)
24.0 44.2 (23.9) 34.0 (13.7) 20.4 (10.4)
48.0 18.9 (27.3) 7.3 (3.9) -12.6 (9.8)
72.0 6.2 (14.7) 2.5 (11.7) -22.4 (15.5)
Values shown are mean (SD) percent inhibition of ACE 
activity.
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Mean % Inhibition Of ACE Activity
TABLE 6.6 
Individual ACE Activity AUC Data
Subject Enalapril
Alone
AUC
1
Enalapril
Analysed
Immediately
AUC
2
plus Captopril
Analysed 
After 1 Month
AUC
3
2 1308 2361 726
3 2376 1591 13.0
4 3916 2504 1756
5 3112 1987 787
6 1799 2920 452
7 2756 2166 730
*
8 1143 1397 999
9 1179 1270 867
Mean 2109 2114 808
SD 863 558 494
**
Mean 2247 2024 781
**
SD 831 575 527
Data have units of EU.h/ml and are calculated from 0-72 
hours.
* - ACE Activity AUC calculated from 0-24 hours.
** - Values calculated excluding data for subject no. 8.
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both were significantly greater than AUC (95% Cl's 687 to
3
2488 and 452 to 2254 respectively).
In order to try and account for the difference in AUC
3
when compared to AUC and AUC , repeated measures ANOVA of
1 2
the ACE activity data was carried out. Significant 
differences were found between the ACE activity profiles 
(p<0.001) and between individual time points (p<0.001). 
Bonferroni multiple comparisons were then calculated to 
show where the differences lay and the results are
illustrated in Figure 6.2, a-d. The first graph, (a), in 
Figure 6.2 illustrates the significant differences between 
the ACE activity profile obtained after enalapril alone 
and the profile obtained after the second analysis of the 
enalapril plus captopril, when any change in ACE activity
is attributable to enalaprilat alone. There were
significant differences between the two profiles at 48 and 
72 hours with ACE activity being higher when captopril and 
enalapril were co-administered. Figure 6.2 (b)
illustrates the differences between the placebo and
enalapril plus captopril (analysed after one month)
profiles. There are obvious significant differences 
between the two profiles from 1 to 24 hours. The point of
interest is at 72 hours where the ACE activity value is 
significantly higher for the enalapril plus captopril 
profile when compared to placebo. The elevated levels at 
48 hours just failed to achieve statistical significance 
(95% Cl -9.8 to 1.3). Figure 6.2 (b) also shows that for
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the enalapril plus captopril analysed after one month 
profile, the 48 and 72 hour time points are significantly 
higher than their respective 0 hour time point. Figure
6.2 (c) highlights the difference between the two analyses 
of the enalapril plus captopril profile. Significant 
differences are indicated at the early time points when 
the ACE activity was already inhibited due to the prior 
dose of captopril. Significant differences were also 
found at 48 and 72 hours. Figure 6.2 (d) compares the 
profile due to enalapril alone and that due to enalapril 
plus captopril, analysed immediately. Significant 
differences were only found at the early time points, 
again due to the prior dose of captopril.
6.3.4 Enalaprilat Pharmacokinetic Analysis
The two enalaprilat profiles obtained for each subject are 
represented graphically in Figures 6.3-6.6.
The enalaprilat AUC data obtained in the presence and 
absence of captopril ( 0-co) are shown in Table 6.7. The 
data for subject no. 8 are for 0-24 hours only. No 
difference was found between any of the pairs of 
enalaprilat AUC's.
One and two compartment models with zero order input were 
fitted to the enalaprilat data. The comparison of the 
models by Akaike criterion and F—Ratio test revealed that 
the majority of the data were best described by a two 
compartment model.
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TABLE 6.7 
Individual Enalaprilat AUC Data
Subject Enalaprilat
Enalapril
Alone
AUC (ng.h/ml) 
Enalapril 
plus Captopril
2 412 441
3 533 310
4 432 364
5 476 529
6 562 530
7 440 461
8* 445 357
9 298 297
Mean 450 419
SD 87 97
**
Mean 440 413
SD 86 91
Values are from 0 - <X> except * which are 0 - 2 4  
hours.
** - Values calculated excluding data for subject no. 
8.
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The parameters Vc, alpha and K21 from the two compartment 
model are shown in Table 6.8. Comparison of Vc, alpha and 
K21 for enalaprilat by paired t-test revealed no 
significant difference for any of the parameters in the 
presence of captopril. The calculated terminal half lives 
for enalaprilat are shown in Table 6.9. Again, the 
presence of captopril had no effect on the terminal 
elimination rate for enalaprilat.
6.4 DISCUSSION
The study described in this chapter sought to characterise 
the pharmacokinetics of enalaprilat in the presence and 
absence of saturated plasma and tissue binding sites. For 
analytical reasons, captopril was chosen as the agent to 
saturate plasma and tissue ACE. Pharmacokinetic analysis 
of the enalaprilat plasma profiles did not reveal any 
significant differences in the presence and absence of 
captopril. However, analysis of the plasma ACE activity 
data revealed some interesting findings. There are a 
number of possible explanations for the lack of any 
observable effect of captopril on enalaprilat's kinetics; 
Firstly, since binding to ACE is thought to be responsible 
for the long terminal half life of the ACE inhibitors, 
captopril would have to be present during the terminal 
phase, where clearance is due to the dissociation of 
enalaprilat from ACE, to have an effect. The analytical
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TABLE 6.8
Enalaprilat Pharmacokinetic Parameters
Subject Parameter
Vc Alpha K21
Enalapril Enalapril Enalapril Enalapril Enalapril Enalapril
Alone Captopril Alone Captopril Alone Captopril
2 167 169 0.18 0.19 0.055 0.061
3 311 516 0.09 0.10 0.048 0.035
4 209 203 0.14 0.19 0.031 0.045
5 101 99 0.29 0.25 0.030 0.022
6 74 72 0.31 0.35 0.017 0.106
7 216 210 0.16 0.16 0.026 0.020
9 398 287 0.15 0.16 0.020 0.077
Mean 211 222 0.19 0.20 0.032 0.052
SD 114 148 0.08 0.08 0.014 0.031
Vc has units of litres. 
Alpha has units of h*”1 . 
K21 has units of h“ .^
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Individual
TABLE
Enalaprilat
6.9
Terminal Half Lives
Subject Terminal Half Life 
Enalapril Enalapril 
Alone Plus Captopril
2 14.9 15.4
3 20.5 30.9
4 27.0 20.5
5 29.7 39.6
6 50.6 9.4
7 40.6 65.6
9 59.1 14.1
Mean 34.6 27.9
SD 16.1 19.6
Values have units of h-1.
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methodology used to measure captopril levels in the study 
did not use an internal standard and so the results for 
total captopril concentration are semi qualitative.
However, the mean values are not dissimilar to levels 
previously reported for total captopril following a single 
oral dose of 50mg (Hayashi et al, 1985). Free captopril 
has a short half life of 1.9 hours (Duchin et al, 1982b)
and plasma levels are no longer detectable by 6 to 8 hours
depending on dose. In contrast, plasma levels of protein 
conjugated captopril are still measurable at 24 hours 
following a single oral dose of 50mg (Hayashi et al, 
1985). It has been proposed that protein conjugated
captopril could act as a storage form of the drug with
subsequent release of free captopril (Duchin et al, 1988).
Studies have been reported demonstrating adequate blood 
pressure control with once daily captopril therapy
(Schoenberger and Wilson, 1986, Garanin, 1986) which 
further support the theory that captopril is released from 
its protein conjugates long after plasma free levels are 
no longer detectable. Thus, it is not impossible that 
captopril may be present during the terminal elimination 
phase for enalaprilat.
Secondly, enalaprilat is a much more potent inhibitor of 
plasma ACE than captopril (chapter 4). It is possible 
that captopril may have bound to plasma and tissue ACE 
binding sites only to be subsequently displaced following 
the administration of enalapril and its conversion to 
enalaprilat. However, the analysis of ACE activity,
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immediately and one month after sampling following the 
combination of enalapril and captopril, revealed a 
significant difference in the two calculated AUC values. 
This indicated that captopril did cause a significant 
inhibition of ACE activity and so displacement of 
captopril by enalaprilat from ACE is unlikely to be the
reason for the lack of measurable change in enalaprilat 
pharmacokinetics.
Finally, there is the possibility of induction of ACE in 
the volunteers following the twice daily dosing of 
captopril, 50mg, for five days and subsequent 
administration of 1Omg enalapril. ACE activity has been 
reported to be induced by treatment with glucocorticoids, 
macrophage activating factors and following chronic
administration of ACE inhibitors (Fyhrquist et al, 1983b).
The precise time course of induction of ACE by captopril 
has not been reported in man. In rat, administration of 
captopril in drinking water (200 ^/g/ml) gave rise to a
significant increase in serum ACE after one day of
treatment (Fyhrquist et al, 1980). The concentration of 
ACE did not change after a single dose of captopril, 
1OOmg, to eight hypertensive subjects but long term 
treatment was associated with a gradual rise in ACE
concentration over a period of weeks (Boomsma et al, 
1981). The ACE activity in hypertensive patients
receiving an increasing daily dose of enalapril achieved
statistical significance after four days (Fhyrquist et al,
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1983b). That induction is occuring in the present study 
is apparent from Figure 6.6 (b). At 72 hours the ACE 
activity value following captopril plus enalapril, 
analysed after one month, was significantly greater than 
the ACE activity measured 72 hours after the placebo dose. 
The difference at 48 hours just failed to achieve 
statistical significance. In addition, the 48 and 72 hour 
time points for the enalapril plus captopril curve, 
analysed after one month, were significantly higher than 
their respective zero hour time point. It may be that ACE 
activity was induced prior to 48 hours but that the 
presence of enalaprilat in the plasma masked the increase. 
Thus, the lack of detectable change in enalaprilat 
pharmacokinetics could be due to the induction of ACE by 
the dosing regime employed in the second phase of the 
study. The resulting increase in the number of ACE 
binding sites may have negated the effect of captopril's 
occupancy of original ACE binding sites.
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CHAPTER 7
AGE AND THE PHYSIOLOGICALLY RELEVANT CHARACTERISATION 
OF BENAZEPRILAT PHARMACOKINETICS IN MAN
189
7.1 INTRODUCTION
7.1.1 Scope Of Chapter
Drugs which inhibit ACE are increasingly used in the 
management of hypertension and heart failure. Both 
conditions are particularly common in the elderly. The 
work presented in this chapter describes a study in which 
benazepril hydrochloride was administered to young and 
elderly volunteers. The pharmacokinetics of acute and 
chronic benazeprilat have been characterised in a 
physiologically relevant manner and the influence of age 
examined. In addition, the protein binding of 
benazeprilat was measured, and again, the effect of age 
assessed.
7.1.2 Benazepril Hydrochloride And Benazeprilat.
Benazepril hydrochloride is a new ACE inhibitor currently 
under development. It is a prodrug and after oral 
administration the ethoxycarbonyl moiety is hydrolysed in 
the liver to form the active carboxylic acid metabolite, 
benazeprilat. In normal volunteers benazepril
hydrochloride has a high first pass effect and is rapidly 
and extensively converted to benazeprilat (Kaiser et al, 
1989). The elimination of benazepril hydrochloride is 
virtually complete by four hours post dose. Peak levels 
°f benazeprilat are achieved by one and a half hours post
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dose. The elimination of benazeprilat is mainly renal in 
subjects with normal renal function. Benazeprilat 
elimination is biphasic, the half lives of elimination are 
of the order of three and twenty four hours.
7.1.3 Description Of ACE Inhibitor Pharmacokinetics
A characteristic feature of the ACE inhibitors is a long 
terminal half life of elimination which has been
attributed to the saturable binding to, and subsequent 
dissociation from, ACE itself. In addition to model 
independent and standard compartmental analysis, the 
pharmacokinetics of this group of drugs have been
described by two novel approaches. Both methods 
incorporate binding of the inhibitor drug molecules to ACE 
as part of the model (Francis et al, 1987, Lees et al, 
1989). The approach described by Francis et al proposed a
model for cilazaprilat, formed after the oral
administration of cilazapril, which incorporated binding 
to plasma ACE only. Furthermore, due to low plasma 
protein binding of cilazaprilat, non specific binding was 
considered to be zero. Lees et al (1989) proposed a 
series of models to describe the pharmacokinetics of 
perindoprilat administered by intravenous infusion. These 
models incorporated binding to plasma ACE, binding to 
tissue ACE or a combination of both binding sites.
The approach proposed by Lees et al (1989) has been
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utilised in this chapter. The model has been extended to 
describe the pharmacokinetics of acute and chronic 
benazeprilat, formed after the oral administration of
benazepril hydrochloride.
7.1.4 Influence Of Age On Drug Disposition
Many physiological changes occur as the human body ages, 
the influence of these changes on drug disposition are 
summarised briefly below.
Despite theoretical considerations there is little
evidence to suggest that the absorption of drugs is 
affected by ageing, whilst absorption may be slightly 
delayed it tends to be just as complete. Conflicting 
reports are available in the literature as to the effect 
of age on first pass metabolism. Both reduced and
unaltered first pass effects have been reported for the 
beta-blockers in the elderly (Castleden and George, 1979, 
and Schneider et al, 1980).
The influence of changes in body composition on volume of
distribution, decrease in body water, increase in body
fat, depend upon the physico-chemical characteristics of
the drug under consideration. Protein binding tends to
decrease with age, serum albumin levels fall with
advancing years but alpha -acid glycoprotein levels rise,
1
albeit to a lesser extent.
Glomerular filtration falls by about 10% per decade after 
the age of forty. Consequently the elimination of renally
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cleared drugs is decreased in the elderly.
7.2 METHODS
7.2.1 Study Design
Nine young (9 males) (Subjects 1-9) and nine elderly (7 
males, 2 females) (Subjects 10-18) were recruited after 
routine screening to confirm good health. All subjects 
were living freely in the community. Written informed 
consent was obtained from all subjects and the study
design was approved by the local Ethical Review Committee. 
The mean ages (SD) for the young and elderly groups were 
26(7) and 71(3)years respectively. Correspondingly
weights were 75(11) and 66(11)kg, heights were 176(5) and
168(11)cm and creatinine clearances were 112(31) and 
78(25)ml/min respectively. Individual demographic data 
are shown in Table 7.1.
The study protocol consisted of four study days. The 
first three days formed a single blind three way crossover 
design in which single oral doses of benazepril
hydrochloride, 10mg, enalapril maleate, 10mg, and placebo 
were compared in each subject. On the fourth study day 
all subjects were studied after repeated once daily oral 
administration of benazepril hydrochloride, 1Omg once 
daily, for eight days. All study days were at least one 
week apart. Each study day involved timed blood sampling
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TABLE 7.1
Individual Demographic Data For Benazeprilat 
Pharmacokinetic Study In Man
Subject Sex Age
(Y)
Weight
(Kg)
Height
(Cm)
Creatinine
Clearance
(ml/min)
Young
1 M 23 75 177 91
2 M 22 70 170 162
3 M 27 102 185 160
4 M 21 62 170 97
5 M 39 73 172 87
6 M 39 71 175 112
7 M 24 73 175 100
8 M 21 69 180 90
9 M 21 76 179 -
Mean 26 75 176 112
SD 7 11 5 31
Elderly
10 M 76 73 180 74
11 M 73 83 182 110
12 F 74 50 162 44
13 F 74 58 158 80
14 M 66 73 168 74
15 M 70 64 161 98
16 M 73 55 152 44
17 M 69 64 176 72
18 M 68 76 176 104
Mean 71 66 168 78
SD 3 11 11 25
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until 72 hours after drug administration. Two extra blood 
samples were taken at 2 and 6 hours after acute and 
chronic administration for protein binding determination. 
Subjects 2-9 then took part in a further study which has 
been described in detail in chapter 6.
The results reported in this chapter consider the acute 
and chronic administration of benazepril hydrochloride and 
the pharmacokinetic analysis thereof. In addition, the 
analysis of the protein binding determinations is also 
reported.
7.2.2 Sample Analysis
Plasma concentrations of benazepril and benazeprilat for 
pharmacokinetic analysis were kindly measured by GC-MS by 
Ciba Geigy (CRB, Rueil Malmaison, France). The method 
which has been described in greater detail in chapter 2, 
section 2.2.5 and chapter 3 (quality control data) is 
sensitive and specific and determines levels of benazepril 
and benazeprilat independently. The samples taken for 
benazeprilat protein binding determination were analysed 
by IBA, the details of which are given in Chapter 2, 
section 2.2.7 and chapter 3 (quality control data). The 
IBA method is specific for any pharmacologically active 
moiety.
Plasma ACE activity was assayed by HHL, the details of 
which are given in chapter 2, section 2.2.2 and chapter 3 
(quality control data). Plasma ACE activity was
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determined following placebo and the acute and chronic 
doses of benazepril hydrochloride. Plasma ACE activity 
measurements obtained following the two doses of 
benazepril hydrochloride were corrected for any changes 
that occurred following placebo prior to further analysis.
7.2.3 Pharmacokinetic Analysis Of Benazepril And 
Benazeprilat.
The acute and chronic benazepril data were analysed by non 
compartmental analysis only, Cmax and Tmax were derived 
directly from the data. AUC was calculated by the linear 
trapezoidal rule.
The acute and chronic plasma benazeprilat data were 
analysed by a variety of techniques. Non compartmental 
analysis was carried out as described for benazepril. 
Five standard compartmental models were fitted to the 
combined acute and chronic data, a one compartment model 
with first order input (Model A), a one compartment model 
with zero order input, with and without lag time (Models B 
and C respectively) and a two compartment model with and 
without lag time (Models D and E respectively). A further 
six, non standard or 'binding' models were also fitted to 
the data. These 'binding' models were based upon a one 
compartment model with zero order input with either 
saturable binding in plasma, (Model F), saturable binding 
in tissue (Model G) or a combination of both binding sites
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(Model H). These three binding models were then analysed 
with an additional parameter to characterise lag time 
(Models I, J and K respectively). In addition to the 
standard parameters, Tabs (length of time over which 
absorption takes place), v/F (oral volume of distribution) 
and Ke (elimination rate constant), two further parameters 
that characterise the binding to ACE were also 
ascertained. Bmax/F is the maximum number of binding 
sites divided by bioavailability and Au(50)/F is the 
amount of drug at 50% binding saturation divided by 
bioavailability. For Models H and K where both plasma and 
tissue binding were characterised the fraction of binding 
sites in the tissue was also quantified.
The values for half life of elimination (t ), oral
1/2
clearance (CL/F) and the concentration of benazeprilat 
required to inhibit ACE by 50% (C(50))were calculated from 
the parameters of the model which best described the data 
for any one subject.
Three further models were fitted to the combined acute and 
chronic benazeprilat data. These further three models 
utilised the plasma ACE activity data in order to better 
characterise Bmax/F and Au(50)/F. The further models did 
not consider lag time, just plasma, tissue or both types 
of binding (Models L, M and N respectively).
Finally, in order to assess any possible changes in Bmax/F 
and Au(50)/F Models L, M or N were refitted to the 
separated acute and chronic plasma benazeprilat data, 
whichever model had best described the combined acute and
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chronic data.
The equations for the 'binding' models are derived in the 
Appendix.
All the standard and 'binding' models were fitted to the 
data using the statistical package BMDP on an ICL 2976 
computer. The derivative free nonlinear regression 
program PAR was used.
Model selection was based upon the Schwarz and Akaike 
criteria and a visual inspection of the residual plots and 
coefficients of variation of the estimated parameters.
A summary of all the models fitted to the data is given in 
Table 7.2 and illustrated schematically in Figures 7.1 and 
7.2.
7.2.4 Protein Binding Of Benazeprilat
The method used to determine the protein binding of 
benazeprilat was equilibrium dialysis. The method has 
been described in full detail in chapter 2, section 2.2.9. 
Two samples were taken at 2 and 6 hours post dose for 
protein binding determination, for all subjects. The 2 
hour sample was timed to coincide with peak plasma 
benazeprilat levels, the 6 hour sample with lower levels 
of benazeprilat.
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TABLE 7.2
Summary Of Models Fitted To Benazeprilat Data
Model No. Of 
Compartments
Input
(Order)
Lag Time Binding
A 1 First No N/A
B 1 Zero No N/A
C 1 Zero Yes N/A
D 2 Zero No N/A
E 2 Zero Yes N/A
F 1 Zero No Plasma
G 1 Zero No Tissue
H 1 Zero No Plasma + Tissue
I 1 Zero Yes Plasma
J 1 Zero Yes Tissue
K 1 Zero Yes Plasma + Tissue
L 1 Zero No Plasma
M 1 Zero No Tissue
N 1 Zero No Plasma + Tissue
Models A to K were fitted to plasma benazeprilat concentration data only, 
Models L to N were fitted simultaneously to plasma benazeprilat 
concentration data and plasma percent inhibition of ACE activity data.
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FIGURE 7.1
Diagramatic Representation Of The Standard 
Models Fitted To The Benazeprilat Data
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FIGURE 7.2
Diagramatic Representation Of The 'Binding' 
Models Fitted To The Benazeprilat Data
7.2.5 Statistical Analysis
The Cmax, Tmax and AUC for the benazepril and benazeprilat
data, for young and elderly subjects after acute and
chronic administration, were compared by ANOVA.
The parameters Bmax/F and Au(50)/F and the calculated
values for t and CL/F for benazeprilat, for the young 
1 / 2
and elderly subjects, were compared by the unpaired t- 
test.
The parameters Bmax/F and Au(50)/F obtained from fitting 
the acute and chronic data separately,for the young and 
old subjects, were analysed by ANOVA. The data were
analysed twice, once using unweighted data and once using 
the reciprocal of the coefficient of variation of the
estimated parameter as the weighting function.
The benazeprilat protein binding data for young and old
subjects, acute and chronic administration, at 2 and 6
hours post dose was analysed by ANOVA.
7.3 RESULTS
7.3.1 Non Compartmental Analysis Of Benazepril And 
Benazeprilat.
Plasma benazepril levels quickly reached a peak at 0.5 to 
1 hour (median) for both young and elderly volunteers 
after acute and chronic administration. Levels then 
declined rapidly and were not detectable beyond 12 hours
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post dose. The mean Cmax and AUC values were reduced in 
the elderly, after both acute and chronic administration 
although this was not statistically significant. Mean 
(SD) Cmax values were 114(42.4) and 96.0 (39.7)ng/ml after 
acute administration and 103(46.5) and 89.5(37.5)ng/ml 
after chronic administration in young and elderly 
volunteers respectively. Mean AUC (SD) values were 
131(37.8) and 106(36.6)ng.h/ml after acute administration 
and 117(28.8) and 97.2(35.9) ng.h/ml after chronic 
administration in young and elderly volunteers 
respectively. Mean plasma benazepril levels are 
illustrated graphically in Figure 7.3 and individual AUC, 
Cmax and Tmax data are presented in Table 7.3.
Conversion of benazepril to benazeprilat was rapid, peak 
levels of benazeprilat were reached by 3 hours in all 
subjects. No difference was found in Cmax for 
benazeprilat between the young and elderly subjects after 
acute or chronic administration. However, within each age 
group there was an increase in Cmax after chronic 
administration although this just failed to achieve 
statistical significance (p=0.06). Mean (SD) Cmax values 
were 189(60.2) and 176(45.3)ng/ml after acute 
administration and 206(39.5) and 197(37.2)ng/ml after 
chronic administration, in young and elderly volunteers 
respectively.
A comparison of the AUC data for benazeprilat (AUC
0-co
after acute administration and AUC after chronic
0-24
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TABLE 7.3
Individual Benazepril Tmax, Cmax And AUC Data
Subject Tmax
(h)
Acute Chronic
Cmax 
(ng/ml) 
Acute Chronic
AUC 
(ng.h/ml) 
Acute Chronic
Young
1 1 0.5 115 106 98.0 114
2 0.5 1 .5 183 62.3 173 128
3 0.5 1 123 51 .2 146 98.0
4 1 .5 1 75.4 84.1 177 106
5 0.5 0.5 141 132 149 129
6 0.5 0.5 139 185 145 182
7 0.5 1 43.3 80.6 59.4 92.6
8 1 0.5 133 158 128 121
9 0.5 1 .5 77.8 63.9 107 84.7
Mean
SD
0.5 1 114
42.4
103
46.5
131
37.8
117
28.8
Elderly
10 0.5 0.5 131 135 117 120
11 1 0.5 57.5 60.3 73.6 80.6
12 0.5 0.5 100 59.9 106 50.8
13 0.5 0.5 121 124 116 116
14 0.5 0.5 82.1 82.1 79.7 66.7
15 0.5 0.5 102 88.5 84.9 80.5
16 1 .5 1 .5 56.0 55.6 139 122
17 0.5 0.5 167 149 176 165
18 0.5 0.5 47.2 50.8 57.6 73.0
Mean
SD
0.5 0.5 96.0
39.7
89.5
37.5
106
36.6
97.2
35.9
Mean data shown for Tmax are median values.
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administration) revealed no significant difference between 
acute and chronic administration. However, although the 
AUC data were increased in the elderly, when compared to 
the young volunteers, after both acute and chronic 
administration, this just failed to achieve statistical 
significance (p=0.07). Mean AUC (SD) values were 
1106(319) and 1486(530)ng.h/ml after acute administration 
and 1097(253) and 1345(407)ng.h/ml after chronic 
administration for young and elderly volunteers 
respectively.
Mean plasma benazeprilat levels are illustrated 
graphically in Figure 7.4 and individual AUC, Cmax and 
Tmax data are shown Table 7.4.
7.3.2 Compartmental Analysis Of Benazeprilat.
Of the five standard models fitted to the combined acute 
and chronic plasma benazeprilat data (Models A-E) ten of 
the volunteers (5 young and 5 elderly) were best described 
by a two compartment model with zero order input and lag 
time (Model E). Four volunteers were best described by a 
one compartment model with zero order input and lag time 
(Model C). A further three volunteers were best described 
by a one compartment model with zero order input (Model B) 
and the remaining volunteer was best described by a two 
compartment model with zero order input (Model D).
A further six models were then fitted to the combined 
acute and chronic plasma benazeprilat data (Models F-K).
203
Pl
as
m
a 
Be
na
ze
pr
ila
t 
Le
ve
ls 
(n
g/
m
l)
Young
Acute
Young
Chronic
Elderly
Acute
Elderly
Chronic
200
150.
100.
50.
T T T
12 24 36 48
TIME (HOURS)
60 72
FIGURE 7 .4  
Mean Plasma Benazeprilat Levels
TABLE 7.4
Individual Benazeprilat Tmax, Cmax And AUC Data
Subject Tmax Cmax AUC
(h) (ng/ml) (ng.h/ml)
Acute Chronic . Acute Chronic Acute Chronic
Young
1 2 1 .5 151 197 861 912
2 1 3 294 198 1677 1289
3 1 .5 3 107 166 916 1282
4 2 1 .5 174 152 1109 907
5 1 .5 1 .5 158 231 902 1038
6 1 1 .5 275 289 1565 1594
7 1 .5 2 177 203 858 840
8 1 .5 1 160 196 847 869
9 2 2 203 219 1221 1139
Mean 1 .5 1 .5 189 206 1106 1097
SD 60.2 39.5 319 253
Elderly
10 1 .0 1 131 202 1179 1169
11 2 1 .5 139 162 984 974
12 1 .5 1 187 145 1845 1193
13 2 1 .5 188 248 1425 1389
14 1 1 .5 202 218 1560 1505
15 1 .5 1 173 159 1016 792
16 3 3 256 242 2564 2178
17 1 .5 1 .5 204 215 1828 1657
18 1 .5 2 106 181 977 1252
Mean 1 .5 1 .5 176 197 1486 1345
SD 45.3 37.2 530 407
Mean data shown for Tmax are median values.
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These models, based upon a one compartment model with zero 
order input, incorporated either saturable binding to 
plasma, tissue or plasma and tissue constituents. In 
addition, the presence and absence of a parameter to 
characterise lag time was also considered. The best model 
to describe the data was then assessed across Models A to 
K. Twelve of the volunteers were best described by Model 
G (5 young and 7 elderly) which incorporated binding to 
tissue constituents only. A further three volunteers were 
best described by Model H which included binding to both 
plasma and tissue constituents (2 young and 1 elderly). 
One volunteer was best described by Model F, plasma 
binding only. The two remaining volunteers were best 
described by standard models, a one compartment model with 
zero order input (Model B) and a two compartment with zero 
order input and lag time (Model E).
Of all the volunteers best described by the 'binding'
models the addition of a parameter to characterise lag
time did not improve the fit of the model to the data.
The calculated parameters t and CL/F as well as V/F,
1/2
Bmax/F and Au(50)/F, and the model from which they were
derived, are shown in Table 7.5. For all volunteers,
except volunteers 2 and 3 (who were best described by
standard models), t , CL/F and V/F represent free drug
1/2
only. For volunteers 2 and 3 the data represent total 
drug. There was no significant difference between young 
and elderly for any of the parameters shown.
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TABLE 7.5
Benazeprilat Pharmacokinetic Parameters Derived From 
Models A to K, Whichever Best Described The Data 
For Any One Subject.
Subject Model t1/2
(h)
CL/F
(ml/min)
Bmax/F
(/J9)
Au(5 0)/F
(pg)
V/F
(1)
Young
1 G 2.39 163 3359 30.3 33.7
2 B 3.15 132 - - 35.9
3 E 5.33 136 - - 63.0
4 G 1 .28 165 3620 318 18.3
5 H 1 .92 172 3095 6.0 28.6
6 G 2.39 95.7 2226 455 19.8
7 G 0.91 193 4273 411 15.2
8 H 1 .87 199 3395 10.5 32.3
9 G 0.72 138 5418 509 8.6
Mean 2.22 155 3627 249 28.4
SD 1 .40 32.7 1000 225 16.0
Elderly
10 G 3.46 124 2940 366 37.1
11 G 2.24 154 3552 348 29.9
12 G 4.62 112 1912 213 44.8
13 G 2.39 105 3343 270 21 .8
14 G 3.47 99.7 2093 363 29.9
15 F 2.10 228 358 21 .7 41 .5
16 G 3.01 67.1 2345 457 17.5
17 H 1 .98 192 4498 585 33.0
18 G 3.01 126 4940 249 32.9
Mean 2.92 134 2887 319 32.0
SD 0.85 49.7 1402 159 8.7
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The mean (SD) percent coefficients of variation for the 
estimation of Bmax/F and Au(50)/F were 31 (22) and 85 
(91)% respectively. The high coefficients of variation 
indicate poor estimation of these parameters. In order to 
try and improve the estimation of Bmax/F and Au(50)/F the 
'binding' Models L-N were fitted to the combined acute and 
chronic plasma benazeprilat data simultaneously with the 
combined acute and chronic plasma percent inhibition of 
ACE activity data. The addition of a parameter to describe 
lag time was not considered since this parameter had not 
previously helped to describe the fit of the 'binding'
models to the data. The mean (SD) coefficients of
variation for Bmax/F and Au(50)/F, for whichever model (L,
M or N) best described the data, were 22 (8) and 28 (12)%. 
Thus, the simultaneous fitting of plasma benazeprilat and 
percent inhibition of ACE data considerably improved the 
precision in estimation of the binding parameters. One 
volunteer was best described by the model with plasma 
binding only (Model L), fifteen volunteers were best 
described by the model with tissue binding only (Model M) 
and the two remaining volunteers were best described by 
the model with both plasma and tissue binding (Model N). 
It was not possible to compare the fit of Models L, M or N 
to the data with the fit to Models A to K since the 
inclusion of the percent inhibition of ACE data increased
the total sum of squares and the number of degrees of
freedom for the data.
The parameters t and Cl/F were recalculated and together
1 / 2
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The parameters t and Cl/F were recalculated and together
1 / 2
with V/F, Bmax/F and Au(50)/F, from whichever model (L, M
or N) best described the data are shown in Table 7.6.
Mean (SD) CL/F (free drug) was 146(27.8) and
123(28.8)ml/min for young and elderly volunteers. Mean
(SD) t (free drug) was 2.09(1.05) and 2.97(0.86)hours 
1/2
for young and elderly volunteers respectively. Mean (SD)
V/F (free drug) was 25.2(10.4) and 31.2(10.4)litres for
young and elderly volunteers respectively. The mean (SD)
values for the binding parameters Bmax/F and Au(50)/F were
3250(1046) and 2824 (1480)/U g and 242(1 25) and 252
(240)Ug for young and elderly volunteers respectively.
Again no significant difference was found between the
young and elderly although in the case of t the
1 / 2
difference only just failed to achieve significance 
(p=0.07).
The mean C(50) value calculated from the parameters from 
models L-N, whichever best described the data for any one 
subject was 8.89 (5.84) ng/ml.
The actual and predicted data for the best model to 
describe the data for each subject are shown in Figures
7.5 to 7.22.
All the models described so far were fitted to the 
combined acute and chronic data. The final analysis 
refitted either Model L, M or N (whichever previously best 
described the data) to the separated acute and chronic 
data. The values for Bmax/F and Au(50)/F were then
208
TABLE 7.6
Benazeprilat Pharmacokinetic Parameters Derived From 
Models L to N, Whichever Best Described The Data 
For Any One Subject.
Subject Model tl/2
(h)
CL/F
(ml/min)
Bmax/F
(/ig)
Au(50)
(£/g)
/F v /f 
(1)
Young
1 M 1 .28 167 5119 180 18.6
2 M 2.04 124 2655 222 21 .8
3 M 4.62 131 2611 412 52.3
4 M 1 .65 167 3002 177 23.8
5 M 1 .65 145 3933 261 20.7
6 M 2.77 94.6 1587 115 22.7
7 M 1 .31 186 3480 181 21 .1
8 M 1 .78 163 4170 144 25.1
9 M 1 .69 139 2692 484 20.4
Mean 2.09 146 3250 242 25.2
SD 1 .05 27.8 1046 125 10.4
Elderly
10 N 3.15 158 2499 96.7 43.1
11 M 2.39 155 3280 242 32.1
12 M 4.62 114 1905 154 45.5
13 M 2.57 103 3211 187 22.9
14 L 3.46 124 348 49.2 36.4
15 M 1 .65 145 3949 265 20.7
16 M 2.57 65.2 3531 265 14.5
17 N 3.65 115 1376 53.1 36.4
18 M 2.67 128 5317 407 29.6
Mean 2.97 123 2824 252 31 .2
SD 0.86 28.8 1480 240 10.4
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FIGURE 7.5
Actual And Predicted Benazeprilat Data For Subject No. 1
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FIGURE 7.6
Actual And Predicted Benazeprilat Data For Subject No. 2
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FIGURE 7.7
Actual And Predicted Benazeprilat Data For Subject No. 3
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FIGURE 7.8
Actual And Predicted Benazeprilat Data For Subject No. 4
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FIGURE 7.9
Actual And Predicted Benazeprilat Data For Subject No. 5
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FIGURE 7.10
Actual And Predicted Benazeprilat Data For Subject No. 6
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FIGURE 7.11
Actual And Predicted Benazeprilat Data For Subject No. 7
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FIGURE 7.12
Actual And Predicted Benazeprilat Data For Subject No. 8
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FIGURE 7.13
Actual And Predicted Benazeprilat Data For Subject No. 9
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FIGURE 7.14
Actual And Predicted Benazeprilat Data For Subject No. 10
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FIGURE 7.15
Actual And Predicted Benazeprilat Data For Subject No. 11
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FIGURE 7.16
Actual And Predicted Benazeprilat Data For Subject No. 12
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FIGURE 7.17
Actual And Predicted Benazeprilat Data For Subject No. 13
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FIGURE 7.19
Actual And Predicted Benazeprilat Data For Subject No. 15
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FIGURE 7.20
Actual And Predicted Benazeprilat Data For Subject No. 16
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FIGURE 7.21
Actual And Predicted Benazeprilat Data For Subject No. 17
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FIGURE 7.22
Actual And Predicted Benazeprilat Data For Subject No. 18
and elderly subjects. No significant effect of age was 
found. The mean (SD) values for Bmax/F and Au(50)/F for 
all subjects were 2986(1104) and 4622(4115) fjg and 
170(131) and 264(218) jj g for acute and chronic 
administration respectively. Although both Bmax/F and 
Au(50)/F were increased after chronic administration, this 
did not achieve statistical significance, irrespective of 
whether the weighted or unweighted data were used (p=0.17 
and p=0.13 for Bmax/F and Au(50)/F respectively for the 
unweighted data analysis). Individual data for Bmax/F and 
Au(50)/F after acute and chronic administration are shown 
in Table 7.7.
7.3.3 Protein Binding.
The protein binding of benazeprilat was measured at 2 and 
6 hours post dose for young and elderly volunteers after 
acute and chronic administration. The data were analysed 
by repeated measures ANOVA. There was one data point far 
outwith the range of the data for the remaining subjects, 
subject no. 11, 2h after acute administration. The amount 
of drug bound for this point was found to be 76.2% which 
was confirmed by repetition. However, the point was 
omitted since inclusion rendered the data non normal and 
invalidated the assumption of homoscedasticity.
No effect due to acute or chronic administration was 
found. There was a significant effect of age on binding 
(p=0.02), however, there was an age time interaction and
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TABLE 7.7
The Individual Values For Bmax/F and Au(50)/F Derived From 
Separate Fitting Of Benazeprilat Acute And Chronic Data.
Subject Bmax/F
(/jg)
Acute Chronic
Au(5 0)/F
(fj g)
Acute Chronic
Young
1 4762 2754 53.6 472
2 2620 5310 175 114
3 2130 2966 206 617
4 2731 5778 119 152
5 3742 1873 136 487
6 1948 2596 145 151
7 3230 5118 131 115
8 4136 2452 82.5 154
9 2400 5615 549 223
Mean 3078 3774 177 276
SD 961 1664 146 194
Elderly
10 1552 3891 77.6 110
11 3004 19216 396 44.4
12 4239 4897 99.0 383
13 3529 5969 246 134
14 307 335 38.0 48.4
15 3053 1701 86.0 182
16 3101 7392 288 715
17 2825 1151 76.8 63.2
18 4444 4191 153 590
Mean 2895 5416 162 252
SD 1284 5663 121 251
Young + Elderly
Mean 2986 4622 170 264
SD 1104 4115 131 218
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so binding had to be assessed at the individual time 
points. A significant difference was found only at 6 
hours (Bonferroni 95% confidence interval 1.45 to 4.48) 
and not at 2 hours (Bonferroni 95% confidence interval 
-0.32 to 2.78). The mean protein binding for benazeprilat 
was 91.5(1.56) (n=18) and 90 . 3(1.83)% (n=17) at 2 hours 
post dose and 92.2(1.29) and 89.2(2.40)% (both n=18) at 6 
hours post dose for the young and elderly subjects 
respectively. No relationship was found between the 
degree of protein binding and the plasma concentration of 
benazeprilat. The range of benazeprilat concentrations 
observed in the protein binding samples was 46.7 to 
495ng/ml.
7.4 DISCUSSION
A long terminal half life of elimination has important 
pharmacological implications in terms of drug accumulation 
and possible toxicity. The long terminal half life of the 
ACE inhibitors makes little contribution to the 
accumulation of these drugs (Till et al, 1984 and 
Nussberger et al, 1987). The characterisation of a value 
for the effective half life of accumulation for 
enalaprilat (Till et al, 1984), which was consistent with 
the observed accumulation of the drug, approximated the 
half life of the phase immediately preceeding the terminal 
phase. The proposal that the long terminal phase of
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elimination is due to the dissociation of these drugs from 
ACE is supported by the loss of dose linearity during the 
terminal phase (Till et al, 1982 and Meredith et al, 
1989) .
Two different approaches have been used to characterise 
the pharmacokinetics of these drugs using models which 
incorporate saturable binding. The model proposed by 
Francis et al (1987) has been used to describe the 
pharmacokinetics of cilazaprilat after different oral 
doses of cilazapril (Francis et al, 1987 and Meredith et 
al, 1989). The model incorporates binding to plasma ACE 
only. Furthermore, due to the low plasma protein binding 
of cilazaprilat, the nonspecific binding of cilazaprilat 
was assumed to be zero. Benazeprilat is a highly protein 
bound drug (approximately 90%) so this assumption cannot 
be made. Hence, it was not possible to use the approach 
described by Francis for the analysis of benazeprilat.
The second method, described by Lees et al (1989) was used 
to characterise the pharmacokinetics of perindoprilat 
after intravenous infusion. Models that described 
saturable binding in plasma, tissue or both plasma and 
tissue were proposed. It was the approach put forward by 
Lees that has been extended and used to describe the 
pharmacokinetics of benazeprilat after oral, acute and 
chronic, administration of benazepril hydrochloride.
The combined acute and chronic plasma benazeprilat data 
were fitted to a range of standard and 'binding' models. 
The vast majority of the data were best described by a one
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compartment model with zero order input and tissue 
binding. Of the volunteers who were best described by the 
model which incorporated both plasma and tissue binding, 
the majority of the binding took place in the tissues. 
This is consistent with the results reported by Lees et al 
(1989) where the amount of binding of perindoprilat in the 
tissue was 250% greater than that in the plasma. The 
characterisation of tissue as the major site of binding is 
not unexpected. It is now widely recognised that the 
pharmacodynamic actions of the ACE inhibitors are as a 
consequence of inhibition of tissue ACE (Unger et al, 
1985, Unger et al, 1987, Dzaii, 1988, Swales and Samani, 
1989 and Ganten et al, 1989).
The calculated parameter t represents free drug only
1/2
(characterised in Models L to N). The value of 
approximately 3.0 hours is consistent with that reported 
for the initial half life of elimination for benazeprilat 
after oral administration of benazepril hydrochloride to 
normal volunteers (Kaiser et al, 1989). This lends 
further support to the argument that the long terminal 
half life of elimination of ACE inhibitors is due to the 
slow dissociation of the drug from ACE.
The calculated mean (SD) value for the C(50) of 
benazeprilat of 8.89 (5.84) ng/ml is similar to the in 
vitro value obtained for benazeprilat of 5.14 (1.08) ng/ml 
(Chapter 4).
The accumulation characteristics of benazeprilat after
214
repeated administration have also been characterised by 
use of the 'binding' models used to describe the data. 
The 'binding' model which best described the data for any 
one subject predicted very little accumulation of the drug 
after chronic administration. The predicted plasma levels 
fell to the same level as those predicted for acute 
administration. This was not the case for the best 
standard model where the predicted plasma levels after 
chronic administration were higher and declined in a 
parallel fashion to those predicted for acute 
administration.
The phenomenon of induction of ACE by administration of 
ACE inhibitors has been well documented (Fyhrquist et al, 
1983a and Boomsma et al, 1981) although there appears to 
be little clinical significance of the phenomenon. The 
effect of induction of ACE synthesis was studied by 
examining the parameters Bmax/F and Au(50)/F obtained 
after analysis of the separated acute and chronic data. 
Both parameters increased after chronic administration 
although this did not achieve statistical significance, 
suggesting that limited induction of ACE synthesis may 
have occurred. The lack of a significant change may be
due to the possibility that the dosage regime employed in 
the present study was insufficient to induce ACE, or, that 
a change in bioavailability occurred with chronic 
administration. The latter could have masked any changes 
in the binding parameters. The results obtained for the 
protein binding analysis of benazeprilat also did not
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change between acute and chronic administration. It can 
be concluded therefore, that, in the absence of any 
changes in bioavailability, once daily dosing with 1Omg 
benazepril hydrochloride is insufficient to cause a 
significant increase in the amount of ACE.
Two different analytical techniques were used to measure 
benazeprilat concentrations within this chapter. The GC- 
MS method used to measure plasma benazeprilat levels is 
specific for benazeprilat only. The IBA method used to 
determine the protein binding of benazeprilat is specific 
for any pharmacologically active moiety. Thus, the 
protein binding results may not be specifically for 
benazeprilat but could also include any other active 
molecules that bound to plasma proteins. Glucuronides of 
benazeprilat have been detected in considerable amounts in 
urine after oral administration of benazepril 
hydrochloride (Waldmeier et al, 1990). However, the 
result obtained in this chapter for the amount of drug 
bound to plasma protein is slightly lower than that 
previously reported (95%, Dieterle et al, 1989) and so the 
results found in the present study may reflect the binding 
of benazeprilat only. The high degree of protein binding 
and low reported value for volume of distribution at 
steady state (8.7 litres, Dieterle et al, 1989) for 
benazeprilat may also have implications in explaining the 
long terminal half life previously reported for this 
compound. ACE inhibitors bind to ACE by a two step
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mechanism.
*
The inhibitor (I) rapidly binds to the enzyme (E) to form
an initial enzyme inhibitor (El) complex which then
undergoes a slow isomerisation to form a tightly bound 
*
complex (El ) which has a very small dissociation constant 
(Blinning 1987). Ahnfelt et al (1989) demonstrated that 
highly protein drugs with low volumes of distribution that 
undergo a two stage binding process, similar to that 
described for the ACE inhibitors, exhibit extremely long 
terminal half lives of elimination. The long half lives 
were inversely related to the dissociation constant for 
the tightly bound enzyme inhibitor complex.
The influence of age on the pharmacokinetics of 
benazeprilat was also examined in the present study. 
Initially it was thought that ACE inhibitors were unlikely 
to be of clinical benefit in elderly hypertensives since 
PRA tends to fall with increasing age (Meade et al, 1983). 
However, it was shown that the fall in blood pressure was 
not consistently related to the pretreatment PRA (Gavras 
et al, 1981) thus belying the reason for not using ACE 
inhibitors in elderly hypertensives.
Benazeprilat is mainly eliminated by the renal route but 
some degree of hepatic elimination does occur (Kaiser et 
al, 1989). A decrease in renal clearance in the elderly 
has been reported to contribute to the enhanced intensity
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and duration of action of the ACE inhibitors (Lees et al, 
1988). The creatinine clearances of the elderly 
volunteers in the present study were significantly lower 
(p=0.02) than those of the young volunteers, but they did 
not approach the value of 30ml/min, below which, for 
enalapril, dosage adjustment has been reported as 
necessary (Kelly et al, 1986).
No significant effect was found for the effect of age on
any of the pharmacokinetic parameters reported for the
present study although in the case of benazeprilat Cmax,
AUC and t (free drug), this just failed to achieve 
1/2
statistical significance. The non significant increases 
in these data are likely to be caused by an age dependent 
decline in renal function.
In conclusion, physiologically relevant models have been 
used to describe the benazeprilat data. The models have 
characterised the binding of the drug to ACE and have 
given a much shorter, clinically realistic estimate of the 
terminal half life of elimination which is in keeping with 
the accumulation characteristics of the drug. No 
significant differences were found between the young and 
elderly for the parameters calculated and this suggests 
that, on pharmacokinetic grounds, dosage adjustment will 
not be required. It must be appreciated that where more 
profound degrees of renal impairment are present in 
diseased elderly patients, this may not hold true.
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CHAPTER 8 
GENERAL DISCUSSION
219
In the late 1960’s, ACE was a poorly defined peptidase of 
little interest. Since then, extensive study of the
active site of the enzyme has enabled potent and specific
inhibitors of ACE to be developed as antihypertensive
drugs. The ACE inhibitors are now also being successfully
used in the treatment of cardiac failure, and in the 
future new therapeutic indications may be defined. The 
work presented in this thesis has been concerned with the 
evaluation of the disposition characteristics of the ACE 
inhibitors and their concentration effect relationships, 
with a view to optimising therapy with existing ACE 
inhibitors and discerning desirable characteristics in a 
new ACE inhibitor.
Before the pharmacokinetics of any novel compound can be 
characterised, accurate, precise, sensitive and specific 
assay methodology must be available. In the case of the 
ACE inhibitors, in addition to methods to quantify plasma 
drug levels, assay techniques were also required to 
measure ACE activity. Where more than one method is being 
used for the same measurement, a comparison of methods is 
essential to ensure the compatibility of results. Three 
groups of methods have been compared within this thesis, 
two different methods to measure ACE activity, three 
different methods to measure plasma enalaprilat levels and 
three different methods to measure plasma benazeprilat 
levels. The statistical approach adopted to assess the 
methods compared both the means and the variability within 
the methods. The two methods used to measure ACE activity
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produced results that were in good agreement with each 
other. This was not the case for determination of 
levels of enalaprilat or benazeprilat. In the case of 
enalaprilat no further metabolism has been reported, 
therefore, all analytical techniques, whether specific for 
enalaprilat or any pharmacologically active moiety, should 
give the same result. One method gave consistently lower 
results, the method which relies on the displacement of 
the binding of radiolabelled MK-351A. No obvious reason 
could be found for this. In contrast, benazeprilat has 
been reported to be metabolised further, glucuronides of 
both benazepril and benazeprilat have been identified in 
human urine after an oral dose of benazepril hydrochloride 
(Waldmeier et al, 1990). Glucuronides have also been 
found in baboon urine, however they were reported to be 
unstable (Waldmeier and Schmid, 1989). It could be that 
possible instability of the human glucuronides may have 
contributed to the discrepancy between the three methods 
to measure plasma benazeprilat. The results found for the 
three groups of assay methods highlight the need to know 
the specificity of the technique being used.
The definition of ACE inhibition is dependent upon the 
methodology used, different results are obtained when 
alternative substrates or different substrate conditions 
are utilised (Nussberger et al, 1989). It is not possible 
to compare the efficacy of the ACE inhibitors when 
identical assay techniques have not been applied. Within
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this thesis all measurements of ACE activity were based on 
the formation and quantification of hippuric acid from the 
synthetic substrate Hip-His-Leu.
The concentration effect relationship of two different 
series of ACE inhibitors was assessed in vitro, within 
plasma from individual rabbits and human volunteers. The 
potency of the different drugs was assessed by comparing 
the C(50) values, the concentration of drug required to 
inhibit ACE activity by 50%. Significant differences were 
found for individual drugs between rabbit and man, also, 
variations were found in the rank order of potency of the 
series of compounds between rabbit and man. The 
differences in C(50) in rabbit and man reflect that 
different doses would be needed to obtain the same degree 
of ACE inhibition and, presumptively, other associated 
pharmacological effects.
The comparison of the in vivo/in vitro relationship for 
perindoprilat and quinaprilat in plasma from individual 
subjects was also investigated. For both compounds the in 
vivo potency was significantly lower than that 
characterised in vitro, indicating greater inhibition of 
ACE in vivo.
After the introduction of captopril and enalapril onto the 
market, the therapeutic dose range for both drugs was 
reduced. Since the therapeutic range for any drug is 
initially characterised in animals, the differences in 
potency found between rabbit and man may be one of the 
factors that contributed to the post marketing dosage
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reduction. The discrepancy between the in vivo and in 
vitro values may also help to explain the reduction in 
recommended doses for captopril and enalapril. Any 
calculations based upon less potent in vitro values would 
have overestimated the amount of drug needed to elicit the 
same response in vivo.
Further in vitro studies were carried out that may provide 
an explanation for an in vivo hysteresis observed with 
perindoprilat. Lees (1986) carried out two in vivo 
studies to characterise the pharmacokinetics of 
perindoprilat. Firstly, after oral administration of 
perindopril and secondly, after intravenous administration 
of perindoprilat. Following oral administration of parent 
compound, when the plasma perindoprilat concentrations 
were plotted against percent inhibition of ACE activity, a 
hysteresis loop was observed. The hysteresis loop was not 
observed after intravenous administration of the active 
metabolite. The presence of hysteresis after an oral but 
not after an intravenous dose of a compound is unusual. 
Conventional thinking would predict the presence of 
hysteresis after intravenous administration, where the 
appearance of effect lags behind the immediate peak plasma 
levels of the compound. Hysteresis would not be predicted 
after oral administration where both peak effect and peak 
plasma levels are delayed after administration. 
Hysteresis was also not observed after oral administration 
of enalapril or benazepril.
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Many of the new ACE inhibitors currently under development 
are prodrugs with very low activity, these prodrugs 
require deesterification in the liver to form the active 
metabolite. Since the hypotensive action of the ACE 
inhibitor prodrugs is a consequence of the inhibition of 
ACE by the active metabolite, the in vitro studies were 
carried out to study the effect of the parent compound on 
the efficacy of the metabolite. The in vitro dose 
response curves for the active metabolites were 
characterised in the presence and absence of parent 
compound. In man, enalapril caused a small decrease in 
the potency of enalaprilat, manifested by a 21% increase 
in the C(50) value. Also in man, perindopril caused a 
large, significant decrease in the potency of
perindoprilat, the C(50) value for perindoprilat increased 
by 109%. No effect was observed of benazepril on 
benazeprilat. Thus, it may be speculated that the 
decrease in potency for perindoprilat may be due to steric 
hindrance caused by the parent compound binding on or near 
the active site of ACE. This affords a possible 
explanation of the hysteresis seen after the oral
administration of perindopril but not after the
intravenous administration of perindoprilat.
Severe problems with first dose hypotension have been 
observed after the administration of enalapril (Webster et 
al, 1985). Unpublished anecdotal evidence suggests that 
there may be a reduced incidence of first dose hypotension 
following administration of perindopril. Thus, it appears
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that there are differential effects between different ACE 
inhibitors with respect to first dose hypotension. The 
differential may be related to the different affinities of 
the various parent compounds for the ACE molecule. It may 
be interesting to consider whether more potent steric 
inhibitors of ACE binding could be of benefit in the 
treatment of patients with profound first dose hypotension 
or ACE inhibitor poisoning.
With the exception of captopril, it is a characteristic 
feature of the ACE inhibitors that they have a long 
terminal half life of elimination. Values in excess of 30 
hours have been reported (Meredith et al, 1989, Hockings 
et al, 1986). A long terminal half life of elimination 
usually bears the risk of accumulation of drug and 
possible subsequent side effects. This is not the case 
for the ACE inhibitors, little accumulation has been 
observed for this group of drugs (Till et al, 1984, 
Nussberger et al, 1987). Till and co-workers proposed 
that the prolonged elimination is due to binding to, and 
subsequent dissociation from, ACE itself. Thus, there is 
a 'one-time' contribution of binding to accumulation.
Two practical approaches have been explored to examine the 
disposition characteristics of these drugs, especially the 
contribution of binding to ACE to the terminal elimination 
phase of the ACE inhibitors. Firstly, the
pharmacokinetics of intravenous radiolabelled spiraprilat 
were assessed in the presence and absence of saturated ACE
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binding sites in rabbit. The ACE binding sites were 
saturated by predosing the animals with unlabelled 
spiraprilat. No change in the terminal elimination half 
life or clearance was found. However, since the value for 
the terminal half life was found to be only of the order 
of 2.5 hours, coupled with the previously observed 
variations between man and rabbit for the in vitro 
parameters calculated, it was concluded that the rabbit 
was not a good model for the disposition of ACE inhibitors 
in man. Secondly, the pharmacokinetics of enalaprilat 
were characterised in the presence and absence of 
saturated ACE binding sites in man. In this instance 
captopril was chosen as the agent to saturate the binding 
sites. Again no change was detected in enalaprilat 
pharmacokinetics, although the observation of induction of 
ACE may have negated the effect of captopril's occupancy 
of original ACE binding sites. These results are in 
agreement with those published by Waldmeier et al (1990) 
who investigated the disposition of radiolabelled 
benazepril hydrochloride after single and repeated oral 
doses. No change was found in the radiolabelled 
benazeprilat pharmacokinetics, the authors do not report 
whether induction of ACE had occurred to confound their 
results.
A third, mathematical approach was explored to 
characterise the binding of ACE inhibitors to ACE. The 
pharmacokinetics of benazeprilat, formed after the oral 
administration of acute and chronic benazepril
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hydrochloride, were described using extended versions of 
the models proposed by Lees et al (1989) to describe the 
pharmacokinetics of perindoprilat infusions. The models 
incorporate saturable binding in plasma, in tissue or in 
both types of binding site. When the combined acute and 
chronic plasma benazeprilat data were fitted 
simultaneously with the plasma percent inhibition of ACE 
data, over 80% of the volunteers were best described by a 
one compartment model with zero order input and tissue 
binding only. One of the assumptions made by the model is 
that there is instant access to the tissue binding sites 
from the plasma. In a physiological sense tissue sites 
could be considered to be on the surface of the vascular 
endothelium. The value for the volume of distribution 
divided by bioavailability, characterised by the model, 
was of the order of 30 litres. No absolute data have been 
published on the bioavailability of benazeprilat, however, 
Waldmeier et al, (1990), have stated that at least 37% of 
a 20mg dose of benazepril is absorbed. Thus the actual 
value for the volume of distribution would be 
approximately 11 litres, close to the value for the 
extracellular fluid volume. Since the drug is not 
extensively distributed outwith the plasma, the assumption 
made by the model that the drug has instant access to 
tissue binding sites is not invalidated by benazeprilat. 
The value for the half life of elimination of free drug 
obtained from the model was of the order of 2.5 hours.
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This is consistant with the initial half life value of 3 
hours characterised in normal volunteers (Kaiser et al, 
1989) and is in keeping with the accumulation 
characteristics of the drug. The effective half life of 
accumulation for enalaprilat, proposed by Till et al, 
(1984) also closely approximated the half life of the 
phase immediately preceeding the terminal phase.
The models used quantified the binding site capacity 
available and also the amount of drug required to inhibit 
binding by 50%. Whilst the values for these parameters 
are complicated by the unknown bioavailability, they do 
give an estimate of the total amount of ACE available for 
binding, and hence to produce an effect.
In conclusion, the practical approaches were unable to 
characterise the contribution of binding to ACE to drug 
pharmacokinetics. However the models used to describe the 
benazeprilat data have characterised the binding of the 
drug to ACE and have given a physiologically appropriate 
value for the half life of elimination.
One of the major aspects of ACE inhibition is the clinical 
dissociation between the duration of antihypertensive 
activity and the time course of plasma ACE inhibition. 
This can be accounted for by the wide consensus of opinion 
that the major site of action of the ACE inhibitors is in 
the tissues. The existence of many localised RAS1s in 
different tissues has been demonstrated, including 
widespread distribution within blood vessels. Some 
investigators have raised the interesting possibility that
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the structure of ACE may vary in different organs 
(Sakharov et al, 1988). Other investigators have suggested 
that it may be possible to design inhibitors more specific 
for one tissue than another (Johnston et al, 1989). 
Cushman et al (1987) proposed that tissue bioavailability 
may be more important than a differing ability to bind to 
the active site of ACE from different tissues. Low 
concentrations of esterase activity have been found in a 
variety of tissues (Larmour et al, 1985). It is not yet 
known if these tissues have the capacity to significantly 
convert prodrugs to active metabolites.
The physicochemical characteristics of the new ACE 
inhibitors under development are likely to be of 
importance in the pharmacological differentiation between 
these drugs. Chemical structure and lipophilicity will be 
major determinants of the penetration of the drug into the 
various tissue sites of action, the duration of action and 
the route of elimination. It may be that ACE inhibitors 
cleared by non renal mechanisms will offer an important 
alternative in the therapy of hypertension and cardiac 
failure.
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APPENDIX
DERIVATION OF EQUATIONS FOR THE 'BINDING1 MODELS
All the 'binding' models were based on a one compartment 
model with zero order input. The total amount of drug 
present in the body was unknown, due to the unknown 
bioavailability of benazeprilat. The dose of benazepril 
hydrochloride administered was 1 Omg which is equivalent to 
8600/F jjq of benazeprilat in the body. Benazeprilat was 
assumed to be present in bound and unbound states, and 
that binding was a saturable phenomenon. Blood withdrawn 
from the compartment contained unbound benazeprilat plus 
any drug bound to circulating binding sites. Benazeprilat 
bound to tissue binding sites was not available for 
sampling. It was also assumed that benazeprilat had 
instant access to the tissue binding sites, thus these 
sites could be considered to be on the surface of the 
vascular endothelium. The concentration of benazeprilat 
in any plasma sample was the sum of the unbound and 
circulating bound drug, divided by the volume of the 
compartment (V). Elimination of benazeprilat was assumed 
to occur as a first order function of the unbound drug. 
The volume of the compartment is constant but since amount 
of total benazeprilat measured in a sample is dependent on 
the dose, due to the saturable binding, Vss is also 
dependent on the dose.
The rate of change of total drug in the body can be 
described by
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dA/dt = 8600 - Au.Ke (1)
Tabs.F
where Tabs is the duration of absorption 
Au is the amount of free drug 
Ke is the elimination constant for free drug 
F is the bioavailability.
Binding was assumed to be saturable and to be described by 
a Michaelis- Menten equation, thus total benazeprilat in 
the body could be described in terms of free and bound 
benazeprilat.
Since A = Au + Bmax.Au (2)
Au50 + Au
where A is the total drug in the body
Bmax is the maximum number of binding sites 
Au50 is the affinity constant for binding.
It should be noted that the parameters Bmax and Au50 are 
really Bmax/F and Au50/F since they are also affected by 
the unknown bioavailability, however the parameters are 
presented just as Bmax and Au50 in the following equations 
for clarity.
Therefore A = Bmax.Au + Au.(Au50 + Au)
Au50 + Au
A (Au50 + Au) = Bmax.Au + Au.(Au50 + Au)
2
A.Au50 + A.Au = Bmax.Au + Au.Au50 + Au 
2
And Au + (Bmax + Au50 - A).Au - A.Au50 = 0 (3)
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2
This is simply aAu + bAu + c = 0 (4)
Equation (4) can be solved using
= -b + /
2
Au Vb - 4ac (5)
Za------
Thus i------------------------------
/ 2Au = -(Bmax + Au50 - A) + V (Bmax + Au50 - A) + 4(A.Au50)
 2---------------------
which is equation (6 ).
Equations (1) and (6 ) were combined to describe the rate 
of change of total benazeprilat in the body, dA/dt.
dA/dt = 8600 - 0.5*Ke [-Bmax - Au50 + A {(Bmax + Au50
tabs.F
2 0.5
- A) + 4*A*Au50} ] (7)
The combined equation was used by the function subroutine 
in BMD-PAR as described in the manual for the software 
(Ralston, 1983) and was the same for all the 'binding' 
models described in chapter 7.
The equations derived so far have been for amounts of drug 
rather than concentration. The dose dependency of Vss 
makes this essential. BMD-PAR rescaled the estimates of A 
for each time of interest. This was done differently for 
each of the 'binding' models.
Models F, I and L assume that all the benazeprilat was 
available for sampling (ie. no drug was bound to tissue 
binding sites) thus the estimate of concentration was
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A / V (8)
Models G, J and M assumed that only unbound benazeprilat 
was available for sampling (ie. benazeprilat bound to
tissue binding sites only). This is equivalent to Au / V
but since Au was not known it had to be expressed in terms 
of A
2
0.5 [-Bmax - Au50 + A + {(Bmax + Au50 - A)
0.5
+ 4 * a * Au50} ] / V (9)
Models H, K and N assumed that benazeprilat bound to
plasma and tissue binding sites. Bmax was scaled by the
fraction of binding which took place in the tissues, f.
Tissue binding = f * Bmax (10)
The total concentration of benazeprilat measured in plasma
was equal to unbound plus plasma bound drug,
0.5 [-f*Bmax - Au50 + A + {(f*Bmax + Au50 
2 0.5
- A) + 4 * A * Au50} / V (11)
This is equivalent to total drug minus tissue bound drug
A - f*Bmax * Au / (Au50 + Au) (12)
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The fortran subroutine for Model H is shown below to 
demonstrate how the function was applied in practise. .
MODEL H
CALL DEFUN(F,P,X,N,KASE,NVAR,IPASS,XLOSS)
RETURN
END
SUBROUTINE DIFEQ(F, P, X,N,KASE,NVAR,NPAR,IPASS,XLOSS) 
IMPLICIT REAL *8 (A-H, 0-Z)
COMMON/DECON/Z(10),DZ(10),T,NEQN,I GO,IT,NEW 
DIMENSION X (NVAR),P(NPAR)
GOTO (100,200,300),IGO 
100 CONTINUE 
IT=1 
NEQN=1 
Z(1 ) = 0 .0 
TABS=P(1)
RETURN 
200 CONTINUE
IF(T .LE.TABS)DZ(1)=8600/P(1))-0.5*P(2)*(-P(4)-P(5)+ 
+Z(1)+((P(4)+P(5)-Z(1))**2+4*Z(2)*P(5))**0.5)
IF(T .GT.TABS)DZ(1)=-0.5*P(2)*(-P(4)-P(5)+
+Z(1)+((P(4)+P(5)-Z(1))**2+4*Z(1)*P(5))**0.5 
RETURN 
300 CONTINUE
F=0.5*(-(P(6)*P(4))-P(5)+Z(1)+(((P(6)*P(4))+
+P(5)-Z(1))**2+4*Z(1)*P(5))**0.5/P(3)
IF(X (3).LT..5)RETURN 
TABS=X(1)+P(1)
NEW= 0
P(1) = Tabs
P (2) = Ke
P (3) =  v / f
P (4) = Bmax/F
P (5) = Au(50)
P (6) =  f .
Where
(C (50) = Au50 / V)
The ACE activity data in models L, M and N were fitted
simultaneously to the equation
% ACE Inhibition = P(7) * Au
P(5) + Au
where P(7) is the maximum % inhibition of ACE activity and 
Au is as defined in equation (6 ).
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